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Abstract 
Osteoclastogenesis is closely controlled by local and systemic factors, and tran- 
scriptional regulators. Previous results have shown that mice lacking c-Fos develop 
osteopetrosis due to a complete block in osteoclast differentiation, whereas mice 
overexpressing c-Fos develop remodelling osteosarcomas containing numerous osteo- 
clasts. The aims of this project were to understand further the function of c-fos on 
osteoclast differentiation and function both in vivo and in vitro. 
The expression of osteoclast, macrophage and osteoblast marker genes were first 
mapped in both c-Fos knockout bones as well as in c-Fos transgenic osteosarcomas, 
in order to investigate the consequences of altered c-Fos levels on these cell types in 
vivo. The osteoclastic phenotypes in c-fos knockout mice suggest that in the cascade 
of osteoclast differentiation, c-fos is downstream of PUA, c-fms and RANK, up- 
stream of mi, and in a similar position to NFKB. In c-Fos transgenic osteosarcomas, a 
large number of multinucleated and mononuclear cells with osteoclast and macrophage 
phenotypes are present not only within neoplastic bone areas but also in the fibrous 
tumour margins not containing any bone. The strong expression of osteoblastic 
marker genes and osteoclast cytokines may partially account for the ectopic osteo- 
clastic cells. 
To further investigate the effects of c-fos on osteoclast precursors, in vitro 
studies were performed using primary M-CSF-dependent bone marrow and spleen 
cells derived from c-fos knockout mice and transgenic mice. Surprisingly, functional 
TRAP positive multinucleated cells were formed from newborn bone marrow cells 
lacking c-Fos, but not from mutant spleen cells, and this osteoclastic potential in c- 
Fos knockout precursors was lost with increasing age. Semi-quantitative RT-PCR 
analysis showed that in younger animals, upregulation offra-I may compensate for 
the deficiency of c-Fos. Addition of growth factors, such as TGF-P and TNF-a 
could not fully substitute for the absence of c-Fos in osteoclastogenesis. Bone mar- 
row precursors expressing exogenous c-fos exhibited an increased responsiveness to 
RANKL and M-CSF signalling, which resulted in enhanced osteoclast forination and 
resorption pit formation. The data suggested that these effects may be mediated by 
5 
molecules downstream of RANKL/RANK signalling, such as TRAF-6, fra-1 and 
IFN-ß. 
Taken together, these data provide novel information on the role of c-Fos in 
osteoclast differentiation which may challenge the current published theories. 
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1.1 Bone structure 
Bone is a specialised form of connective tissue. It provides structural support 
for the body in all higher vertebrates, protects delicate structures and maintains cal- 
cium homeostasis (Watts, 1999). Morphologically there are two forms of bones: flat 
bones (e. g. bones in the skull) and long bones (e. g. tibia, femur, humerus). Long bones 
have epiphyses on both ends, a diaphysis in the middle and a metaphysis in between. 
in growing long bones, the epiphysis and metaphysis are separated by a layer of 
cartilage, called the growth plate, which is responsible for longitudinal growth and 
which becomes calcified and replaced by bone in mature long bones. Mature bones 
consist of dense surface plates of calcified tissues, the cortex, within which is a net- 
work of thin calcified trabeculae that are oriented along lines of forces. In the diaphy- 
sis, a hollow marrow space full of haernatopoietic cells and adipose tissues is en- 
closed by cortex (Blair, 1998) (Fig. 1.1). As in all connective tissue, bone is com- 







Bone marrow space 
Trabecular 
bone 
Figl. l Structure of a long bone 
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1. Introduction 
1.2 Extracellular matrix 
Bone matrix consists of both organic and inorganic components. The main 
components of the inorganic bone are calcium phosphate in the form of calcium hy- 
droxyapatite [(HA), Ca, O(PO4)6(OH)21, Small quantities of sodium, magnesium and 
fluoride are present in the bone in association with HA. 90% of the total organic bone 
matrix is type I collagen secreted by osteoblasts (Marks and Popoff, 1988). Type I 
collagen is oriented along lines of stress, which resists compression. The remainder of 
the organic phase consists of non-collagenous; proteins, as described below. 
1.2.1 Osteonectin 
The most abundant non-collagenous protein is osteonectin. Osteonectin, also 
known as SPARC, is a 43kDa acidic phosphorylated glycoprotein, which is synthe- 
sised by osteoblasts and odontoblasts (Young et al., 1992). In vitro studies indicated 
that osteonectin binds collagen and hydroxyapatite and can regulate cell proliferation 
and cell-matrix interactions (Lane and Sage, 1994). Osteonectin knockout mice devel- 
oped a low-turnover osteopenia with decreased osteoblast and osteoclast numbers 
(Delany et al., 2000), suggesting osteonectin is critical for bone remodelling. 
1.2.2 Osteocalcin 
Osteocalcin, also named bone gla-protein, is a low molecule weight, y- 
carboxyglutarnic acid-containing protein (5.9kDa) (Lian et al., 1993; Owen et al., 
1990). It is the most abundant osteoblast specific non-collagenous protein (Ducy and 
Karsenty, 1995). Its synthesis is vitamin K-dependent and is stimulated by 
1,25(OH)2D3- Osteocalcin plays an important role in bone remodelling. Levels of 
osteocalcin increase markedly during periods of intense skeleton growth. Subcutane- 
ous implantation of bone particles deficient in osteocalcin was poorly resorbed com- 
pared to the normal bone particles, suggesting osteocalcin may act as a matrix signal 
in the recruitment and activation of osteoclasts (Glowacki and Lian, 1987; Glowacki 
et al., 1991; Mundy and Poser, 1983). In the presence of M-CSF and GM-CSF, 
osteocalcin enhances osteoclast formation from stroma-free haernatopoietic precur- 
sors (Liggett et al., 1994). Osteocalcin-deficient mice have an accelerated rate of bone 
formation with normal osteoblast surface. The number of osteoclasts was increased 




Osteopontin (OPN) is a 32kDa phosphorylated calcium binding protein. This 
protein contains RGD (Arg-Gly-Asp) integrin-binding sequence that interacts with 
integrins of the (x, class (Ross et al., 1993). Osteopontin has been shown to be a 
potentially important protein in bone remodelling (Terai et al., 1999; Yamazaki et al., 
1999). It is expressed during bone development at sites of remodelling. The attach- 
ment of osteoclasts during bone resorption depends upon the interaction between 
osteopontin and the integrin avP3 (Miyauchi et al., 1991; Ross et al., 1993). Anti- 
bodies against osteopontin and (43 inhibited the attachment of osteoclasts to the 
intact bone matrix. Osteoclast avP3 and bone matrix osteopontin colocalise. In murine 
osteoclasts, osteopontin localizes to the clear zone and ruffled border membranes. It 
is secreted into the resorption pits during bone resorption, where it binds to avP3 and 
stimulates osteoclast migration by cytoskeletal rearrangement (Chellaiah and Hruska, 
2003; Reinholt et al., 1999). Osteopontin-deficient (OPN-I-) mice generated by tar- 
geted disruption of spp] (secreted phosphoprotein 1) gene showed normal bone de- 
velopment and structure, but with an increased trabecular bone area in OPN-1- fe- 
murs. Osteoclasts isolated from OPN-1- mice were significantly less motile and ex- 
hibited decreased bone rcsorptive activity (Chellaiah and Hruska, 2003). The number 
of osteoclasts formed from OPN knockout haernatopoietic precursors in the coculture 
system was significantly increased (Rittling et al., 1998), which may be due to a 
compensation for the reduced bone resorption. Exogenous osteopontin rescued the 
defect in motility, but only partially rescued the function suggesting deposition of 
osteopontin into the resorption pits from the osteoclast itself enhanced osteoclastic 
bone resorption. Osteopontin also plays a role in osteoclastogenesis, since antiserum 
specific to osteopontin inhibited osteoclast formation from bone marrow cultures 
(Yamate et al., 1997). 
Osteopontin is also involved in bone resorption induced by hormonal and me- 
chanical changes. It was reported that OPN deficiency prevent bone loss following 
ovariectomy in mice (Yoshitake et al., 1999). Furthennore, OPN knockout mice were 
resistant to bone resorption induced by mechanical unloading (Ishijima et al., 2001). 
In the unloaded OPN knockout mice, osteoclast number was decreased compared to 
the wild-type, but in vitro, RANKL-induced osteoclast formation was similar, sug- 
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gcsting the mechanisms by which osteopontin regulates osteoclastogenesis might 
involve the expression of RANKL. 
1.2.4 Bone sialoprotein 
Bone sialoprotein (BSP) is an acidic bone phosphoprotein. It is highly ex- 
pressed in mature osteoblasts, but not in immature precursors (Bianco et al., 1991; 
Chen et al., 1993). It has been reported that BSP is involved in extracellular matrix 
mineralisation (Hunter and Goldberg, 1993). In addition, BSP, Like OPN, contains an 
RGD (Arg-Gly-Asp) integrin-binding sequence, suggesting it may play a role in os- 
teoclast adherence to bone similar to osteopontin. In fact, RGD-containing peptides 
derived from BSP inhibited the attachment of ostcoclasts to bone matrix (Ross ct al., 
1993). 
Taken together, although bone matrix proteins are secreted by osteoblasts, they 
are important for osteoclast formation, recruitment and function, which suggests that 
during bone remodelling, bone formation and bone resorption are tightly coupled 
together. 
1.3 Bone cells 
The cells in bone are generally subdivided into (1) osteoblasts (bone fonning 
cells), (2) osteocytes and bone lining cells and (3) osteoclasts (bone resorbing cells). 
1.3.1 The osteoblast phenotype 
Osteoblasts are cuboidal cells situated along the bone surface, which are re- 
sponsible for the production of the matrix constituents (collagen and ground sub- 
stance). They also play an essential role in regulating osteoclast differentiation and 
activation by producing factors (Hofbauer et al., 2000) (see also section 1.5.2-4). 
Osteoblasts have a round nucleus at the base of the cell and a strongly basophilic 
cytoplasm (Holtrop, 1975). The plasma membrane of the osteoblast is rich in alkaline 
phosphatase, and has receptors for many osteotropic hormones, including parathy- 
roid hornione, estrogen and vitamin D3 (Bodine et al., 1998; Li et al., 1997). Alkaline 
phosphatase (ALP) is used as a marker of osteoblastic development (Stein and Lian, 
1993). The function of ALP has been demonstrated by gene inactivation studies: 
Tissue non-specific alkaline phosphatase (TNAP) knockout mice appeared nortnal at 
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birth, but die of epileptic seizures before weaning. Osteoblasts isolated from TNAP - 
/- mice differentiated normally and were able to form cellular nodules in vitro, but 
were unable to mineralise these nodules. TNAP+I- osteoblasts also showed delayed 
mineralisation. Differentiation and function of osteoclasts were unaffected by the 
deletion of TNAP (Wennberg et al., 2000). 
1.3.1.1 Osteoblast differentiation 
Osteoblasts originate from local mesenchymal stem cells (bone marrow stro- 
mal stem cell or connective tissue mesenchymal stem cells), which also give rise to 
chondrocytes, fibroblasts, myoblasts, and adipocytes (Fig. 1.2). These precursors, 
with the right stimulation, undergo proliferation and differentiate into preosteoblasts 
and then into mature osteoblasts. It has been reported that ostcoblasts undergo a 
three-stage process of differentiation: proliferation, matrix maturation and mineralisa- 
tion (Aubin et al., 1995; Owen et al., 1990). A well-characterized temporal and spa- 
tial expression pattern of extracellular bone matrix proteins and other genes occurs in 
this process. During proliferation period, growth related genes and genes associated 
with formation of the extracellular matrix (ECM) are actively expressed, including 
type I collagen, fibronectin and TGF-P. After the downregulation of proliferation, 
proteins associated with the osteoblast phenotype are detected, such as ALP, 
PTH/PTHrP receptor, bone sialoprotein and osteocalcin. ALP gene is maximally 
expressed at this stage. Finally, the ECM is calcified and the level of ALP is down- 
regulated (Stein and Lian, 1993). Fig. 1.3 shows the genes involved in osteoblast and 
chondrocyte differentiation (Adapted from Aubin et al., 1995). 
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1.3.1.2 Role of Cbfa-I in osteogenesis 
To date, only two genes are known to control osteoblast differentiation directly 
or indirectly: Cbfa- I and Indian hedgehog (Ihh) (Karsenty, 1999). In endochondral 
ossification during embryogenesis, the mesenchymal progenitors grouped in skeletal 
condensations first differentiate into type 11 collagen producing cells. Cbfa-I then 
promotes their differentiation into Ah-secreting hypertrophic chondrocytes or into 
type I collagen-producing preosteoblasts. In addition to regulating nonhypertrophic 
chondrocyte proliferation, Ihh also affects osteoblast differentiation. Mice deficient 
in 1hh have a disorganized growth plate and no osteoblasts present in the mutant long 
bones (St-Jacques et al., 1999), suggesting that during endochondral ossification, 
Cbfa-I is upstream of Ihh in the control of chondrogenesis but downstream in the 
control of osteogenesis. 
Cbfa- I (core-binding factor)/ Runx2 (runt-related gene 2), also called osJ2 (os- 
teoblast-specific transcription factor 2) is a transcription factor of the runt domain 
gene family that is essential for bone formation during embryogenesis. During skeletal 
development, Cbfa-I is expressed exclusively in mesenchymal cell condensation at 
early stages (12.5 dpc), and the expression is restricted to osteoblast lineage thereaf- 
ter and turned off in differentiated chondrocytes (Fig. 1.3). It has been used as the 
earliest and most specific marker gene for osteogenesis. 
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Fig 1.3 Osteoblast and chondrocyte differentiation. Osteoblasts and chondrocytes are 
derived from the same chondro-osteo progenitors. Cbjý- I promotes osteoblast differentiation 
and chondrocyte maturation. Osx acts downstream of Cbfa- I and promotes osteoblast matura- 
tion. Other chondrocyte and osteoblast markers are indicated. 
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Cbfa-I is critical for osteoblast development. Cbfa-I deficient mice developed a 
cartilaginous skeleton. Both intramembranous and endochondral ossification were 
completely suppressed because of the lack of osteoblast differentiation. These mice 
also showed defects in chondrocyte maturation, which was arrested at a stage before 
hypertrophy. In Cbfa-I +/- mice, the defects were confined to intramembranous bone 
formation and the phenotype was similar to a human skeletal disease called Cleido- 
cranial dysplasia (CCD) (Lee et al., 1997; Otto et al., 1997). It was also reported that 
Cbfa-I enhances osteoblast differentiation at an early stage but inhibited it at a later 
stage, as transgenic mice overexpressing Cbfa-I developed a high bone turnover os- 
teopenia with numerous osteoclast invasion. The number of osteoblasts was in- 
creased but their terminal maturation and function were inhibited (Liu et al., 2001). 
Cbfa-I is also expressed in mature osteoblasts and regulates the expression of bone 
matrix proteins (Ducy et al., 1997). Cbfa-1 binding sites are present in the promoters 
of several osteoblastic genes, such as osteocalcin, bone sialoprotein (Bsp), collagen 
type I and osteopontin, and control their expression. Transfection of a Cbfal expres- 
sion vector induced the expression of Osteocalcin and Bsp in primary skin fibroblasts 
and fibroblastic cell lines (Ducy et al., 1997). 
Cbfa-I affects osteoclastogenesis indirectly via osteoblasts. In Cbfa-I deficient 
mice, only some mononuclear osteoclastic cells and limited numbers of multinucleated 
H+-ATPase positive osteoclasts with poorly developed ruffled borders were present 
in the perichondriurn (Hoshi et al., 1999; Komori et al., 1997; Otto et al., 1997). Cal- 
varial cells isolated form Cbfa-I +/+, +/- and -/- embryos were cocultured with normal 
spleen cells in the presence of 1,25(OH)2D3 and Dexamethasone, and the number and 
the bone resorption activity of osteoclasts formed in coculture with mutant calvarial 
cells were significantly decreased in comparison with heterozygous and wild-type 
(Gao et al., 1998). RANKL expression was upregulated by 1,25(OH)2D3 and Dex- 
amethasone treatment in heterozygous and wild type calvarial cells, but not in homo- 
zygous mutant cells. On the other hand, OPG expression was inhibited similarly in 
all three genotypes (Gao et al., 1998). In contrast, osteoblastic cells overexpressing 
Cbfa-I have an increased ability to support osteoclast formation, probably by 
upregulating RANKL and M-CSF expression and downregulating OPG expression 
(Geoffroy et al., 2002). However, Thirunavukkarasu et al. reported that there are 12 
putative Cbfa-1 binding elements (osteoblast-specific element 2 (OSE2) sites) pre- 
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sent in the OPG promoter. Overexpression of Cbfa-I in osteoblastic cell lines in- 
creased OPG protein levels (Thirunavukkarasu et al., 2000). 
Recently, Osterix (Osx) has been identified as a transcription factor that is re- 
quired for osteoblast differentiation during development and acts downstream of 
Cbfa-I (Nakashima et al., 2002). Osx is a zinc finger-containing protein, which is 
expressed in osteoblast progenitors. Mice lacking Osx developed a cartilaginous 
skeleton without osteoblasts, which is similar to the Cbfa-I knockout mice but less 
severe. However, the fact that Cbfa-I is expressed in Osx mutant mice, while OSX 
expression is absent in Cbfa-I mutant mice, suggests that Osx is genetically located 
downstream of Cbfa-1. In addition, fully functional osteoclasts were present in Osx 
mutant long bones. 
In conclusion, Cbfa-I controls osteoblast differentiation which further affects 
osteoclastogenesis, suggesting that osteoblast are crucial for osteoclast differentiation. 
Not only fully differentiated osteoblasts but also osteoblast progenitors have the 
ability to support osteoclast formation, as osteoclastogenesis are not affected in Osx 
knockout mice. 
1.3.2 Osteocytes and lining cells 
1.3.2.1 Osteocytes 
Osteocytes are considered the most mature or terminally differentiated cells of 
the osteoblast lineage (Holtrop, 1975; Jande and Belanger, 1973). They are embedded 
in the bone matrix and communicate with each other and the surface lining cells via 
gap junctions on cytoplasmic projections within canaliculi through the mineralised 
matrix (Menton et al., 1984). Recently, a bone-specific cDNA named os- 
teoblast/osteocyte factor 45 (OF45) was identified as an osteocyte specific marker 
gene, which is only expressed in cells embedded within bone matrix. This cDNA 
encodes a serine/glycine-rich secreted protein containing one RGD sequence motif, 
which may play a role in regulating bone cell activity (Petersen et al., 2000). 
Osteocytes are capable of synthesising osteopontin which in turn induces os- 
teoclasts and osteoblasts to attach to the bone matrix (Gerstenfeld, 1999). Evidence 
showed that osteocytes negatively regulate osteoclast function. Conditioned medium 
from an osteocyte cell line inhibited bone resorption of isolated osteoclasts, and this 
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effect was enhanced by estrogen pre-treatment and abolished by an antibody against 
transforming growth factor-P (TGF-P) (Heino et al., 2002). 
It has been suggested that osteocytes are the mechano-sensors of bone, re- 
sponding to mechanical stimuli. They signal information to the endosteal and pe- 
riosteal surfaces via their cell processes in canaliculi that form a continuous network 
(Lanyon, 1993). Osteocytes produce nitric oxide and prostaglandins (Pitsillides et al., 
1995; Rawlinson et al., 1995) upon mechanical loading. They also undergo apoptosis 
by damage-inducing loads, which may serve as a signal for osteoclast activation and 
stimulating local bone resorption (Noble et al., 2003). The responsiveness of osteo- 
cytes to mechanical loading is regulated by estrogen. Osteocytes express both a and 
P estrogen receptors (Vidal et al., 1999). Osteocyte apoptosis was increased by ova- 
riectomy in rats, which was abolished by estrogen treatment, suggesting that they 
may play a role in estrogen deficiency-induced bone loss after menopause 
(Tomkinson et al., 1998). 
1.3.2.2 Bone lining cells 
Another form of terminally differentiated osteoblasts are the bone lining cells, 
which are flat and highly elongated with a spindle shaped nuclei (Menton et al., 
1984). These cells are found on newly formed bone surfaces, but their functions are 
not clear. It was suggested that bone lining cells are involved in bone remodelling. 
During bone remodelling, targeting of osteoclast precursors to a specific location on 
bone depends on the "homing" signals sent from bone lining cells, which are under 
control of osteocytes (Parfitt et al., 1996). Chambers et al. reported that osteoblastic 
cells (bone lining cells) initiated bone resorption by digesting unmineralised osteoid, 
which protects bone mineral from osteoclastic contact (Chambers and Fuller, 1985). 
Bone lining cells are also thought to be able to revert to an earlier osteoblastic pheno- 
type with parathyroid hormone (PTII) stimulation (Menton et al., 1984). After me- 
chanical stimulation, bone lining cells changed to a cuboidal shape with rounded nuclei 
and abundant rough endoplasmic reticulurn characteristic of osteoblasts, suggesting 
these cells are reactivated (Chow et al., 1998). Some studies showed that they might 
be reactivated to synthesise osteoid at specific times e. g. during fracture healing 
(Bland et al., 1999). It was also reported that bone lining cells cleaned up the resorp- 
tion pits left by osteoclasts, which contained nondigested demineralised bone colla- 
24 
1. Introduction 
gen. This "cleaning up" is a prerequisite for the subsequent deposition of collagenous 
proteins by osteoblasts in the resorption pits (Everts et al., 2002). 
Although osteocytes and bone lining cells are terminally differentiated os- 
teoblasts, they play an important role in bone remodelling and osteoclastic bone re- 
sorption. 
1.3.3 The osteodast phenotype 
Osteoclasts are the bone cells responsible for bone resorption. They are giant 
multinucleated cells, containing four to 20 nuclei. Osteoclasts are usually found in 
contact with calcified bone surfaces and within lacunae (Howship's lacunae) (Lucht, 
1980). Their cytoplasm contains many vacuoles and mitochondria. The most promi- 
nent feature of active osteoclasts is the deep foldings of the plasma membrane in the 
area facing the bone matrix, named the ruffled border, which is surrounded by a ring 
of contractile proteins (sealing zone). The sealing zone serves as a barrier, preventing 
the leakage of secreted protons and proteases from the resorption area, and also plays 
a crucial role in osteoclast polarisation (Stenbeck and Horton, 2000). Formation of 
the sealing zone involves the rearrangement of the cytoskeleton so that actin forms a 
dense belt-like structure, called the "actin ring" (Lakkakorpi et al., 1989). 
Osteoclasts express several unique phenotypic features that distinguish them 
from other multinucleated giant cells. To date, the expression of calcitonin receptors 
(CTR) and lacunar bone resorption are widely accepted as the two most specific 
features for osteoclasts. The unique ability of osteoclasts to form resorption lacunae 
provides a specific and reliable way of identifying these cells (Boyde ct al., 1984; 
Chambers and Horton, 1984). Other cell types, including monocytes and macro- 
phages, are able to dissolve both the inorganic and the organic matrix components of 
bone, but don't form lacunae (Teitelbaum ct al., 1979). 
1.3.3.1 Calcitonin receptor (CTR) 
Osteoclastic activity is directly and specifically inhibited by calcitonin, and the 
demonstration of receptors that bind calcitonin is a reliable and highly specific marker 
of a mammalian osteoclast (Takahashi et al., 1988a). The calcitonin receptor (CTR) 
belongs to a subfamily of G protein-couplcd receptors. There are two different CTR 
isoforms expressed in murine tissues: Cla, and Clb which is primarily expressed in 
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brain (Pondel, 2000). CTR is expressed on committed osteoclast precursors and ma- 
ture osteoclasts (Lee et al., 1995; Quinn et al., 1999). The expression of CTR mRNA 
was coincident with the development of osteoclasts in bone marrow culture and was 
more specific than TRAP expression (Lee et al., 1995). 
1.3.3.2 MMP-9 
The expression of matrix metalloproteinase-9 (MMP-9) is the earliest marker 
for cells in the osteoclast lineage (Roodman, 1999). MMP-9 (92kDa type IV colla- 
genase /gelatinase B) cleaves native collagens of type IV, V and XI, and elastin. It has 
a role in the removal of denatured collagen fragments following the action of cysteine 
proteinases as an early step in bone resorption (Reponen et al., 1994; Wucherpfennig 
et al., 1994). During embryonic development, MMP-9 is highly expressed by tro- 
phoblast cells at the implantation site and by osteoclasts (Alexander et al., 1996; 
Reponen et al., 1994). MMP-9 plays an important role in the migration of preosteo- 
clasts from the perichondrium into the cartilaginous bone model, to transforrn it into 
the bone marrow cavity during endochondral ossification (Blavier and Delaisse, 
1995). Mice deficient in MMP-9 are viable but exhibit a delay in osteoclast recruit- 
ment, resulting in delayed endochondral ossification and an excessively wide zone of 
hypertrophic cartilage, with no effects on intramembranous bone formation (Engsig et 
al., 2000). The differentiation of hypertrophic chondrocytes was normal, but apop- 
tosis, vascularisation and ossification were delayed. In vitro angiogenesis assays 
showed that MMP-9 mutant cartilage induced a delayed angiogenic response, sug- 
gesting the release of an angiogenic activator, identified as VEGF, is delayed in the 
absence of MMP-9 (Vu et al., 1998). Transplantation of wild-type bone marrow 
cells rescued the defects of vascularisation and ossification, suggesting the defect was 
intrinsic to haematopoietic cells. 
1.3.3.3 TRAP 
Osteoclasts contain high levels of acid hydrolases. One of them is Tartrate- 
resistant acid phosphatase (TRAP) (purple acid phosphatase, type 5 acid phospha- 
tase, Acp5). TRAP is expressed in a variety of tissues, but bone expresses the high- 
est level among normal tissues. In bone, TRAP is highly expressed in osteoclasts and 
is prcscnt in lysosomes, Golgi, extracellular channels of the ruffled border, and the 
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space between the cells and bone (Hammarstrom et al., 1971; Minkin, 1982). TRAP 
is considered as a reliable marker for osteoclasts. 
The function of TRAP in osteoclasts is not clear. It has been reported that 
TRAP can dephosphorylate osteopontin and bone sialoprotein, which have been 
implicated in cell attachment (Ek-Rylander et al., 1994). TRAP-deficient mice have a 
mild osteopetrotic phenotype due to an intrinsic defect of osteoclastic remodelling 
activity. Osteoclasts were present in Acp5-1- long bones, but their resorptive ftinction 
was impaired (Hayman et al., 1996), suggesting that TRAP may play an important 
role in osteoclastic bone resorption. 
1.3.3.4 Cathepsin K 
Cathepsin K is a cysteine protease of the papain family of proteases that is 
abundantly and selectively expressed within osteoclasts, while other cystein protein- 
ases (cathepsin B, H, L or S) are absent or expressed at very low levels (Drake et al., 
1996; Soderstrom et al., 1999). It is a 39kDa protein synthesised as a pre-proenzyme 
that can be converted autocatalytically to the mature enzyme form (McQueney et al., 
1997). Cathepsin K expression during embryogenesis is restricted to osteoclasts and 
preosteoclasts at sites of active cartilage and bone remodelling (Dodds et al., 1998). In 
situ hybridisation showed that cathepsin K is highly and specifically expressed in 
human and rabbit osteoclasts (Drake et al., 1996; Tezuka et al., 1994). It is secreted 
by activated osteoclasts into the resorption lacunae on bone surface (Yamaza et al., 
1998). 
Cathepsin K functions as a matrix-degrading proteinase in bone resorption. It 
has both gelatinase and collagenase activity and can effectively degrade types I and 11 
collagen, osteopontin and osteonectin at low pH (Garnero ct al., 1998). Cathepsin K 
knockout mice developed pronounced osteopetrosis and extramedullary haematopoi. 
esis. Histological analysis showed that the number of osteoclasts was not decreased, 
but that these osteoclasts failed to resorb and endocytosc the bone matrix (Gowen et 
al., 1999). The resorptive surface of bone in the mutant mice was poorly defined with 
a broad dernineralised matrix fringe containing undigested fine collagen fibrils (Saftig et 
al., 1998), suggesting cathepsin K deficient osteoclasts are capable of dernineralising 
the extracellular matrix but are unable to adequately remove the demineralised bone 
(Gowen et al., 1999). Cathepsin K deficient osteoclasts had irregular ruftled borders, 
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detached sealing zone and large irregular vacuoles in the cytoplasm, resulting in a 
severely impaired function. A deletion of cathepsin K has been related to a human 
disease called pycnodysostosis with short stature and osteosclerosis (Gelb et al., 
1996). 
Mice overexpressing the Ctsk gene, which codes for cathepsin K, developed 
high turnover osteoporosis with increased number of osteoblasts. Furthermore, im- 
munohistochemistry showed that cathepsin K expression was confined to osteo- 
clasts. These results suggested that bone resorption and formation are tightly coupled 
during bone remodelling (Kiviranta et al., 2001). 
1.3.3.5 Carbonic anhydrase 11 
Osteoclasts express high levels of carbonic anhydrase IL Carbonic anhydrase II 
(CAII) is an enzyme catalysing the association Of C02 and H20 to form H2C03. 
which dissociates to H" and HC03-. Osteoclasts actively resorbing bone express 
higher levels of CAH than resting osteoclasts (Asotra et al., 1994). 1,25(OH)2D3 and 
PTH stimulate CAH expression in bone marrow cultures, which could be due to the 
stimulatory effect on osteoclast differentiation (Biskobing ct al., 1997). CAII plays 
an important role in osteoclastic bone resorption. Antisense constructs against CAH 
block osteoclastic bone resorption both in isolated osteoclasts and in bone organ 
cultures (Laitala and Vaananen, 1994; Laitala-Leinonen et al., 1999). Congenital ab- 
sence of CAH in children results in osteopetrosis, renal tubular acidosis and cerebral 
calcification (Sly et al., 1983). Osteoclasts in these patients fail to develop a ruffled 
border and are unable of resorb bone (Marks, 1989). Bone marrow transplantation 
cured the osteoclast defect and osteopetrosis, but not the renal lesions (McMahon et 
al., 200 1), suggesting that the skeletal defects are intrinsic to the haematopoictic line- 
age. It was also reported that CAII plays an important role in osteoclast differentia- 
tion through p1l regulation. CAII specific inhibitors suppressed 1,25(OH)2D3, in- 
duced osteoclast formation in a dose-dependent manner (Lehenkari et al., 1998). 
1.3.3.6 H-ATPase 
The central role of activated osteoclasts is acid secretion via the highly ex- 
pressed vacuolar (V-type) electrogenic H+-ATPase. The V-ATPase-deficient atp6i 
mice (Li et al., 1999b), which carry the same mutation as the spontaneous ocloc 
mouse (Scimeca et aL, 2000), also have dysfunctional osteoclasts, which are unable to 
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acidify the resorption lacuna. Disruption of a late endosomal/lysomal Cl- channel, 
CIC-7 Cl- channel, which provide the chloride conductance required for efficient pro- 
ton pumping by the H"-ATPase, results in a phenotype similar to the atp6i mice 
(Kornak et al., 2001). Osteoclasts are present in both mutant long bones, but they fail 
to resorb bone due to the deficiency in acidifying the extracellular resorption lacuna. 
1.3.3.7 Vitronectin receptor 
Integrins are a superfamily of cell surface receptors composed of non-covalent 
heterodimers containing a and P subunits. There are at least 15 different a chains and 
8 different P chains have been identified. The extracellular domain of many integrins 
interacts with the RGD (Arg-Gly-Asp) tripeptide found in many extracellular pro- 
teins, such as vitronectin, fibronectin, osteopontin and bone sialoprotein. Integrins 
mediate cell-matrix and cell-cell interactions (Hynes, 1992). Mammalian osteoclasts 
express high levels Of aP3. the vitronectin receptor; also (XA, a collagen/laminin 
receptor and cc, pj, another vitronectin receptor. At the ultrastructural level, otA is 
localised to the ruffIcd border, the basolateral membrane (Lakkakorpi et al., 1993) and 
the clear zone (Reinholt et al., 1999). 
Integrins regulate osteoclast activity by mediating osteoclast adhesion and 
regulating the cytoskeletal. Organisation required for both cell migration and formation 
of the sealing zone (Nakamura et al., 1999). The vitronectin receptor, CE. 03, mediates 
the attachment of osteoclasts to bone matrix by binding to osteopontin (Ross et al., 
1993). RGD-containing peptides, which can inhibit the function Of C039 inhibit os- 
teoclast resorption in vitro by disrupting the ruffled border and clear zone (Nakamura 
et al., 1996; Sato et al., 1990). Monoclonal anti-vitronectin receptor avP3 complex 
antibody induced significant osteoclast retraction in chick osteoclasts and inhibited 
their resorption (Horton et al., 1991). Inhibition of avP3 integrins also inhibits osteo- 
clastic bone resorption in vivo. RGD-containing peptides and a monoclonal antibody 
to P3 subunits blocked the PTH-induced increase in serum calcium in thyroparathy- 
roidectomised (TPTX) animals (Crippes ct al., 1996; Fisher et al., 1993). Synthetic 
RGD mimetics prevent the rapid bone loss after estrogen withdrawal, suggesting that 
CEA blockade may prevent postmenopausal osteoporosis (Engleman et al., 1997). 
Mice lacking P3 developed osteosclerosis and hypocalcaemia with age. The number of 
osteoclasts was increased in the mutant mice, but they were dysfunctional. Osteo- 
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clasts isolated from these mice failed to spread, lacked the actin rings and exhibited 
reduced bone resorption activity in vitro (McHugh et al., 2000). 
Integerin C03 also plays a role in osteoclast differentiation. RGD-containing 
peptides inhibited multinucleated osteoclast formation by preventing M-CSF- 
induced migration and fusion of preosteoclasts in a co-culture system (Boissy et al., 
1998; Nakamura et al., 1998). On the other hand, Miyamoto ct al. reported that 
RGD-containing peptides and antibodies against 03 inhibited multinucleation of 
TRAP positive cells in a dose-dependent manner by downregulating cell prolifera- 
tion, rather than affecting the initial attachment (Miyamoto et al., 2000). Under nor- 
mal in vitro culture conditions, bone marrow macrophages ftom 03 knock out mice 
formed much less multinucleated osteoclasts than the wild-type, and these cells were 
dysfunctional as well (McHugh et al., 2000). High dose M-CSF completely rescued 
the 63-1- osteoclastogenesis defect, but not the resorption function, by activating the 
ERK (extracellular signal-regulated kinases)/c-Fos signalling pathway (Faccio et al., 
2003). 
Activated C03 exerts its biological effects through Pyk2/Src/Cbl (Sanjay et al., 
2001), p130"' (cas, Crk associated substrate) (Lakkakorpi et al., 1999), P13-K 
(phosphatidyl inositol 3-kinase) (Chellaiah et al., 1998) and Rho (Chellaiah et al., 
2000) signalling pathways. 
1.3.3.8 RANK 
RANK (receptor activator of NF-icB), also named osteoclast differentiation 
and activation receptor (ODAR) is the receptor for RANKL. It was originally idcnti- 
fied in a dendritic cell cDNA library (Anderson et al., 1997). RANK is a type I 
transmembrane protein. It is present on osteoclasts and their precursors (Myers et 
al., 1999; Nakagawa et al., 1998), and mediates the function of RANKL in osteoclast 
differentiation and activation (11su et al., 1999). The expression of RANK is upregu- 
lated by M-CSF (Arai et al., 1999; Lacey et al., 1998). Antibodies against the ex- 
tracellular domain of RANK stimulated osteoclast fortnation in vitro (11su et al., 
1999; Nakagawa et al., 1998). 
Deletion of RANK leads to severe osteopetrosis (Li et al., 2000). The mutant 
mice lack osteoclasts and have a profound defect in bone resorption and remodelling 
and in the development of the cartilaginous growth plates of endochondral bone. 
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They also exhibit a marked deficiency of B cells in the spleen and have a lymph node 
deficiency, whereas macrophages and dendritic cells are not affected (Dougall et al., 
1999). Spleen cells from RANK-1- mice could not form osteoclasts in vitro in the 
presence of RANKL and M-CSF, but this could be rescued when these cells were 
infected with a RANK-expressing retrovirus. Bone marrow transplantation from ragl- 
/- mice, which have normal osteoclast precursors, cured the osteopetrosis, suggesting 
that the defect was restricted to the osteoclast lineage. Injection of PTHrP, 
1,25(OH)2D3 and IL- I into RANK mutant mice didn't induce osteoclastic bone re- 
sorption, suggesting that the proresorptive activity of these factors is mediated by 
the RANK signalling pathway. Surprisingly, injection of TNF-a induced rare TRAP 
and cathepsin K positive osteoclast formation on the bone surface, suggesting that 
TNF-(: x may act through an alternative compensatory pathway to stimulate osteo- 
clast differentiation in the absence of RANK (Li et al., 2000). Transgenic mice ex- 
pressing a soluble form of RANK, which binds to RANKL with high affinity, devel- 
oped osteopetrosis due to a reduction in osteoclastogenesis, similar to OPG trans- 
genic mice (Hsu et al., 1999) (see also below). 
In conclusion, although some of the markers shown above are not complete os- 
teoclast specific, when used in combination, they specifically localise osteoclasts 
both in vivo and in vitro, and are of great benefit to osteoclast studies. 
1.3.4 Osteoclastic bone resorption 
Osteoclastic bone resorption is a multistep process involving recognition, at- 
tachment to bone surface, establishment of cell polarity, migration, and subsequent 
degradation of bone matrix components. Bone resorption depends on the ability of 
the osteoclast to generate an acid extracellular compartment between itself and the 
bone surface. Acidic p1l is essential for solubilisation of the alkaline salts of bone 
mineral as well as digestion of the organic bone matrix by acid lysosomal enzymes 
secreted by osteoclasts. The combination of these two processes is responsible for 
bone resorption. Carbonic anhydrase II catalyses the formation of carbonic acid 
(H2CO3) from water and carbon dioxide. Carbonic acid spontaneously dissociates to 
bicarbonate HC03- and H". The protons are subsequently transported through the 
cell membrane to the bone surface by H--ATPase, located in the ruffled border. While 
protons are extruded into the resorption lacuna, chloride ions are translocated to the 
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bone site through a Cl- channel, resulting in a net transport of hydrochloric acid. Hy- 
droxyapatite crystals are dissolved by the acidic microenvironment under osteoclasts. 
The bicarbonate remaining in the cytoplasm is eliminated from the cell via a HC03-/ 
Cl- exchanger, replacing the Cl- secreted into the resorption lacuna. Subsequently, the 
organic components exposed after dissolution of the mineral are digested via lysoso- 
mal enzymes and collagenase, which are excreted into the lacuna by osteoclasts. Cys- 
teine proteinases are activated first at low pH and digest part of the bone matrix. 
After the pH has increased somewhat, MMPs digest the rest of the matrix (Everts et 
al., 1998). Additionally, actively resorbing osteoclasts release oxygen-derived radi- 
cals, especially superoxide, which probably contribute to the degradation of the bone 
matrix (Felix et al., 1996; Rousselle and Heymann, 2002). Mouse bone explants ex- 
periment showed that osteoclastic resorption of calvarial bone depends on activity of 
both cysteine proteinases and MMPs, while long bone resorption depends only on 
cysteine proteinases (Everts et al., 1999). After extracellular digestion, the degraded 
products are removed by endocytosis and vesicular transcytosis through osteoclasts 
(Palokangas et al., 1997; Zhao et al., 2002) (Fig. 1.4)(Adapted from Stenbeck, 2002). 
Exit site 
Figl. 4 Mechanism of osteoclastic bone resorption 
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1.4 Bone development and remodelling 
There are two types of processes involved in bone formation: intramembranous 
ossification (flat bones) and endochondral ossification (long bones). 
1.4.1 Intramembranous ossification 
In intramembranous ossification, a group of mesenchymal cells within a highly 
vascularised area of the embryonic connective tissue proliferates and differentiates 
directly into preosteoblasts and then into osteoblasts. These cells synthesise a bone 
matrix with irregular collagen fibre bundles, numerous osteocytes and irregularly dis- 
tributed ossification patches. This type of bone is called woven bone. Later, this 
woven bone is progressively replaced by mature lamellar bone. 
1.4.2 Endochondral ossification 
In endochondral ossification, mesenchymal cells proliferate and differentiate 
along chondrocytic lineage. The chondrocytcs secrete cartilaginous matrix and form a 
cartilage template which prefigures the future bone. The cartilage is then surrounded 
by a bone collar and undergoes calcification. Cartilage is replaced by bone through the 
simultaneous invasion of osteoclasts and capillary endothelial cells that direct os- 
teoblast progenitors to the cartilaginous scaffolds to synthesise bone (Karsenty, 
2001; Stevens and Williams, 1999). Upon vascular invasion of the cartilage template, 
the chondrocytes die through apoptosis and are replaced by osteoblasts brought in 
from the periosteum and bone collar. Osteoblasts; synthesise and secrete type I Colla- 
gen, which is subsequently assembled into a collagenous matrix or osteoid. The os- 
teoid layer then calcified by the process of mineralisation (Ducy et al., 2000). 
1.43 Bone remodelling 
Throughout the life, the vertebrate skeleton is under constant bone remodelling, 
which is crucial for maintaining a well-adapted skeleton. Bone remodelling is a very 
complex process of tightly coordinated action by the bone resorbing osteoclasts and 
the bone forming osteoblasts. The two processes are usually tightly regulated by a 
complex interplay of cell-cell and ccll-matrix interactions involving the production of 
enzymes and activation of inhibitors and regulatory molecules such as cytokines and 
growth factors. Dysfunction of and imbalance between osteoblasts and ostcoclasts 
lead to bone metabolic diseases, such as osteoporosis in which bone resorption ex- 
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ceeds formation, or in contrast, osteopetrosis in which bone formation exceeds re- 
sorption. 
In cortical bone, bone remodelling is carried out by a structure called basic mul- 
ticellular unit (BMU) (Parfitt et al., 1996). A typical BMU comprises osteoclasts in 
the front, osteoblasts in the rear, and a central vascular capillary, a nerve supply and 
connective tissues in the middle. All remodelling begins on a quiescent surface, which 
is covered by bone lining cells. Bone lining cells produce collagenase and digest the 
layer of unmineralised matrix so that the bone surface is exposed to osteoclasts 
(Chambers et al., 1985a). Inactivated osteoclast precursors migrate to the site that is 
to be resorbed in response to some unknown signals. Mesenchymal cells synthesise 
cytokines that induce and modulate growth and differentiation of osteoclast precur- 
sors to mature osteoclasts (Burger et al., 1984). After adhesion to the mineralised 
bone matrix, activated osteoclasts form a tight sealing zone that enclose the resorp- 
tion lacunae and create an isolated microenvironment, where the low pH and high 
concentration of enzymes are maintained. The ruffled border develops beneath the 
osteoclast surrounded by the sealing zone. Osteoclasts resorb bone by producing and 
releasing hydrogen ions, lactate and proteolytic enzymes to the subeellular space. As 
the BMU progresses through the surface of bone, the transition from resorption to 
formation occurs (Parfitt, 1994). Osteoclastic bone resorption is terminated by os- 
teoclast apoptosis (Parfitt et al., 1996), the surface of the resorption cavity becomes 
smoother and covered by a thin layer of cement substance and mononuclear cells. 
Finally, mesenchymal precursors are recruited to the resorption site and differentiate 
into osteoblasts. Osteoblasts lay down a protein matrix filling in the lacunae, called 
osteoid, which then becomes calcified. After bone formation, some osteoblasts be- 
come flat and line the quiescent bone surfaces, that is, they become bone lining cells 
(Fig. 1.5) (Adapted from Christenson, 1997). 
In cancellous bone, a bone remodelling compartment (BRC) is associated with 
bone remodelling (Hauge et al., 2001). The difference between BMU and BRC is the 
maintenance of the bone lining cell barrier throughout bone remodelling. After the 
digestion of unmineralised matrix, bone lining cells become the marrow lining cells, 
allowing bone resorption and bone formation to proceed under a common roof of 
lining cells. At the end of bone formation, new lining cells derived from osteoblasts 
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replace the marrow lining cells and close the BRC. The two layers of lining cells even- 
tually become a single layer. 






Fig 1.5 Bone remodelling cycle 
Osteoclasts 
Resorption 
The mechanism of coupling between bone resorption and bone formation is not 
clear. It was suggested that growth factors such as TGF-P are stored in bone matrix 
and would be released during bone resorption (Bonewald and Mundy, 1990). The 
capillary in the middle of BMU may also play a role in coupling. Vascular pericytes 
could serve as a source of osteoblasts. Cultured pericytes expressed many features of 
the osteoblast phenotype and have been reported to have the capacity to form nod- 
ules (Brighton et al., 1992). 
1.5 Modulation of osteoclast differentiation 
Osteoblasts and osteoclasts are equally important for maintaining healthy 
skeleton. Since this thesis focuses mainly on osteoclasts, this next section will review 
the many advances that have been made in the last decades in osteoclast biology. 
1.5.1 Origin of osteoclasts 
It is widely accepted that osteoclasts are haernatopoietic in origin and are de- 
rived from cells in the monocyte/macrophage lineage (Fig. 1.6)(Adapted from 
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Karsenty and Wagner, 2002). During early embryogenesis, haernatopoietic stem cells 
are initially generated and expanded in the intraembryonic AGM (aorta-gonads- 
mesonephros) region and the yolk sac, which peak on days 10- 11 p. c. and 12p. c. 
respectively. These cells then migrate to and accumulate in the fetal liver, and subse- 
quently colonise the bone marrow (Kumaravelu et al., 2002). Different types of 
myeloid and lymphold progenitors are carried to various organs by the circulation. 
Histological analysis showed that the embryonic distribution of osteoclast progeni- 
tors coincides with the distribution of immature macrophages. In adult animals, os- 
teoclast progenitors are only found in haernatopoietic organs (Thesingh, 1986), and 
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Several lines of evidence have suggested that the osteoclast derives from cells 
in the monocyte/macrophage lineage. The multipotential precursors divert to different 
pathways by the regulation of growth factors secreted by osteoblastic/stromal cells in 
the bone marrow (Shinar et al., 1990). Osteoclasts and macrophage polykaryons are 
both formed by fusion of mononuclear precursors (Zambonin Zallone et al., 1984), 
and there are several ultrastructural similarities between them. In addition, both os- 
teoclasts and macrophages show trypsin-resistant adherence to a glass or plastic 
substrate (Chambers, 1979). Furthermore, osteoclasts share some immunopheno- 
typic characteristics with monocytes and macrophages. Tsurukai et al. reported that 
osteoclast precursors are positive for Mac-1, Mac-2 and Gr-1, but negative for 
F4/80, B220 and CD3e (Tsurukai et al., 1998). Niida et al. also showed that both 
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preosteoclasts and osteoclasts highly expressed Mac-2, but not MOMA-2, Mac-1, 
F4/80 or BN18 (Niida et al., 1994). 
In vivo experiments showed that the mononuclear cells that initially attached 
to the bone surface contained non-specific esterase, a macrophage marker. These cells 
expressed TRAP after they differentiated, and eventually lost their non-specific es- 
terase activity and formed multinucleated osteoclasts (Baron et al., 1986). Many in 
vitro studies showed that osteoclasts can be generated not only from immature non- 
adherent M-CSF-dependent bone marrow cells (Quinn et al., 1998c), but also from 
monocytes, resident peritoneal or alveolar macrophages and tumour-associated 
macrophages (Fuller and Chambers, 1998). Takahashi et al. reported that postmitotic 
osteoclast precursors are mononuclear phagocytes expressing some of the macro- 
phage phenotypes, including NSE, Mac-1 and Mac-2 but not 174/80, some of which 
disappear during differentiation into osteoclasts (Takahashi et al., 1994). In addition, 
osteoclasts can be induced from several clonal macrophage cell lines (Huang et al., 
2000; Miyamoto et al., 1998). Lean et al. demonstrated that functional TRAP posi- 
tive multinucleated cells can be induced from F4/80 and Fc receptor positive macro- 
phage cell lines after infected with RANKL-expressing retrovirus (Lean et al., 2000). 
Although osteoclasts share some cell surface markers with macrophages, they 
also express high levels of TRAP, vitronectin and calcitonin receptors that are absent 
in macrophages. Most importantly, osteoclasts cultured ex vivo are able to resorb 
bone within hours, whereas macrophages cannot (Chambers and Horton, 1984). 
These data demonstrate that osteoclasts and macrophages are two different cell types 
in spite of all these similarities. 
Even though it is well established that osteoclasts and macrophages are derived 
from the same progenitors, how osteoclast precursors diverge from the macrophage 
lineage is not fully understood. It has been reported that osteoclasts derive from im- 
mature c-Kit' haematopoietic cells and pass through a c-fms-dependent stage at some 
point during differentiation (Hayashi ct al., 1997; Sudo et al., 1995). Early osteoclast 
precursors are c-Kit-'Mac-ld"lc-Fms+ cells. These cells express RANK after M-CSF 
stimulation, and differentiate into osteoclasts in the presence of RANKL and M- 
CSF, but differentiate into macrophages with M-CSF only. RAW cells differentiate 
into osteoclasts more efficiently than RANW, as their proliferative activity is higher 
(Arai et al., 1999). Takeshita et al. demonstrated that early osteoclast progenitors in 
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bone marrow are mainly populated from Mac- I T4/80dull cells which differentiate into 
M-CSF-dependent bone marrow macrophages (the osteoclast progenitors) expressing 
Mac- I +F4/80intermediate in response to M-CSF stimulation (Takeshita et al., 2000). 
Taken together, osteoclasts and macrophages are derived from the same haema- 
topoietic progenitors, but differentiate into specific cell lineages in response to differ- 
ent stimuli. 
1.5.2 Factors that affect osteoclast formation and function 
Osteoclast differentiation and activation are tightly controlled in vivo by cellu- 
lar and hormonal factors. Tablel. 1 summarises the effects of the systemic and local 
factors on osteoclast formation and function. 
Table 1.1 Factors regulating osteoclast formation and function 
Factors Formation Resorption References 
Systemic hormones 
PTHTTHrP increase increase (Chambers ct al., 1985b; thara et al., 2001) 
increase/ (Kurihara and Roodman, 1990; Sakai ct al., 2001; Shibata ct 
Calcitriol decrease increase al., 2002) 
calcitonin decrease decrease (Chambcrs and Magnus, 1982; Gorn et al., 1995) 
estrogen decrease decrease (Manolagas, 2000) 
PGE2-mouse increase increase (Takahashi ct al., 1988b) 
human decrease decrease (Chenu et al., 1990) 
Local factors 
F-, kN &L increase increase 
M-CSF decrease increase 
TNF-a increase increase 
IL-1 increase increase 
IL-6 increase increase 
IL-11 increase increase 
TGF-A-direct increase increase 
indirect decrease decrease 
OPG decrease decrease 
IFN-y decrease decrease 
IL-3 decrease decrease 
IL-4 decrease decrease 
IL-18 decrease decrease 
Nitric oxide decrease 
(Fuller ct al., 1998; Lacey et al., 1998) 
(Fuller et al., 1993; Udagawa ct al., 1999) 
(Fuller et al., 2002; Lam et al., 2000) 
(Azuma et al., 2000; Fuller et al., 2002) 
(Devlin et al., 1998; Poli et al.. 1994) 
(Ahlcn et al., 2002; Quinn ct al., 2000) 
(Fuller et al., 2000b; Koscki et al., 2002) 
(Chenu et al., 1988; Hughes et al., 1996; Takai et al., 1998) 
(Fuller et al., 1998; Lacey et al., 1998) 
(Fox and Chambers, 2000; Gowen and Mandy. 1986) 
(Shinar ct al., 1990) 
(Nakano et al., 1994; Riancho et al., 1993) 
(Horwood et al., 1998b) 
(Brandi et al., 1995) 
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Among these factors, M-CSF and RANKL are indispensable for osteoclasto- 
genesis (Fig. 1.7)(Adapted from Kong et al., 2000). In the bone microenvironment, the 
relative ratio of RANKL: OPG is more important than the concentration of R-ANKL 
per se in osteoclast differentiation (Hofbauer et al., 2000). 
Myeloid osteoclast Mature 













Figl. 7 Regulation of osteoclast differentiation and function 
1.5.2.1 Macrophage Colony Stimulating Factor (M-CSF) 
Macrophage Colony Stimulating Factor (M-CSF), also called CSF-1, is one of 
the Colony Stimulating Factors (CSFs). CSFs are haernatopoietic growth factors that 
induce the clonal growth of haernatopoietic progenitors both in vitro and in vivo. M- 
CSF is synthesised as a secreted or membrane-bound protein by macrophages and 
stromal cells, endothelial cells and T lymphocytes in the bone marrow microenviron- 
ment. The M-CSF receptor, encoded by the proto-oncogene c-fms, is a transmem- 
brane glycoprotein with ligand-induced tyrosine kinase activity (Sherr et al., 1985). 
The fact that c-fms is expressed by osteoclast precursors and mature osteoclasts 
suggests that M-CSF may affect osteoclast formation and function directly 
(Hofstetter et al., 1992; Weir et al., 1993). 
The essential role of M-CSF in osteoclastogenesis is unequivocally demon- 
strated in mice lacking M-CSF. Mice deficient in M-CSF, named oplop mice which 
have a point mutation in the coding region of M-CSF gene, develop osteopetrosis due 
to a deficiency of osteoclast (Begg et al., 1993; Yoshida et al., 1990). These mice also 
have reduced numbers of monocytes and macrophages. When osteoblasts from oplop 
mice cocultured with wild type spleen cells, no osteoclasts were induced without 
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exogenous M-CSF. Osteoclasts were generated in the coculture of wild-type os- 
teoblasts and spleen cells from oplop n-fice (Takahashi et al., 1991 a). These data sug- 
gest that the haematopoictic stem cells in oplop mice were not affected, and the os- 
teopetrosis was due to the defect of M-CSF production in osteoblasts. A single injec- 
tion of M-CSF into oplop mice cured the skeletal sclerosis (Sundquist et al., 1995), 
and also restored the development of molar tooth germs and led to tooth eruption 
(Kodama et al., 1991). Multiple injections of M-CSF are required for the recruitment 
of macroPhages in the bones (Niida et al., 1994). The observation that during skeletal 
development, the transcription of M-CSF is spatiotemporally related to osteoclast 
recruitment and formation (Hofstetter et al., 1995), further confirmed that M-CSF is 
necessary for osteoclast differentiation. 
M-CSF stimulates both the proliferation and differentiation of osteoclast pre- 
cursors. M-CSF-dependent bone marrow cells formed numerous osteoclasts when 
cocultured with osteoblasts in the presence of 1,25(OH)2D3 (Takahashi et al., 
199 1 b). Osteoclastogenesis was significantly reduced by an anti-c-Fms antibody at 
later stages of differentiation in embryonic stem (ES) cell and in a stromal cell cocul- 
ture system (Yamane et al., 1997). In a human bone marrow culture system, addition 
of M-CSF enhanced osteoclast formation and bone resorption in a dose- and time- 
dependent manner in the presence of 1,25(OH)2D3 (Sarma and Flanagan, 1996). 
In addition to its effects on osteoclast precursors, M-CSF also affects mature 
osteoclasts. M-CSF stimulated bone resorption of primary osteoclasts isolated from 
rabbit by increasing the average size of osteoclasts (Lees and Heersche, 1999). How- 
ever, Corboz et al. reported that M-CSF stimulated bone resorption by increasing the 
number of osteoclasts in a bone explant experiment (Corboz et al., 1992). Recently, it 
was identified that M-CSF also Plays a role in maintaining the survival and chemotac- 
tic behaviour of mature osteoclasts. M-CSF prevented osteoclast apoptosis, en- 
hanced motility, and inhibited bone resorption (Fuller et al., 1993; Hattersley et al., 
1988; Udagawa et al., 1999). 
It was reported that osteopetrosis in oplop mice improved with age, suggesting 
that M-CSF is required for early osteoclast development, but other cytokines can 
compensate the effects at later stage (Begg et al., 1993; Nilsson et al., 1995). Recent 
experiments showed that vascular endothelial growth factor (VEGF) is one of the 
candidates. One single injection of VEGF induced osteoclasts recruitment in oplop 
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mice similar to M-CSF (Niida et al., 1999). Osteoclasts predominantly express 
VEGF receptor I (VEGFR-1), and VEGF increased bone resorption of primary os- 
teoclasts in a dose-dependent manner in vitro, partially by prolonging their survival 
(Nakagawa et al., 2000). In addition, VEGF also plays an important role in osteoclast 
recruitment during embryonic bone development, as soluble VEGF receptor inhibited 
osteoclast invasion into hypertrophic cartilage (Engsig et al., 2000). 
SHP-1, Src-hornology domain-2 phosphatase I (SHP-1) (also known as haerna- 
topoictic cell phosphatase, PTP-IC, src homology PTP-1, or PTP nonreceptor type 
6), is a cytoplasmic protein-tyrosine phosphatase (PTP). It has been reported that 
SHIM is a negative regulator of M-CSF signalling in osteoclast. The mothcaten 
(mev) mutation resulted in a partial loss of SHP-I catalytic activity and led to osteo- 
porosis in mice. The double homozygous mevImeloplop mice displayed less severe 
osteopetrosis than oplop mice. TRAP positive mononuclear cells were present on the 
endosteal surface of double mutant long bones, suggesting that M-CSF-independent 
mechanisms for osteoclastogenesis might be present in melme'loplop mice to com- 
pensate for the absence of M-CSF (Umeda et at., 1999). 
1.5.2.2 Receptor Activator of NF-jcB Ligand (RANKL) 
Receptor activator of NF-KB ligand (RANKL), also named ODF (osteoclast 
differentiating factor) was found by screening a cDNA expression library of ST2 cells 
treated with 1,25(OH)2D3 and Dexamethasone using OPG as a probe (Lacey et al., 
1998; Yasuda et al., 1998b). It is identical to TRANCE (TNF-related activation- 
induced cytokine), and osteoprotegrin (OPG) ligand, which were cloned as factors 
regulating T-cell and dendritic-cell functions (Anderson et al., 1997; Wong et al., 
1997a). RANKL is a type 11 transmembrane protein, and belongs to the TNF ligand 
family. It was reported that RANKL is present in both membrane-bound and soluble 
forms (Lacey et al., 1998), and it can be released from the cell surface by a metallo- 
proteinase (Lurn et al., 1999). RANKL is expressed by a number of different cell 
types. The highest mRNA levels are in trabecular bone and lymphoid tissues (Wong 
et al., 1997a; Wong et al., 1997b; Yasuda et al., 1998b). In bone tissues, during mouse 
embryogenesis, RANKL mRNA is expressed in prehypertrophic and hypertrophic 
chondrocytes. In newborn and adult mouse, high levels of RANKL mRNA are ex- 
pressed in mesenchymal cells of the periosteum and mature osteoblasts. Unexpect- 
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edly, osteoclasts within resorption lacunae show strong RANKL expression 
(Kartsogiannis et al., 1999). Osteoblast/stromal cell lines that could support osteo- 
clast formation in cocultures also express RANKL (Lacey et al., 1998). 
RANKL mediates the cell-to-cell signals responsible for osteoclastogenesis 
(Yasuda et al., 1998a). RANKL acts directly on osteoclast precursors and stimulate 
osteoclastogenesis. In the presence of M-CSF, RANKL is sufficient to support os- 
teoclast differentiation in vitro from human peripheral blood mononuclear cells, 
mouse bone marrow and spleen cells and macrophage cells lines in the absence of 
osteoblast/stromal cells (Lacey et al., 1998; Matsuzaki et al., 1998; Quinn et al., 
1998a; Yasuda et al., 1998b). RANKL also plays an important role in osteoclast 
activation and survival. RANKL stimulated bone resorption of mouse and rat mature 
osteoclasts in vitro (Burgess et al., 1999; Lacey et al., 1998). Injection of RANKL 
into normal mice induced systemic hypocalcaemia (Burgess et al., 1999). RANKL 
activates mature osteoclasts to resorb bone by inducing pseudopodial motility, 
spreading and actin ring formation (Burgess et al., 1999; Fuller et al., 1998; Udagawa 
et al., 1999). It was also reported that RANKL stimulated cathepsin K mRNA level 
in primary and cultured osteoclasts, which led to enhanced bone resorption (Corisdeo 
et al., 200 1). RANKL enhances osteoclast survival by inhibiting apoptosis (Fuller ct 
al., 1998; Jimi et al., 1999a; Udagawa et al., 1999). 
Targeted deletion of RANKL in mice led to severe osteoPetrosis with no os- 
teoclasts and impaired tooth eruption (Kong et al., 1999b). Transgenic overexpres- 
sion of RANKL in lymphocytes of RANKL-deficient mice only partially rescued the 
osteopetrosis. The mice exhibited sclerotic metaphyses, unerupted teeth and growth 
plate defects (Kim et al., 2000). 
RANKL also plays an important role in the immune system. A soluble form of 
RANKL containing only the extracellualr domain activates c-Jun N-tenninal kinase 
(JNK) specifically in T cells (Wong et al., 1997b). It also mediates survival of den- 
dritic cells in the immune system (Anderson et al., 1997; Kong et al., 1999d; Wong et 
al., 1999b; Wong et al., 1997a). RANKL knockout mice have immunologic abnormali- 
ties including defects in early differentiation of T and B lymphocytes and a lack of 
lymph nodes (Kong et al., 1999b). The level of RANKL is increased in many immune 
diseases, such as rheumatoid arthritis (Kong et al., 1999a; Kong et al., 1999b). In 
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addition, sRANKL has been found in lymphocyte supernatants (Kong et al., 1999b). 
This may explain the bone loss seen in many diseases, e. g. rheumatoid arthritis, that 
involves the immune system. 
1.5.2.3 OPG 
OPG (osteoprotegrin)/ OCIF (osteoclastogenesis inhibitory factor) was identi- 
fied by two groups (Simonet et al., 1997; Tsuda et al., 1997; Yasuda et al., 1998a). It 
was identified as a novel member of the TNF- receptor (TNF-R) superfamily during 
a sequencing project of rat intestinal cDNA (Simonet et al., 1997), and as a heparin- 
binding basic glycoprotein purified from conditioned medium of human embryonic 
lung fibroblasts (Tsuda et al., 1997). OPG contains no hydrophobic transmembrane- 
spanning sequence, indicating that it is a soluble receptor (Simonet et al., 1997; Tan et 
al., 1997). OPG is produced by most cell types in bone marrow microenvironment. 
OPG acts as a decoy receptor for RANKL and inhibits osteoclastogenesis both 
in vivo and in vitro by preventing RANKL binding to RANK, the real receptor on 
osteoclast precursors (Lacey et al., 1998). OPG blocked osteoclast formation induced 
by RANKL-exprcssing stromal cell lines in the presence of 1,25(011)2D3, and inhib- 
ited 1,25(OH)2D3,, PTH and IL-1 I stimulated osteoclast formation in cocultures 
(Tsuda et al., 1997). OPG blocked RANKL-induced osteoclastogenesis in a dose- 
dependent manner in vitro. It suppressed ovariectomy-induced bone loss in rat, and 
injection of OPG into animals increased bone mass and suppresses osteoclastic bone 
resorption (Simonet et al., 1997; Yasuda et al., 1998a). 
Overexpression of OPG in mice resulted in severe osteopetrosis due to an ar- 
rest of osteoclast differentiation, but with normal tooth eruption and bone elongation 
(Simonet et al., 1997). Detailed histological analysis showed that overexpression of 
OPG specifically inhibits osteoclast differentiation and activation at the endosteal 
bone surface, but not the periostcal bone surface (Min et al., 2000). Mice in which 
the OPG gene has been disrupted develop severe osteoporosis due to enhanced os- 
teoclastogenesis (Bucay et al., 1998; Mizuno et al., 1998), which can be rescued by 
injection of recombinant OPG or transgenic overexpression of OPG (Min et al., 
2000). Furthermore, OPG deficiency led to an increased vascular calcification in the 
aorta and renal arteries, a phenomenon also seen in human osteoporosis, suggesting a 
role of OPG in preventing these arteries from pathological calcification. Osteoblasts 
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from OPG-deficient mice had higher potential to support osteoclast differentiation in 
vitro, although the level of RANKL mRNA expression was similar to the wild-type 
(Udagawa et al., 2000). 
In addition to its capacity to inhibit osteoclastogenesis, OPG inhibits osteo- 
clastic bone resorption (Fuller et al., 1998; Hakeda et al., 1998) by disrupting the 
formation of F-actin rings (Burgess ct al., 1999) and inhibits osteoclast survival in 
vitro (Lacey et al., 2000). In addition to RANK, OPG also binds to turnour necrosis 
factor-released apoptosis-inducing ligand (TRAIL) (Emery et al., 1998), which 
doesn't bind RANK. OPG inhibits TRAIL-induced apoptosis of Jurkat cells, and 
TRAIL blocks the anti-osteoclastogenic activity of OPG. 
1.53 Regulatory factors for osteoclast formation and function 
Most factors that regulate osteoclast fonnation and ftinction act indirectly by 
binding to stromal. cells and osteoblasts, which in turn modulate the expression of 
RANKL and OPG (Hofbauer et al., 1998; Horwood et al., 1998a; Udagawa et al., 
1999; Yasuda et al., 1998b). Table 1.2 summarises the effect of hormones and cyto- 
kines on RANKL and OPG expression. 
Table 1.2 Factors that modulate RANICI, and OPG exvression 
RANKL OPG References 
Hormones 
Dexamethasone stimulate inhibit (Hofbauer et aL, 1999a; Vidal et al., 1998) 
stimu- 
Vitamin D3 stimulate late/inhibit (Hofbauer et al., 1998; Horwood et al., 1998a) 
PTIMWP stimulate inhibit (Yasuda et al., 1998b) 
Estradiol No change stimulate (Hofbauer et al., 1999b) 
(Brandstrom et al., 1998a; Murakami et al., 1998) 
Prostaglandin E2 stimulate inhibit 
Glucocorticoid stimulate inhibit (Huang et al., 2001) 
Cytokines 
TNF-a stimulate stimulate 
(Brandstrom et al., 1998b; Hofbauer et al., 1999c) 
IL-1 stimulate stimulate (Kwon et al., 1998; Vidal et al., 1998) 
IL-6 stimulate ? (Menaa et al., 2000) 
IL-I I stimulate ? (Ahlen et al., 2002) 
IL-17 stimulate ? (Kermanac et al., 2002) 
Growth factors 
TGF-P inhibit stimulate (Murakami et al., 1998; Takai et al., 1998) 




Metabolites of vitamin D3 are potent stimulators of osteoclastic bone resorp- 
tion and osteoclast formation. The most active metabolite, 1,25(OH)2D3, acts as a 
fusigen for committed osteoclast precursors (Kurihara and Roodman, 1990). Mice 
treated with 1,25(OH)2D3 developed hypocalcaernia (Abe et al., 1989). On the other 
hand, mice lacking vitamin D receptor (VDR) developed normally up to 3 weeks, but 
exhibited a marked increase in osteoid tissues in the primary spongiosa at 7 weeks, 
with abundant osteoclasts present on bone surfaces. Spleen cells from VDR-1- mice 
were able to form osteoclasts when cultured with wild type ostcoblasts in the pres- 
ence of 1,25(OH)2D3- In contrast, osteoblasts from VDR-1- mice failed to support 
osteoclast formation from wild-type spleen cells in the presence of 1,25(OH)2D3. 
which could be rescued by PTH or IL-1, suggesting 1,25(OH)2D3 regulates osteoclast 
development indirectly by osteoblasts and the actions of 1,25(OH)2D3 on osteoclas- 
tic bone resorption can be compensated by other osteotropic factors (Takeda et al., 
1999). The mouse RANKL promoter contains a vitamin D responsive element and 
transient transfection studies showed that treatment of ST2 stromal cells with 
1,25(OH)2D3 upregulates RANKL gene expression at the transcriptional level, sug- 
gesting that RANKL is a direct 1,25(OH)2D3 target gene (Kitazawa and Kitazawa, 
2002; Kitazawa et al., 1999). Yasuda et al. (Tsukii et al., 1998) reported that 
1,25(OH)2 D3 induced RANKL expression by osteoblasts. 1,25(OH)2D3 also in- 
creased the expression level of M-CSF in human bone marrow cultures (Sarma and 
Flanagan, 1996). Furthermore, 1,25(OH)2D3 enhances osteoclastic bone resorption 
stimulated by parathyroid hormone. However, it was also reported that 1,25(OH)2D3 
in vivo inhibited ovariectomy-induced bone resorption by suppressing osteoclasts 
formation (Sakai et al., 2001; Shibata et al., 2002). 
It is unknown whether 1,25(OH)2D3 acts on mature osteoclasts directly, al- 
though mature osteoclasts have been shown to express vitamin D receptors (Menaa 
and Roodman 1997). In murine stem cells, 1,25(OH)2D3 downregulated c-fms (the 
receptor for M-CSF) expression in early monocytic precursors, but upregulated ex- 





Calcitonin is a polypeptide hormone secreted by the parafollicular cells of the 
thyroid gland. It regulates calcium homeostasis by inhibiting osteoclastic bone resorp- 
tion and by enhancing calcium excretion by the kidney (Warshawsky et al., 1980). 
Calcitonin inhibits both osteoclast formation and the bone-resorbing capacity of ma- 
ture osteoclasts (Chambers et al., 1985b; Lee et al., 1995). The physiological effects 
of calcitonin are mediated by high affinity calcitonin receptors (CTR). Calcitonin acts 
directly on osteoclasts by binding to CTR, then activates adenylate cyclase activity 
and induces cAMP accumulation, resulting in immobilisation of the osteoclast and 
contraction of the osteoclast away from the bone surface (Chambers and Magnus, 
1982; Gorn et al., 1995). Calcitonin also inhibits osteoclast secretory activity, par- 
ticularly of TRAP (Yumita et al., 1991). It downregulates global transcriptional ac- 
tivity of resorbing osteoclasts in vitro, which was reversible (Boissy et al., 2002). 
Osteoclasts continuously exposed to calcitonin can escape the effects of calci- 
tonin (Wada et al., 1997). In neonatal mouse calvarial and adult bone marrow cultures, 
CTR mRNA expression was constitutively present and was markedly decreased after 
calcitonin treatment Qkegarne et al., 1996; Lee et al., 1995). The mechanism responsi- 
ble for this ligand-induced desensitisation is unclear, but it is consistent with classical 
receptor desensitisation processes observed with other polypeptide hormones, such 
as PTH. It has been shown that calcitonin downregulated CTR gene expression on the 
surface of osteoclasts by a transcriptional mechanism (Inoue et al., 1999; Lee et al., 
1995; Rakopoulos et al., 1995). Besides the inactivation effect on osteoclasts, calci- 
tonin promotes osteoclast survival by delaying the onset of apoptosis (Selander et 
al., 1996). 
1.5.3.3 Estrogen 
Estrogen is one of the major inhibitors of osteoclast formation. In humans, loss 
of estrogen after menopause results in a progressive reduction of bone mass and 
causes osteoporosis. Estrogen replacement therapy improves postmenopausal os- 
teoporosis (Jilka et al., 1992; Kimble et al., 1996; Pacifici, 1996). In rodents, osteo- 
elastic bone resorption and osteoclast formation were increased after ovariectomy. 
It is well known that estrogen deficiency induces bone resorption by enhancing 
osteoclast formation, reducing osteoclast apoptosis and increasing osteoclast activity 
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(Manolagas, 2000). Estrogen increases OPG expression, and decreases M-CSF and 
RANKL expression in osteoblastic cells (Hofbauer et al., 2000; Pacifici, 1996; Shevde 
et al., 2000). It suppresses RANKL-induced osteoclast formation through a repres- 
sion in the level and functional activity of c-Jun (Shevde et al., 2000). In addition, 
estrogen inhibits osteoclastic bone resorption in vivo by downregulating the expres- 
sion of proinflammatory cytokines, such as IL-6, IL-1, TNF-a and PGE2. Estrogen 
promoted osteoclasts apoptosis mediated by TGF-P in coculture system (Hughes et 
al., 1996). It was also reported that estrogen suppresses osteoclastogenesis by inhib- 
iting T cell production of TNF-a in ovariectornised mice (Cenci et al., 2000). 
Although osteoblasts are the effectors for estrogen action, Oursler and cowork- 
ers demonstrated that osteoclasts also contain estrogen receptors (Oursler et al., 
1991). Estrogen inhibited osteoclast formation from rat haernatopoietic precursors in 
the presence of M-CSF and RANKL, suggesting that estrogen has a direct effect on 
osteoclast precursors (Gyda et al., 2001). 
1.5.3.4 Interleukin 1 (IL-1) 
Interleukin 1 (IL-1) is a cytokine produced by monocyte-macrophages and 
marrow stromal cells and osteoblasts. It is one of the most potent stimulators of bone 
resorption (Thomson et al., 1986). IL-1 induces bone resorption and osteoclast-like 
cell formation in murine and human marrow cultures (Gowen et al., 1983; 
Pfeilschifter et al., 1989). 
IL-1 affects all stages of osteoclast development (Uy et al., 1995). It stimulates 
proliferation of osteoclast precursors (Pfeilschifter et al., 1989) and it induces the 
multinucleation of prefusion osteoclasts and bone-resorbing activity even in the ab- 
sence of osteoblasts/stromal cells (Jimi et al., 1999b; Jimi et al., 1998). TNF-oE- 
induced osteoclasts resorb bone only in the presence of IL-1 (Kobayashi et al., 2000). 
IL-I enhances the survival of osteoclasts in vitro by activation of NF-xB (Jimi et al., 
1999a; Jimi et al., 1998). Proteasome inhibitors, which inhibit NF-KB activation by 
preventing IKB degradation, and antisense oligonucleotides to NF-xB, suppressed IL- 
la induced osteoclast survival. However, Miyazaki et al. reported that IL-la sup- 
ports osteoclast survival by inducing ERK activity, and stimulates resorption by NF- 
KB activation (Miyazaki et al., 2000). It has been reported that IL-1 can replace 
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RANKL to induce fusion, activation and survival, but not differentiation of osteo- 
clasts (Suda et al., 1999). 
IL-1 enhances osteoclastogenesis indirectly via ostcoblastic cells (Thomson et 
al., 1986). It induces the expression of other cytokines, which stimulate osteoclast 
differentiation, such as IL-6, M-CSF and RANKL (Elias and Lentz, 1990; Felix et al., 
1989; Kwon et al., 1998; Vidal et al., 1998). IL-1 is suggested to play an important 
role in several pathological conditions associated with increased bone loss, such as 
postmenopausal osteoporosis, rheumatoid arthritis, Paget's disease and tumours 
(Fried et al., 1989; Kitazawa et al., 1994; Mino et al., 1998; Pioli et al., 1989; Sato et 
al., 1989). 
1.5.3.5 Tumour Necrosis Factor-a (TNF-a) 
Tumour Necrosis Factor-a (TNF-cc) is a member of the tumour necrosis factor 
ligand superfamily. It is a multifunctional proinflammatory cytokine regulating cell 
proliferation, differentiation and apoptosis in various types of cells (Ashkenazi and 
Dixit, 1999). TNF-(x plays an important role in host defence mechanisms, including 
the induction of macrophage cytocidal activity. It has been reported that TNF-a 
plays an important role in bone resorption of inflammatory bone diseases, such as 
periodontal disease (Abu-Amer et al., 1997) and rheumatoid arthritis (Keffer et al., 
1991; Redlich et al., 2002). TNF-a also mediates bone loss in estrogen deficiency 
osteoporosis (Kimble et al., 1997; Kimble et al., 1996). 
TNF-a affects osteoclasts both directly and indirectly. TNF-a stimulates os- 
teoclast differentiation and function by inducing M-CSF and RANKL expression in 
osteoblasts (Hofbauer et al., 1999c; Yao et al., 2000). Thomson et al. showed that IL- 
1 or TNF-a stimulated bone resorption in a coculture system of mature osteoclasts 
and osteoblastic cells (Thomson et al., 1987). However, several recent studies 
showed that TNF-a stimulates osteoclastogenesis and activation directly. TNF-(x 
augmented osteoclast formation induced by RANKL in a dose-dependent manner 
(Lam et al., 2000), and promoted actin ring formation and bone resorption of both 
primary osteoclasts and osteoclasts induced in vitro (Fuller et al., 2002). TNF-a and 
RANKL synergistically upregulated RANK expression in osteoclast precursors 
(Zhang et al., 2001). It was also reported that TNF-a stimulated bone marrow 
macrophages to differentiate into functional osteoclasts even in the absence of 
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RANKL (Kobayashi et al., 2000). The bone resorptive function of TNF-a-induced 
osteoclasts was enhanced by IL-I without an increase in the number of osteoclasts 
(Azuma et al., 2000; Fuller et al., 2002). However, Kobayashi et al. reported that the 
bone resorption was induced only in the presence of IL-1 (Kobayashi et al., 2000). In 
contrast, Lam et al. showed that TNF-cc alone failed to induce osteoclast formation at 
any concentration, but potentiated osteoclastogenesis from osteoclast precursors 
exposed to permissive levels of RANKL (Lam et al., 2000; Zhang et al., 2001). 
TNF-a exerts its biological effects by binding to its two receptors present on 
osteoclast precursors: TNF receptor I (p55r) and 2 (p75r). P55r is the major form 
involved in osteoclast differentiation. The osteoclastogenesis induced by TNF-a was 
completely inhibited by an anti-p55r antibody and partially inhibited by an anti-p57r 
antibody (Azuma et al., 2000; Kobayashi et al., 2000). T cells from ovariectomised 
mice lacking TNF-a receptor p55 failed to augment RANKL-induced osteoclasto- 
genesis (Cenci et al., 2000). Osteoclast formation induced by RANKL and the en- 
hanced effect of TNF-cE were both decreased in bone marrow cultures from p55, but 
not p75 knockout mice (Zhang et al., 2001). The activation of licB, NF-KB, ERKs 
and c-Jun/AP-1 was reduced in p55 deficient precursors. Soluble TNF-a binds pri- 
marily to p55r, while membrane bound TNF-ct targets both receptors (Abu-Amer et 
al., 2000). After interaction with the ligand, both receptors transduce intracellular 
signals and stimulate the proteolytic breakdown Of IKB, which is a cytoplasmic in- 
hibitor of NF-KB. The activated NF-icB is then translocated into the nucleus and 
induces the transcription of TNF-a responsive genes (Kruppa et al., 1992; Verma et 
al., 1995). It was also suggested that TRAF-6 is involved in TNF-(x-induced osteo- 
clastogenesis, as much less osteoclasts were induced from TRAF-6-deficient haema- 
topoietic precursors in the presence of TNF-oE (KaJi et al., 2001). 
1.5.3.6 Interferon gamma (IFN-y) 
Interferon gamma (IFN-y) is cytokine secreted by activated T cells. It is a po- 
tent inhibitor of bone resorption (Gowen and Mundy, 1986; Takahashi et al., 1986). 
Injection of IFN-y suppresses the formation of osteoclasts in vivo, resulting in de- 
creased plasma calcium concentrations (Tohkin et al., 1994). Mice lacking one of the 
IFN-y receptor components (IFNGRI) (IFN-yR-1-) developed exacerbation of osteo- 
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clast formation and bone destruction. Collagen-induced arthritis in IFN-yR-1- mice 
developed earlier and had more severe bone destruction than normal mice (Manoury- 
Schwartz et al., 1997; Vermeire et al., 1997). IFN-y directly suppresses both 
RANKL and TNF-(x induced osteoclast formation and maturation (Fox and Cham- 
bers, 2000; Takahashi et al., 1986; Takayanagi et al., 2000). It primes macrophages 
for cytocidal activation by TNF-ot (Fox et al., 2000). 
The molecular mechanism by which IFN-y acts on osteoclasts is not clear. The 
inhibitory effect of IFN-y on osteoclastogenesis was completely abrogated in STA T1- 
/- mice, but not in IRF-1-1- mice suggesting that IFN-y acts through the GAF (IFN-y- 
activated factor, the active form of Statl)-mediated IRF-1 -independent gene induction 
pathway. The fact that TRAF-6 expression and RANKL-induced activation of NF- 
icB and JNK (see also below) in osteoclast precursors were markedly inhibited by 
IFN-y, and osteoclast precursors overexpressing TRAF-6 were resistant to IFN-y, 
suggests that TRAF-6 is one target gene of IFN-y. It was suggested that IFN-y exerts 
its inhibitory effect by activating the ubiquitin-proteasome pathway after binding to 
its receptor on osteoclast precursors, which causes the degradation of TRAF-6 
(Takayanagi et al., 2000). Interestingly, the TRAF-6 degradation by IFN-y requires 
RANKL signalling, since IFN-y alone has no effect on TRAF6 expression. Thus, 
IFN-y provides a negative link between T-cell activation and bone resorption. 
1.5.3.7 Transforming growth factor-A (TGF-P) family 
The transforming growth factor-P (TGF-P) superfamily, including TGF-Ps, ac- 
tivins and bone morphogenetic proteins (BMPs), regulates cell proliferation, differen- 
tiation and apoptosis of many cell types (Josso and di Clemente, 1997; Moses and 
Serra, 1996). There are three TGF-P isoforms: TGF-P I, -P2 and -P3 expressed in 
mammalian tissues (Fox and Chambers, 2000). TGF-Ps are secreted by osteoblasts 
and osteoclast progenitors, and are present in their latent forms within bone matrix 
(Kaneda et al., 2000; Robcy et al., 1987; Sandberg et al., 1988; Seyedin et al., 1985). 
Active TGF-P is a 25 kD homodimer and contains nine cysteines which must be 




It has been known for a long time that TGF-P is a potent inhibitor of osteoclas- 
tic bone resorption. It modulates osteoclastic bone resorption, migration and osteo- 
clast differentiation in bone organ cultures (Dicudonne et al., 1991). Chenu et al. 
(Chenu et al., 1988) reported that TGF-P inhibits both the proliferation and fusion of 
human osteoclast precursors. TGF-P also increased apoptosis of osteoclasts induced 
in a coculture system in a dose-dependent manner (Hughes et al., 1996). However, 
recent experiments showed that the effects of TGF-P on osteoclastogenesis in vitro 
vary with the model employed. TGF-P enhanced osteoclast differentiation in the 
presence of IL-1 in a coculture system (Koide et al., 1999). It promotes osteoclast 
differentiation induced by sRANKL and M-CSF in the absence of stromal cells 
(Koseki et al., 2002), and suppresses apoptosis in osteoclasts (Fuller et al., 2000b)., 
consistent with the increase in cell size and multinuclearity (Sells Galvin et al., 1999). 
The stimulatory effect was only seen when TGF-P was added at early stages in the 
culture (Fuller et al., 2000b; Quinn et al., 2001). TGF-P also strongly promoted 
TNF-(x induced osteoclast-like cell formation in the absence of RANKL in vitro (Fox 
et al., 2000; Quinn ct al., 2001). As a macrophage deactivator, TGF-P may promote 
osteoclast formation by directing TNF-a activated precursors towards the osteoclast 
lineage (Fox et al., 2000; Fuller et al., 2000b). 
TGF-P represents one growth factor that can either inhibit or stimulate osteo- 
clast differentiation via different mechanisms. In the coculture system, TGF-P inhib- 
its osteoclastogenesis by upregulating OPG expression and downregulating RANKL 
expression in osteoblastic and stromal cells (Murakami et al., 1998; Quinn et al., 
2001; Takai et al., 1998). However, in the absence of ostcoblasts/stromal cells, TGF- 
P may act directly on osteoclast progenitors (Sells Galvin et al., 1999), as osteoclast 
precursors express TGF-P receptors (Kaneda et al., 2000). Antibodies against TGF- 
P blocked osteoclastogenesis in vitro (Kaneda et al., 2000), suggesting that endoge- 
nous TGF-P is required for osteoclast differentiation. 
TGF-P is one of the key factors involved in coupling bone formation to previ- 
ous bone resorption. Bone matrix is one of the major storage sites for TGF-Ps. Dur- 
ing bone remodelling, TGF-P is released by bone lining cells and osteoclastic bone 
resorption, and modulates bone formation and resorption. Transgenic mice overex- 
pressing cytoplasmically truncated type II TGF-P receptors using an osteocalcin 
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promoter had an age-dependent increase in bone mass with lower levels of osteolysis 
(Filvaroff et al., 1999). The defect was due to the imbalance between bone formation 
and bone resorption, as the rate of osteoblastic bone formation was not altered, but 
the number and activity of osteoclasts were decreased. On the other hand, transgenic 
mice overexpressing TGF-, 82 using an osteocalcin promoter developed age-dependent 
high turnover osteoporosis with increased osteoblastic matrix deposition and osteo- 
clastic bone resorption (Erlebacher and Derynck, 1996). Detailed analysis showed 
that TGF-P2 directly stimulates osteoblast differentiation, while the increased min- 
eral apposition rate depended on osteoclastic activity. Also, at sites undergoing active 
bone remodelling, the TGF-P2-induced increase in osteoblast differentiation was 
enhanced by osteoclast activity (Erlebacher et al., 1998). 
Activin A is another member of TGF-P superfamily. It is a cytokine produced 
by bone marrow stromal cells, osteoblasts and osteoclasts and is abundantly present 
in bone matrix. Activin A enhances osteoclastogenesis induced by RANKL similarly 
to TGF-P in vitro (Fuller et al., 2000a). 
The TGF-P superfamily acts through heteromeric complexes of type I and 
type 11 serine/threonine kinase receptors. The intracellular signalling downstream of 
these receptors is mediated by the Smad family. Smad2 and Smad3 are specifically 
involved in TGF-P and activin signalling pathways, and form hcteromcric complexes 
with the common Smad, Smad4. Following nuclear translocation, Smads induce tran- 
scriptional activation of specific target genes through cooperation with other tran- 
scriptional factors (ten Dijke et al., 2000). TGF-P and activin A enhance RANKL 
induced osteoclast formation by upregulating JunB expression (Koseki et al., 2002). 
TGF-P may also synergistically increased the translocation of NF-ICB into nuclei 
induced by RANKL in osteoclast precursors (Kaneda et al., 2000). 
1.5.4 Role of bone marrow microenvironment in osteoclast development and 
function 
It has been known for many years that stromal cells or osteoblasts are required 
for osteoclast differentiation from haernatopoietic precursors both in vivo and in 
vitro. When osteoblastogenesis is absent, as in Cbfa-I knockout mice, osteoclasto- 
genesis is impaired (Ducy et al., 1997; Komori et al., 1997). Osteoclast precursors 
recognise signals expressed -by osteoblasts/stromal cells in response to osteotropic 
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factors and differentiate into osteoclasts. Cell-to-cell contact between os- 
teoblasts/stromal cells and haernatopoietic cells was indispensable for osteoclast 
differentiation (Takahashi et al., 1988b), since it was reported that when osteoclast 
precursors and stromal cells were separated by a semi-permeable membrane in the 
coculture system, no osteoclasts formed, and most of the cells were 174/80-positive 
macrophage-like cells (Tsurukai et al., 1998). Now it is clear that two molecules 
expressed in these cells are essential and sufficient for osteoclastogenesis: M-CSF and 
RANKL (Kodama et al., 1991; Yasuda et al., 1998b). During osteoblast differentia- 
tion, RANKL expression remains constant, while OPG expression is increased after 
the onset of mineralisation resulting in a decreased RANKL/OPG ratio, suggesting 
immature osteoblasts have higher osteoclastogenic potential than mature osteoblasts 
(Thomas et al., 200 1). 
In addition to their expression of M-CSF and RANKL, osteoblasts/stromal 
cells are target cells for osteotropic hormones and cytokines to induce osteoclast 
development. Osteotropic factors e. g. PTH, 1,25(OH)2D3, and prostaglandin E2 act 
indirectly by binding to osteoblasts or marrow stromal cells, which in turn induce 
upregulation of RANKL expression and downregulation of OPG. RANKL then binds 
the RANK receptor on osteoclast precursors and induces osteoclast formation 
(Atkins et at., 2000; Hofbauer and Heufelder, 1998; Itoh et al., 2000; Yasuda et al., 
1998b) (see also above). McSheehy and Chambers showed that when the stimulating 
factors were added directly to isolated osteoclasts, there was no increase in bone 
resorption, but when these agents were added to the osteoblasts and conditioned 
medium was applied, bone resorption was increased (McSheehy and Chambers, 
1986). 
Osteoblasts/bone marrow stromal cells are also required for osteoclast function. 
Highly purified osteoclasts cultured on dentine slices failed to form resorption pits, 
and the resorptive capability of these purified osteoclasts was restored when calvarial 
osteoblasts were added. Several stromal cell lines such as KS-4, MC3T3-G2/PA6, 
and ST2 also potentiated pit-forming activity of enriched osteoclasts. When cell-to- 
cell contact between osteoblasts/stromal cells and osteoclasts was prevented, osteo- 
clasts failed to form resorption pits (Jimi et al., 1996; Suda et al., 1997). 
Other cell types in the bone marrow also have the ability to support osteoclast 
differentiation. The expression of the factors regulating osteoclast differentiation is 
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not restricted to the cells of the osteoblastic lineage. Although similar to the Cbfa-I 
knockout mice, Osx null mice developed only cartilagenous skeleton, functional os- 
teoclasts were still present in the mutant long bone (Nakashima et al., 2002), sug- 
gesting that other cells are synthesising the appropriate osteoclastogenic factors. 
In pathological conditions, immune cells, especially activated T cells, in the 
bone marrow contribute to the regulation of bone resorption. Immune cells produce a 
variety of cytokines, including IL-1, TNF-a, IL-6 and prostaglandins, which have 
been shown to stimulate osteoclast development and activation (Greevic et al., 
2001)(see also below). Evidence also showed that B-lymphoid lineage cells expressed 
RANKL and supported osteoclast formation in vitro. A decrease in B-lymphoid cells 
in klotho mutant mice (KL-I-) led to a decrease in osteoclast numbers, and osteoclast 
formation from KL-1- bone marrow cells are reduced. It was suggested that 13- 
lymphocytes might be involved in the pathophysiology of bone disorders, such as 
osteoporosis (Manabe et al., 2001). 
T lymphocytes have both stimulatory and inhibitory effects on osteoclasto- 
genesis. RANKL was first identified as TNF-related activation-induced cytokine 
(TRANCE), aT cell product upregulated after activation (Wong et al., 1997a). Dur- 
ing inflammation, activated T cells produce RANKL promoting osteoclastic bone 
resorption and bone loss, but at the same time, T cells also release IFN-y and IFN-P 
(see also below) limiting bone destruction (Kong et al., 1999b; Takayanagi et al., 
2000). Activated T cells play a critical role in the bone destruction which occurs in 
inflammatory diseases, such as rheumatoid arthritis, and periodontal disease (Kong et 
al., 1999c). T cells also play an important role in estrogen deficiency induced bone 
loss (Roggia et al., 2001). For example, ovariectomy induced rapid bone loss was 
absent in T-cell deficient mice. 
In conclusion, osteoclastogenesis is tightly controlled by osteoblasts/stromal 
cells in bone marrow microenvironment. However, in pathological conditions, other 
cell types such as lymphocytes, also play an important role in regulating osteoclast 
formation and function which leads to the imbalance between bone formation and 
resorption, and subsequently causes bone destruction. 
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1.6 Model systems for studying osteoclast formation and bone 
resorption 
In order to study the biological and molecular mechanisms involved in osteo- 
clast differentiation and bone resorption, various model systems, both in vivo and in 
vitro, have been established for different purposes. 
Osteopetrotic animal models generated either by targeted disruption of tran- 
scription factors and signalling molecules, or by naturally-occurring mutations, have 
greatly contributed to the understanding of osteoclast biology. Recent studies in 
knockout and transgenic inice have identified a number of genes that are required for 
osteoclast formation and activation, and these are surnmarised in Table 1.3. 
Table 1.3 Animal models of osteopetrosis 
Mutated No. No. RB BMT References 






mi gene N nr 
Osteosclerosis OCI 16 nr mouse (oc/oc) 
Grey-lethal Chromosome 10 Ej 
mouse (gllgl) 
Toothless rat (tl/tl) ? 
Incisor absent rat ? N nr (ia/ia) 
usteopetronc rat Chromosome 10 
(op/op) 
Microphthal mia mib Blanc (mib) rat 
Osteopetrotic (os) ?I 
rabbit 
N no cure (Yoshida et al., 1990) 
A cure (Hodgkinson et al., 1993) 
A No curc (Marks et al., 1985) 
N cure (Rajapurohitam et al., 2001) 
N no cure (Marks et al., 1993) 
A cure (Reinholt et al., 1999) 
nr PD cure (Marks and Popoff, 1989) 
nr PD (Cielinski and Marks, 1995) 
nr nr no cure (Lenhard et al., 1990) 
Induced mutation 
c-sre knockout c-srC N N A cure (Boyce et al., 1992) 
mouse 
c-fos knockout C-fbs A t - cure (Wang et al., 1992) mouse 
NFKB p50/p55 NFKB I t 
- cure (Franzoso et al., 1997) knockout mouse P501PS5 
PU. I knockout 
mouse 
PUA A - cure (Tondravi et al., 1997) 
Abbreviations: A: absent; BMT: bone marrow transplantation; EJ: elicit Macrophage reduced; N: 
normal; nr: not reported; No. Mac: number of macrophages; No. OC: number of osteoclasts; PD: 
poorly developed; RB: ruffled border; t: elevated; 1: reduced; I 11: severely reduced. 
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1.6.1 Mouse osteopetrosis models 
1.6.1.1 PUA 
The transcription factor PU. 1 is encoded by the Spi-IlSfp-l gene, a member of 
the ets proto-oncogene family. It is expressed specifically in the monocytic and B 
lymphoid lineages (Klemsz et al., 1990). The expression of PU. I mRNA increased 
with the induction of o steocl asto genesis by 1,25(OH)2-D3 or Dexamethasone 
(Tondravi et al., 1997). PU. I regulates monocyte/macrophage differentiation, survival 
and proliferation by controlling the expression of c-fins (Klemsz et al., 1990). PU. I 
expression progressively increased as marrow macrophages assumed the osteoclast 
phenotype in vitro. Mice deficient in PU. I lack not only macrophages but also os- 
teoclasts, leading to the development of severe osteopetrosis (Tondravi et al., 1997), 
suggesting that this transcription factor regulates the initial stages of myeloid differ- 
entiation. Bone marrow transplantation rescued the osteopetrosis with complete 
restoration of osteoclast and macrophage differentiation (Tondravi et al., 1997), sug- 
gesting that the defect is intrinsic to haernatopoietic lineage. In vitro studies showed 
that PU. I-/- haernatopoietic progenitors committed to the monocyte lineage, but were 
unable to develop into mature macrophages in the absent of PUA (Klemsz et al., 
1990). To date, PU. 1 is the earliest known marker of osteoclast differentiation as it 
controls early myeloid cell differentiation, which includes macrophages and osteo- 
clasts. 
1.6.1.2 c-Src 
The c-src proto-oncogene encodes a non-receptor tyrosine kinase. Src kinase is 
activated by a variety of signalling pathways including stimulation of growth factor 
receptors, G protein-coupled receptors, oxidative and UV stress, and integrin- 
mediated signal transduction (Brown and Cooper, 1996). The c-src product, pp60'- 
src, is highly expressed in osteoclasts and is primarily localised on ruffled border 
membranes and vacuoles (Home et al., 1992; Tanaka et al., 1992). The expression of 
pp60'-"c protein and src kinase activity were upregulated in bone marrow cells after 
culturing with 1,25(OH)2D3 (Home et al., 1992). Targeted gene disruption of c-Src 
induced osteopetrosis in mice demonstrating that c-src plays a critical role in osteo- 
clast activation. Osteoclast formation was normal in c-src knockout mice, however, 
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those osteoclasts couldn't form ruffled borders, therefore they are unable to resorb 
bone (Boyce et al., 1992). The distribution of the actin ring in c-src-l- osteoclasts was 
markedly different from the wild-type, with no peripheral podosome arrangement 
(Schwartzberg et al., 1997). TRAP positive osteoclasts could be induced from c-src 
deficient spleen cells cocultured with wild-type osteoblasts, but they were smaller 
and not functional. Osteoblasts from c-src-l- mice supported osteoclast formation 
similarly to wild-type osteoblasts. Fetal liver transplantation rescued osteopetrosis 
and tooth eruption (Lowe et al., 1993), suggesting the defect is intrinsic in the osteo- 
clast lineage. Moreover, transgenic mice overexpressing chicken c-src from the TRAP 
promoter rescued the osteopetrosis and the lack of tooth eruption in c-src-l- mice, 
and osteoclasts developed normal ruffled border. Overexpression of kinase-defective 
alleles of c-src also reduced osteopetrosis and partially rescued the organisation of 
cytoskeleton of osteoclast, suggesting a kinase-independent function of c-src in os- 
teoclast signalling pathways (Schwartzberg et al., 1997). 
Recent studies showed that the tyrosine phosphorylation of c-Cbl, a substrate 
of c-Src, and PYK2, a major adhesion-depcndent tyrosinc kinase in ostcoclasts, are 
markedly reduced in osteoclasts from c-src knockout mice, suggesting these two 
factors act downstream of c-Src in regulating osteoclast activation (Duong et al., 
1998; Tanaka ct al., 1996). 
1.6.1.3 Nuclear Factor-icB (NF-icB) 
Nuclear Factor-KB (NF-KB) is another important transcription factor involved 
in osteoclast differentiation and function. NF-icB is a dimer composed of various 
combinations of proteins: p50 (NFKBI), p52 (NFKB2), p65 (Rel A), Rel B and c- 
Rel (Verma et al., 1995). These proteins are all related by the Rel homology domain 
that contains the DNA-binding motif. NF-icB dimers are generally retained in the 
cytoplasm by association with the inhibitory IicB proteins. In response to extracel- 
lular signals that lead to cell growth, differentiation, inflammatory responses, apopto- 
sis, and neoplastic transformation, IicB is phosphorylated by specific IjcB kinases 
and proteolytically degraded. This allows NF-icB to translocate to the nucleus to 
regulate the transcription of target genes. 
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Inhibitors of NF-icB inhibited osteoclastic bone resorption in vitro in a dose 
dependent manner (Hall et al., 1995b). Single deletion of either the p50 or p52 
subunits didn't induce any developmental defects, although p504- mice had altered 
immune responses (Sha et al., 1995). In contrast, mice deficient in both the p50 and 
p52 subunits of NF-KB develop severe osteoPetrosis caused by the arrested genera- 
tion of osteoclasts from macrophages (Franzoso et al., 1997; Iotsova et al., 1997b). 
Occasionally, one or two weakly TRAP positive osteoclasts were present in the 
mutant long bones. The number of macrophages in bone marrow was increased, sug- 
gesting NF-YcB acts at a point in osteoclast lineage very close to c-fos (see also section 
1.7.3.1 below). Furthermore, the double knockout mice failed to generate mature B 
cells and exhibited defective thymus and spleen structure (Franzoso et al., 1997). 
Wild-type fetal liver or bone marrow transplantation rescued the defect in osteoclas- 
togenesis and resulted in tooth eruption (Iotsova et al., 1997a). Osteoblasts from NF- 
YcB double knockouts supported osteoclast differentiation from wild-type precursors, 
while mutant spleen cells failed to form osteoclasts in coculture with wild-type os- 
tcoblasts suggesting that the defect resides within osteoclast lineage. 
It was demonstrated that NF-xB is a key downstream mediator of RANKL- 
and cytokine-induced osteoclastogenesis, such as IL-1, TNF-a and IL-6 (Beg and 
Baltimore, 1996; Siebenlist et al., 1994). More RANK-expressing osteo- 
clast/macrophage precursors were present in NF-KB double knockout spleen, but 
they were unable to differentiate into mature osteoclasts. IL-1, TNF-a, M-CSF, and 
IL-6 plus soluble IL-6 receptor couldn't rescue the osteoclast defect (Xing et al., 
2002). NF-icB also regulates osteoclast survival, as inhibitors of NF-KB induced 
apoptosis of mature osteoclasts isolated from rabbits and inhibited bone resorption 
activity (Ozaki et al., 1997). Antisense oligonucleotides to p65 or p5O subunits of 
NF-KB induced apoptosis in isolated osteoclasts by preventing translocation of NF- 
KB from the cytoplasm to the nucleus (Jimi et al., 1998). 
1.6.1.4 c-Fos 
C-fos, a proto-oncogene normally associated with osteosarcomas, also appears 
to be a key regulator of osteoclast differentiation. A detailed review of the role of c- 
fos is found in section 1.7.3 below. 
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1.6.1.5 Microphthalmia (mi) 
The microphthalmia (mi) gene encodes a Myc-related basic helix-loop-helix 
leucine-zipper-type (b-HLH-ZIP) protein, which belongs to a family of transcription 
factors including Mitf (microphthalmia transcription factor), TFE3, TFEB, and 
TFEC. Miýf is expressed in osteoclast progenitors and its expression is upregulated 
by M-CSF (Kawaguchi and Noda, 1998; Kawaguchi and Noda, 2000). Cathepsin K 
has recently been identified as a transcriptional target of Mitf (Motyckova et al., 
2001). 
It was reported that mi plays an important role in the fusion of osteoclast pre- 
cursors. Mice deficient in the mi gene, called milmi mice, developed osteopetrosis 
with mononuclear osteoclast-like cells present, and had a defect in pigment cells and 
mast cells (Hodgkinson et al., 1993). Macrophages from mi mice have defects in 
phagocytic recognition and chemotactic responsiveness (Chambers and Loutit, 1979; 
Minkin, 1981). The osteopetrosis can be cured by transfusion with spleen cells from 
wild-type mice (Hodgkinson et al., 1993; Marks and Walker, 1981; Steingrimsson et 
al., 1994). When spleen cells from milmi mice were cultured with ST2 stromal cells, 
osteoclastogenesis was significantly reduced compared with wild-type spleen cells, 
while osteoblastic cells from milmi mice supported osteoclast differentiation in vitro 
similarly to the wild-type, suggesting that the defect of osteoclastogenesis in the 
absence of Miýf is due to the haernatopoietic precursors rather than the stromal cells 
(Kawaguchi and Noda, 2000). Mitf is a target for the RANKL signalling pathway in 
osteoclast differentiation, and phosphorylation of Mitf increases the expression of 
osteoclast specific genes (Mansky et al., 2002). PU. I and Mitf interact with each 
other in regulating osteoclast differentiation. Mice heterozygous for either the mi 
allele (MitPmi) or the PU. I allele (PU. ]+/-) developed normal bone structure, while 
double heterozygous mice (MiWmil PU. ]+/-) developed osteopetrosis at birth. The 
morphology and number of osteoclasts were normal, suggesting that the defect was in 
the later stage of osteoclastogenesis or in mature osteoclasts. The osteopetrosis re- 
solved with age (Luchin et al., 2001). 
1.6.1.6 Grey-lethal (gb mouse 
The gI mouse is the mutant that most closely resembles the severe human auto- 
sornal-recessive fonn of this hereditary defect. It has defect in chromosome 10. Bone 
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marrow transplantation could rescue the osteopetrosis, suggesting it's an osteoclast 
autonomous defect. Histological analysis showed numerous multinucleated osteo- 
clasts present in the long bone, but they are dysfunctional. The gI osteoclasts demon- 
strated a defective cytoskeletal reorganisation and an underdeveloped ruffled border. 
Primary osteoclasts isolated from mutant mice showed significantly reduced resorp- 
tive activity in vitro (Rajapurohitam et al., 200 1). 
1.6.2 Rat osteopetrosis models 
Similarly to mouse mutants, there are naturally occurring osteopetrotic models 
in rats, and these are also summarised in Table 1.3. 
1.6.2.1 Toothless (tl) 
Toothless (tb is an osteopetrotic mutation in rat. The tl rats developed general- 
ised skeletal sclerosis with few osteoclasts, monocytes and macrophages, and a lack 
of tooth eruption, which couldn't be corrected by bone marrow transplantation 
(Marks et al., 1993). It has been suggested that the phenotype in tl mice is due to a 
deficiency in biological active M-CSF. Treatment of tl rats with human recombinant 
M-CSF reduced osteosclerosis and normalised osteoblastic gene expression. Although 
the number of osteoclasts increased significantly after treatment, compared to the 
untreated wild type mice, the osteoclast number and marker gene expression remained 
lower than untreated wild-type (Marks et al., 1993; Wisner-Lynch et al., 1995). M- 
CSF treatment also promoted angiogenesis in tl rats (Aharinejad et al., 1995), sug- 
gesting that M-CSF plays an important role in angiogenesis in rats. 
1.6.2.2 Incisor-absent (ia) 
The incisor-absent (ia) rat developed osteopetrosis which could be cured by 
bone marrow transplantation (Marks, 1976). The fact that metatarsals from mutant 
rats developed a bone marrow cavity when cultured with wild-type spleen cells 
(Lenhard et al., 1990), suggests that the primary defect is intrinsic to the osteoclast 
lineage. Histological analysis revealed that the number of osteoclasts was increased in 
ia mutant rats compared to their wild-type littermates, but these osteoclasts couldn't 
form ruffled borders and exhibited extended clear zones, therefore failing to resorb 
bone (Marks, 1973). Immunocytochernistry showed that the expression level of av#3 
integrin in the mutant osteoclasts was increased, and the osteopontin mRNA level 
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was upregulated in the mutant long bones and was homogenously distributed at the 
surface facing osteoclasts (Reinholt et al., 1999). 
1.6.2.3 Osteopetrosis (op) 
The osteopetrosis (op) in rats is a spontaneous lethal mutation, which can be 
cured by wild-type bone marrow transplantation. In op rats, the number of osteo- 
clasts is significantly reduced, and they are larger and more vacuolated compared to 
the wild-type osteoclasts. The mutant osteoclasts form a ruffled border and clear 
zone, but their ability to break and excavate bone surfaces is impaired (Marks and 
Popoff, 1989). 
1.6.2.4 Microphthalmia Blanc (mib) 
Microphthalmia Blanc (mib) is a spontaneous osteopetrotic mutation in rats. 
The mutant rats were born with osteosclerosis, which was improved with age 
(Moutier et al., 1989). The mild transient osteopetrosis in the mib rat is caused by 
neonatal reductions in osteoclast number and function (Cielinski and Marks, 1994). 
The ruffled border was absent or poorly developed in neonatal mutant osteoclasts, 
and the expression of osteoclast marker genes such as CAII and TRAP were signifi- 
cantly reduced. The defects restored spontaneously within a month (Cielinski and 
Marks, 1995). Bone formation is not affected. 
1.63 Rabbit osteopetrosis (os) 
Osteopetrotic rabbits (os) developed skeletal deformities, abnormalities in os- 
teoclasts and osteoblasts, aberrations in tooth development and eruption and bone 
matrix formation. This mutation is not cured by wild-type bone marrow transplanta- 
tion, suggesting the reduced bone resorption is due to the defects in skeletal microen- 
vironment. Mutant metatarsals cocultured with wild-type spleen, liver and bone 
marrow cells failed to develop bone marrow cavity, while the wild-type metatarsals 
could. The number and activity of osteoclasts induced from mutant culture were 
reduced (Lenhard et al., 1990). This mutant is also summarised in Table 1.3. 
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1.6.4 Culture systems 
In vitro systems have been used to identify osteoclast precursors, and to char- 
acterise factors that affect osteoclast formation and activity. These are surnmarised in 
the following sections. 
1.6.4.1 Primary osteoclast isolation 
Chambers et al. developed a technique whereby primary osteoclasts were iso- 
lated form neonatal rabbit long bones, and these cells were able to resorb bone in vitro 
(Chambers et al., 1984). This technique represents a model system with which to 
assess the direct effects of hormones, cells and substrate composition on the induc- 
tion, stimulation and inhibition of osteoclastic bone resorption and to investigate the 
mechanism by which cells degrade extracellular matrix. 
1.6.4.2 Organ culture system 
Long bones, fetal calvaria or metatarsals from rat and mouse have been widely 
used to examine osteoclast activity (Burger et al., 1986; Pfeilschifter et al., 1988; 
Smith et al., 1987; Weir et al., 1996). Bone organs were cultured with different 
growth factors or conditioned medium in vitro, and osteoclastic bone resorption was 
measured by histology or 4'Ca release. This system is particularly useful for evalu- 
ating the effects of osteotropic factors on osteoclastic bone resorption. 
1.6.43 Coculture system 
Burger et al. developed a coculture system to investigate osteoclast formation 
in vitro, in which murine marrow cells were cultured with stripped fetal bone rudi- 
ments devoid of osteoclast progenitors (Burger et al., 1982). This system provided 
important information on the ontogeny of osteoclasts and differentiation of osteo- 
clast precursors into bone-resorbing osteoclasts (Scheven et al., 1986; Thesingh, 
1986). Subsequently, Takahashi et al. developed an efficient mouse marrow coculture 
system. Numerous TRAP positive multinucleated cells were generated when bone 
marrow cells were cultured with mouse osteoblastic cells in the presence of 
1,25(OH)2D3 or PTH (Takahashi et al., 1988b). It was found later that spleen cells 
can substitute for bone marrow cells as a source of osteoclast precursors in this sys- 
tem (Udagawa et al., 1989). This system is useful for investigating both osteoclast 
formation and bone resorption, and is widely adapted by many groups. 
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1.6.4.4 Stroma-free cell culture system 
Although bone marrow/spleen coculture system closely resembles in vivo os- 
teoclastogenesis, the presence of osteoblasts/stromal cells mixes up the direct and 
indirect effects of osteotropic factors. After the discovery of RANKL, this problem 
has been solved by culturing haernatopoietic precursors, from bone marrow or spleen, 
with M-CSF and RANKL in the absence of stromal. cells (Fox and Chambers, 2000; 
Udagawa et al., 1999). This simplified culture system provides opportunity to study 
osteoclast formation and function without the influence of osteoblastic cells, and is 
most widely used nowadays. 
Recently, a number of groups established a culture system for the development 
of osteoclasts from pluripotent ES (embryonic stem) cells, permitting the whole 
process of osteoclastogenesis to be assessed starting from single ES cells (Hemmi et 
al., 200 1; Yamane et al., 1997). 
1.6.4.5 Human osteoclast generation 
Functional multinucleated osteoclasts were successfully generated from human 
bone marrow cells, peripheral blood mononuclear cells (PBMCs) or tumour cells 
cultured with osteoblastic cell lines in the presence of 1,25(OH)2D3 and M-CSF 
(Fujikawa et al., 1996; MacDonald et al., 1987; Quinn et al., 1998b), which permits 
studies on osteoclast formation in patients with metabolic bone disease. After the 
identification of RANKL, osteoclasts could be generated from human PBMCs in the 
absence of osteoblasts/stromal cells (Lader et al., 2001; Matsuzaki et al., 1998; Quinn 
et al., 1998a). By using this stroma-free culture system, human circulating osteoclast 
precursors were purified as CD14 (+) cells, which express RANK and could give rise 
to functional osteoclasts in the presence of M-CSF and RANKL (Nicholson et al., 
2000). This model is particular helpful for analysing the pathogenesis and treatment 
of metabolic bone diseases, such as rheumatoid arthritis (RA) and bone tumours, and 
is widely used in clinical research. 
Taken together, the in vitro culture systems described above are selectively 
used for different purposes. Among these, the stroma-free culture system is ern- 
ployed by many laboratories as it is particularly helpful in exploring the effect of 
osteotropie factors on osteoclasts and their precursors, and dissecting the molecular 
mechanisms of osteoclast differentiation from haematopoietic stem cells. 
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1.7 AP-1 family in bone biology 
AP- I (activator protein 1) is a transcription factor family, which includes sev- 
eral Fos-related (c-Fos, FosB, Fra- I and Fra-2) and Jun-related (c-Jun, JunB, JunD) 
proteins. The AP-I family genes share a hydrophobic leucine zipper domain that 
mediates protein dimerisation, and a basic region that mediates DNA binding. Tran- 
scriptional regulation by AP- I members involves formation of homodimers and het- 
erodimers between Jun and Fos members, or with Jun dimerisation partners (JDP I 
and JDP2) and ATF/CREB family members, and subsesquently binding of DNA at 
AP-I consensus sequences in regulatory regions of target genes (Angel and Karin, 
1991; Shaulian and Karin, 2001). 
AP-I genes are important mediators of signal transduction, cellular transforma- 
tion, cell proliferation and differentiation, maturation, apoptosis of various cell types. 
The role of AP- I family members in embryonic and postnatal development have been 
identified by genetically modified mice models. Tables 1.4 and 1.5 summarise the 
consequences of targeted gene disruption, and of transgene overexpression in mice 
(Adapted from Jochum et al., 200 1; Wagner, 2002). 
Table 1.4 AP-1 knock out mice 
Phenotype Affected organs/ cell types References 
Fos proteins 
c-Fos Osteopetrosis Bone, osteoclasts (Johnson et at., 1992; Wang et al., 1992) 
Brain, 
FosB Nurturing defect hypothalamus (Brown et al., 1996; Gruda et al., 1996) 
Extraembryonic 
Fra-I Embryonic lethality tissue, placenta (Schreiber et al., 2000) 
Fra-2 Lethal at birth Not published (Wagner, 2002) 
Jun proteins 
Liver, hepatoblasts (Hilberg et al., 1993; Johnson et al., 
c-Jun Embryonic lethality Heart, outflow tract 1993) 
Extraembryonic 
JunB Embryonic lethality tissue, placenta (Schorpp-Kistner et al., 1999) 
JunD Male sterility 
Testis, 
(Thepot et al., 2000) spermatogenesis 
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Table 1.5 AP-1 transgenic mice 
Promoters Phenotype Affected organ/cell ty pes References 
Fos proteins 
c-Fos H2k b Osteosarcorna 
Bone, 
osteoblasts 
(Grigoriadis et al., 1993) 
(chimaeric) Chondrosarcoma, Bone, Chondrocytes (Wang et al., 1991) 
FosB H20 Normal (Grigoriadis et al., 1993) 
TCRb Impaired T cell Thymus, immature (Carrozza et al., 1997; 
, &FosB differentiation thymocytes Sabatakos et al., 2000) NSE osteosclerosis 
Fra- I 112kb osteosclerosis 
Bone, 
osteoblasts 




Eye, anterior eye 
structure 
(McHenry et al., 1998) 
Jun protein 





Thymus, CD4 (Li et al., 1999a; 
CD4 
maturation 
thymocytes Schorpp et al., 1996) 
JunD Not reported 
1.7.1 Molecular biology of c-Fos 
The c-Fos oncoprotein is one of the major components of the AP-1 family. 
The c-fos proto-oncogene is the cellular homologue of v-fos, which is the transform- 
ing gene identified originally in the FBJ- and FBR-murine sarcoma viruses (MSVs). 
The mature c-fos mRNA transcript of 2.2kb encodes a 380-amino acid phosphopro- 
tein that undergoes extensive posttranslational modification and has an apparent 
molecular mass of 55kDa. Due to its rapid expression in response to mitogenic 
stimulation, c-fos is classed as an immediate early gene and has been implicated in 
normal cellular growth control. 
During early mouse development, c-fos is expressed in extraembryonic tissues 
(Muller et al., 1983), while expression during late embryonic development was re- 
stricted to the growth regions of foetal bone (De Togni et al., 1988; Dony and Gruss, 
1987; Sandberg et al., 1988). In adult tissues, c-fos expression was detected in skele- 
tal/haematopoictic tissues, including epiphyseal chondrocytes, osteoclasts, calcified 
trabeculae composed of hypertrophic cartilage and newly deposited bone, periosteal 
bone, and some cells of mycloid and lymphoid lineages of the marrow (Lord et al., 
1993; Sandberg et al., 1988; Smeyne et al., 1992; Sunters et al., 1998). Fig. 1.8 shows 
the role of c-Fos on bone cell biology (Adapted from Grigoriadis et al., 1995). 
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Effect of c-Fos overexpression on the skeleton 
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Fig 1.8 The effect of overexpression and deletion of c-Fos on bone cells. Top panel: 
overexpression of c-Fos in transgenic and chimaeric mice leads to the transformation of os- 
teoblasts and chondrocytes, which results in the formation of osteosarcomas and chondrosar- 
comas. c-Jun co-operates with c-Fos in osteoblast transfon-nation and tumour formation. 
Overexpression of c-Fos also enhances osteoclast formation and activation, which in turn 
plays an important role in tumour progression and tumour remodelling. Bottom panel: Dele- 
tion of c-Fos leads to a block in osteoclast differentiation and an increase in macrophage 
numbers, which results in the development of osteopetrosis. Overexpression offira-1 can 
rescue the defect of osteoclastogenesis in the absence of c-Fos. In both top and bottom pan- 
els, the role of endogenous c-Fos is represented by black arrows, the roles of the c-Fos, c-Jun 
and Fra- I transgenes are represented by blue arrows and the consequences of c-Fos deletion is 
represented by red arrows. 
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1.7.2 Effects of c-fos on the osteoblast/chondrocyte lineage 
1.7.2.1 Transgenic mice overexpressing c-fos develop osteosarcoma 
The role of c-fos gene in skeletal development was first addressed by in vivo 
gain-of-function experiments. Overexpression of c-fos under a ubiquitous promoter 
caused perturbed proliferation of thymic epithelial cells and splenocytes without 
turnour formation (Ruther et al., 1988). However, transgenic mice expressing stable 
and high level of exogenous c-fos from ubiquitous promoters and containing an FBJ 
(Finkel-Biskis-Jinkins)-long terminal repeat (LTR) element (H2-c-fosLTR mice) 
developed chondroblastic osteosarcomas (Grigoriadis et al., 1993). In these mice, the 
c-fos transgene is not expressed during embryogenesis but is expressed 2-3 weeks 
after birth in bone tissues before tumour development, specifically in osteoblasts, 
osteocytes, as well as in osteoblastic cells present within the turnours (Grigoriadis et 
al., 1993; Tickle and Eichele, 1994). Clonal c-fos-expressing cell lines derived from the 
turnours can form bone in vivo and have altered osteoblastic gene expression 
(Grigoriadis et al., 1993). These data suggest that the target cells in c-Fos-induced 
osteosarcomas are osteoblasts. Transgenic mice overexpressing other AP-1 members, 
e. g., cjunjunB, andfosB, exceptfra-1, see section 1.7.4.1 below, do not exhibit bone 
abnormalities, although transgenic mice overexpressing a truncated FosB protein, 
AFosB, develop osteosclerosis due to a cell autonomous defect in osteoblast activity 
(Sabatakos et al., 2000). 
Double transgenic mice overexpressing both c-fos and c-jun developed os- 
teosarcomas at a higher frequency and to a greater extent than single transgenics, indi- 
cating that c-Fos co-operates with c-Jun in osteoblast transformation and tumour 
formation (Wang et al., 1995). Histological analysis showed that the tumours devel- 
oping in double transgenic mice contained greater amounts of neoplastic bone with 
fewer chondrocytes. Also, cell lines isolated from Fos-Jun double transgenic tumours 
expressed high levels of both transgenes and osteoblastic marker genes, further prov- 
ing that osteoblasts are the target cells for c-Fos induced transformation. The ftinction 
of c-Fos in osteosarcoma formation was further investigated by crossing c-fos trans- 
genic mice with heterozygous and homozygous c-fos knockouts. Interestingly, the 
frequency of osteosarcoma, formation and the time of onset were significantly reduced 
in c-fos+l- mice, and turnour formation was almost absent in c-fos-l- mice expressing 
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c-fos transgene (Wang et al., 1995), suggesting that a critical level of c-Fos is neces- 
sary for osteosarcoma development. 
T'he molecular mechanisms by which overexpression of c-fos induces osteosar- 
comas in transgenic mice is not fully understood. Fibroblastic cell lines with a mutant 
allele of c-jun (junAA) infected with v-fos-expressing retrovirus showed reduced 
turnorigenicity in nude mice. In addition, c-Fos-induced osteosarcoma was sup- 
pressed injunAA mice, which are c-Jun mutant mice where the two Jun N-terminal 
kinase (JNK) phosphorylation sites have been mutated, resulting in a mutant "non- 
phosphorylatable" c-Jun protein (Behrens et al., 2000), suggesting that c-Fos-induced 
turnorigenesis is mediated by c-Jun N-terminal phosphorylation. Our laboratory 
reported that overexpression of c-Fos induces osteoblast transforrnation, possibly by 
modifying the expression of cells cycle regulators (Sunters et al., 1998). Recently, c- 
Jos induced growth factor/vascular endothelial growth factor D (FigflVegf-D), has 
been identified as a downstream growth and morphogenic effector of c-fos. Overex- 
pression of FigflVegf-D in fibroblasts caused morphological alterations (Orlandini et 
al., 1996). Furthermore, FigflVegf-D induced angiogenesis both in vivo and in vitro, 
and also induced proliferation and chernotaxis in Kaposi's sarcoma immortalized cell 
line (Marconcini et al., 1999). 
1.7.2.2 Chimaeric mice overexpressing c-fos develop chondrosarcomas 
As exogenous c-fos is not expressed during embryogenesis in Fos-transgenic 
mice, in order to further identify the early target cells for c-Fos transformation, chi- 
maeric mice overexpressing c-fos were generated by introducing a c-fos transgene into 
pluripotential embryonic stem (ES) cells. c-Fos-ES cell chimaeras developed chon- 
drosarcomas with high efficiency at all skeletal sites containing cartilage at 3-4 weeks 
afterbirth (Grigoriadis et al., 1993; Wang et al., 199 1; Wang et al., 1993). In situ hy- 
bridisation and immunocytochemistry showed high levels of exogenous c-fos expres- 
sion in chondrogenic cells in chondrosarcomas. Cell lines isolated from chondrosar- 
comas expressed high levels of c-fos, c-jun and cartilage specific genes. Injection of 
these cells into syngeneic and nude mice induced cartilage turnours (Wang et al., 
1993). These results suggest that ectopic c-fos transgene expression in chimaeric mice 
occurred at an earlier developmental stage, which may affect the common mesenchy- 
mal progenitors of chondrocytes and osteoblasts. Our laboratory has further shown 
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that c-Fos affects cartilage differentiation, as overexpression of c-fos in a chondrocyte 
cell line inhibited chondrocyte differentiation in vitro. The expression of chondrocyte 
marker genes was downregulated by exogenous c-fos, whilefra-I and c-jun expression 
was upregulated (Thomas et al., 2000). 
1.7.23 Mice lacking c-fos develop osteopetrosis 
Deletion of c-fos in mice results in the development of osteopetrosis (Wang et 
al., 1992) (See also section 1.7.3.1), with poorly developed cortical bone and disor- 
ganised growth plates. Although, osteoblasts in c-fos -/- mice express lower level of 
bone sialoprotein and osteocalcin (Demiralp et al., 2002), the fact that osteoblasts 
from mutant mice can fully support osteoclast formation in vitro suggests that the 
defect of osteogenesis may be secondary to the bone remodelling defect caused by the 
lack of osteoclasts (Grigoriadis et al., 1994). Recently, Demiralp et al. reported that 
after PTH administration, bone mineral density and trabecular bone volume were 
decreased in c-fos knockout mice, but were increased in the wild-type littermates 
(Demiralp et al., 2002), suggesting that deletion of c-fos in osteoblastic cells caused an 
altered responsiveness to growth factors during endochondral ossification. 
1.7.3 Effects of c-fos on the haernatopoictic lineage 
1.7.3.1 Inactivation of c-fos 
The indispensable role of c-Fos in osteoclastogenesis is unequivocally demon- 
strated by the osteopetrotic phenotype in mice lacking c-fos gene. The c-fýs knock- 
out mice were generated by disrupting the c-fos gene in embryonic stem cells. A neo- 
mycin-resistance gene (neo) was fused in-frame to c-fos replacing part of the second 
exon and intron (Bg111 fragment), thereby deleting 483 bp of c-fos. Mice lacking c-fos 
are viable but are growth-retarded (Wang et al., 1992), and develop osteopetrosis due 
to a complete absence of functional multinucleated osteoclasts and their immediate 
precursors (Grigoriadis et al., 1994), the failure of tooth eruption and altered haema- 
topoiesis are secondary to the osteopetrosis (Okada et al., 1994; Wang et al., 1992). 
The defect of osteoclastogenesis in c-fos knockout mice is intrinsic in the os- 
teoclast lineage, and is not caused by an altered bone marrow environment. Trans- 
plantation of mutant embryonic limbs into the wild-type kidney supported normal 
bone development, whereas wild-type limbs transplanted under mutant kidney cap- 
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sules lacked a bone marrow space and TRAP positive cells (Grigoriadis et al., 1994). 
Moreover, wild-type bone marrow transplantation rescued lethally irradiated new- 
bom mutant mice, as well as bone marrow space formation and incisor eruption. In 
contrast, injection of mutant spleen haernatopoietic stem cells into irradiated newborn 
wild type mice caused osteopetrosis (Grigoriadis et al., 1994). Osteoblasts isolated 
from wild-type and mutant calvariae supported osteoclast formation in coculture 
with wild-type spleen cells, while mutant spleen cells could not form osteoclasts 
when cultured with wild-type osteoblasts. Finally, mutant spleen cells infected with 
a c-fos-expressing retrovirus formed ftinctional osteoclasts in vitro (Grigoriadis et al., 
1994). Taken together, these experiments demonstrated unequivocally that the defect 
in c-fos knockout mice was cell autonomous in the osteoclast lineage. This was also 
shown subsequently by Udagawa and coworkers, who showed that in a mouse bone 
marrow and osteoblast. coculture system, c-fos antisense oligomers only inhibited 
osteoclast differentiation when the oligonucleotides were added during the prolifera- 
tion phase (day 0 to 4), but not during the second differentiation phase (days 4 to 6), 
suggesting c-Fos might affect the proliferation phase of osteoclast development 
(Udagawa et al., 1996). 
Although osteoclast differentiation is blocked in the mutant mice, the number 
of 174/80 and Mac-2 positive macrophages in c-fos knockout bone marrow is in- 
creased, suggesting c-Fos has a divergent effect on osteoclast and inacrophage lineage 
(Grigoriadis et al., 1994). However, there was no difference in the number of cells 
expressing ER-MP58, a marker for M-CSF-responsive macrophage progenitors. In 
addition, no differences were observed in the number of 174/80 positive macrophages 
in the liver, suggesting that the effects on the potential of macrophage/osteoclast 
precursors may be specific to the bone marrow compartment. It was also reported 
that c-Fos is involved in the lineage determination of osteoclasts and dendritic cells. 
RANKL-induced osteoclast differentiation was inhibited and dendritic cell differen- 
tiation was reciprocally stimulated by GM-CSF through suppression of c-fos in bone 
marrow cultures (Miyamoto et al., 2001). On the other hand, GM-CSF-induced den- 
dritic cell development was inhibited by overexpression of c-fos (Miyamoto et al., 
200 1). Taken together, these data suggest that c-Fos plays a critical role in the differ- 
entiation of osteoclast precursors at the branch point where the osteoclast lineage 
diverges from the macrophages and dendritic cells. 
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The genes upstream of c-fos in regulating osteoclast differentiation are not clear. 
It was reported that c-fos gene can be transcriptionally activated in mononuclear 
phagocytes by M-CSF (Muller et al 1985; Bravo 1987), but in the absence of M- 
CSF, neither a c-fos nor afra-1 expressing retrovirus supported survival or prolifera- 
tion of osteoclast precursors (Owens et al., 1999). Recently, a link between RANK 
signalling and the AP-1 expression during osteoclastogenesis has been identified (see 
also below). 
To demonstrate the possible molecular mechanism by which c-Fos exerts its 
function in osteoclastogenesis, gene rescue experiments have been done both in vivo 
and in vitro. It was demonstrated that the N-terminal portion and the core region of 
Fos proteins were sufficient to rescue osteoclast differentiation. Interestingly, all Fos 
proteins (c-Fos, Fra-1, Fra-2, and Fos-B), but none of the Jun proteins (c-Jun, Jun-B, 
and Jun-D) rescued the defect of osteoclast differentiation from c-fos-1- spleen cells. 
Fra- I has the highest rescue potential of all Fos proteins, in addition, fra- I transgene 
rescue the osteopetrosis in vivo (see also below) (Matsuo et al., 2000). 
1.7.3.2 Overexpression of c-fos 
Prolonged expression of c-fos enhances osteoclast differentiation in vitro. Bone 
marrow precursors infected with c-fos-expressing retrovirus (pMX-c-fos-IRES- 
EGFP) differentiated into TRAP positive cells even in the absence of RANKL, 
though the efficiency was very low (Takayanagi et al., 2002a). Overexpression of c- 
fos in integrin, 63-/- bone marrow precursors rescued the defect in osteoclastogenesis, 
but not the bone resorption (Faccio et al., 2003). Transfection of c-fos cDNA into 
avian osteoclast precursors induced a twofold increase in TRAP activity and osteo- 
clastic bone resorption (Miyauchi et al., 1994). Finally, osteoclasts from Paget's 
patients expressed high levels of c-fos (Hoyland and Sharpe, 1994), which may play 
an important role in the increased bone remodelling of these patients. 
Experiments from our laboratory have also implicated that osteoclasts are in- 
volved in c-Fos-induced tumorigenesis. Transgenic mice overexpressing deregulated c- 
fos in osteoclasts using a TRAP promoter develop large bone lesions and tumours, 
which contained a marked increase in the number of osteoclasts (Beedles et al., 1999). 
Osteosarcomas developing in Fos-Jun double transgenic mice contained a greater 
number of TRAP positive multinucleated osteoclast-like cells compared with c-Fos 
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transgenic mice, and were more remodelled (Wang et al., 1995), suggesting osteoclasts 
may play an important role in bone tumour remodelling and progression. 
1.7.4 Roles of Fra-1 in bone biology 
Fra-I (Fos related antigen- 1) is one of the Fos proteins, encoded by the Fos- 
like-I gene, FosIl. FosIl is a transcriptional target of c-fos in osteoclast progenitors, 
and induction of FosIl upon growth factor stimulation is delayed compared with c- 
fos (Bergers et al., 1995; Matsuo et al., 2000; Schreiber et al., 1997). RANKL induces 
fra-I expression in a c-fos-dependent manner (Matsuo et al., 2000). Structurally, c- 
fos andfra-I show high homology in their leucine zipper and DNA-binding domains. 
The ma or difference between these two genes is that fra-I lacks transcriptional acti- 
vation domains required for cellular transformation or transactivation and fails to 
activate transcription when fused to the DNA-binding domain of Ga14, while c-fos is 
a potent activator of transcription (Cohen et al., 1989). Fra-1 is expressed in ex- 
traembryonic tissues during mouse development and in brain, skin, and testes of adult 
mice (Schreiber et al., 1997; Schreiber et al., 2000). 
1.7.4.1 Overexpression offra-I 
Fra- I transgenic mice were generated using H2-fra- ILTR construct. These mice 
developed ostcosclcrosis due to increased bone formation (Jochurn et al., 2000), but 
no bone turnour formation occurred. Osteoblast differentiation but not proliferation 
was enhanced by overexpression offra-1. The number of osteoclasts and resorption 
pits induced from Fra-I transgenic bone marrow precursors was significantly in- 
creased than that from the wild-type (Matsuo et al., 2000). Fra-I is more potent in 
inducing osteoclast formation than c-Fos in vitro, since infection of bipotential osteo- 
clast/macrophage precursor cell lines with a retrovirus expressing fra-I but not c-fos 
dramatically stimulated the formation of osteoclast in cocultures (Owens ct al., 
1999). Also, as described above, overexpression of fra-I by retrovirus infection in 
spleen cells lacking c-fos rescued the differentiation in vitro more efficiently than 
other Fos members (Matsuo et al., 2000). The osteopetrosis in c-fos-1- mice was 
partially rescued by crossing withfra-I transgenic mice. With advancing age, the mice 
developed increased bone density similar to fra-1 transgene-induced osteosclerosis. 
To further investigate whether Fra- I can substitute for c-Fos, knock-in mice ex- 
pressingfra-I in place of c-fos were gencratcd. Fra-I knock-in mice studies showed 
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that Fra-I can fully compensate for the lack of c-Fos in bone development, but the 
rescue was gene dosage dependent (Fleischmann et al., 2000). 
1.7.4.2 Inactivation offra-1 
Targeted disruption of the FosIl gene leads to early embryonic lethality due to 
impaired vascularisation of the placenta (Schreiber et al., 2000). However, injection of 
fra-1-1- ES cells into tetraploid wild-type blastocysts rescued the placental defect, 
and in these mice, fra-]-/- newborns survived up to two days after birth without any 
organ abnormalities. Bone structures were normal, and TRAP positive osteoclasts 
were present, suggesting that Fra- I is not essential for osteoclast differentiation, and 
regulates osteoclast formation by a mechanism different from c-Fos (Matsuo et al., 
2000). 
1.8 Signalling in osteoclast development 
It's well established that RANKL binds to RANK, the receptor on osteoclast 
progenitors, and promotes osteoclast formation, activation and survival, but the mo- 
lecular mechanisms downstream of RANK are still not clear. Three different path- 
ways have been identified so far, and Figure 1.9 shows signalling pathways involved 
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1.8.1 TNF receptor-associated factors (TRAFs) 
RANICs intracellular domain contains two binding sites for members of a fam- 
ily of proteins called TNF receptor-associated factors (TRAFs) (Damay et al., 
1999). The TRAF family proteins are cytoplasmic adapter proteins that mediate 
cytokine signalling. Both the TNF receptor superfamily and the Toll/interleukin-1 
receptor family recruit TRAF proteins. There are six members in this farrdly (Arch et 
al., 1998), among which TRAF2, TRAF5, and TRAF6 have been shown to be re- 
sponsible for NF-KB activation through IKB kinase (IKK) activation by TNF recep- 
tors (Kim et al., 1999), and they have also been implicated in activation of c-Jun N- 
terminal kinase (JNK) (Anderson et al., 1997; Darnay et al., 1998; Wong et al., 
1997c), which phosphorylates c-jun and activates the AP-I complex. TRAF6, which 
binds to a structural motif different from the region that binds other TRAFs, is nec- 
essary and sufficient for RANK-induced NF-KB activation, while TRAF2 is respon- 
sible for the activation of JNK (Damay et al., 1999; Wong et al., 1998). RANK acti- 
vates not only NF-icB and JNK, but also the expression of c-Fos (Matsuo et al., 
2000). 
The role of TRAF6 involved in osteoclast differentiation is demonstrated by 
the osteopetrosis observed in mice lacking TRAF6. In TR, 4F6 knockout mice, osteo- 
clasts are present in normal numbers on bone surfaces but are non-functional, as they 
were unable to form ruffled borders, a defect also seen in c-src-deficient mice, sug- 
gesting that the interaction between RANK and TRAF6 is indispensable for osteo- 
clast cytoskeletal formation and functional activation (Lomaga et al., 1999). However, 
by using different constructs, Naito et al. reported that only a few weak TRAP posi- 
tive mononuclear cells were present in their TR. 4F6 knockouts. Osteoclast precursor 
cells derived from TR, 4F6-1- mice are unable to differentiate into functional osteo- 
clasts in vitro, suggesting that TRAF6 is essential not only for osteoclast activation, 
but perhaps also for differentiation (Naito et al., 1999). 
TRAF6 is also involved in IL-I signalling (Kobayashi et al., 2001). TRAF6 de- 
ficient mice have a defect in B-cell differentiation, lymph node organogenesis and IL-1 
signalling (Naito et al., 1999). Osteoclasts derived from haernatopoietic progenitors 
harbouring a construct in which RANK was unable to bind to TRAF6 were dysfunc- 
tional, which can be rescued by IL- 10 (Armstrong et al., 2002; Cao et al., 1996). 
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It was also reported that RANKL promotes osteoclast survival by activating 
Akt/PKB, a serine/threonine kinase that regulates cell survival by inactivating 
proapoptotic molecules, through a signalling complex involving c-Src and TRAF6. 
RANKL-induced activation of PKB and survival were significantly reduced in c-src- 
/- osteoclasts, and were blocked by adding P13 or Src family kinase inhibitors (Wong 
et al., 1999a). Coexpression of TRAF6 with limiting amounts of c-Src induced a sub- 
stantial increase in c-Cb1 phosphorylation, suggesting there is a cross-talk between 
RANKL and c-Src signalling pathway. 
Deletion of other TRAF family members, such as TRAF2,3 and 5 didn't affect 
osteoclast formation and function, but led to immunodeficiency with different sever- 
ity (Nakano et al., 1999; Xu et al., 1996; Yeh et al., 1997), suggesting their roles in 
osteoclastogenesis are dispensable. 
1.8.2 Nuclear Factor of Activated T cells (NFAT) 
NFATH, also known as NFAT2 or NFATc, is a member of the NFAT (nuclear 
factor of activated T cells) family of transcription factors. It was demonstrated re- 
cently that NFATcl regulates terminal differentiation of osteoclasts. NFAM is 
downstream of RANKL as the expression of NFAM in bone marrow osteo- 
clast/macrophage precursors is strongly upregulated after RANKL stimulation. M- 
CSF alone or IL- I didn't produce similar effects. Deletion of NFATcl is lethal and 
mice died at day 14.5 of gestation. NFATcl-l- ES cells differentiated into mono- 
cytes/macrophages in the presence of M-CSF, but failed to differentiate into osteo- 
clasts in the presence of RANKL. On the other hand, bone marrow precursors in- 
fected with a retrovirus expressing NFA Tcl differentiated into osteoclasts even in the 
absence of RANKL (Takayanagi et al., 2002a). 
Interestingly, the expression of NFATcl depends on both TRAF6 and c-Fos. 
The induction of NFATcl by RANKL treatment was abolished in c-fos-1- spleen 
cells, and is significantly decreased in TRAF6-1- spleen cells (Takayanagi et al., 
2002a). On the contrary, the expression of TRAF6 and c-fos was normal in NFATcl- 
deficient precursors. Coexpression of NFATH and c-fos synergistically activated the 
TRAP promoter, while such effect was not observed in coexpression of an NFAM 
mutant (NFATcIRL) and c-fos, suggesting that NFAM cooperates with c-fos in 
regulating osteoclast differentiation (Takayanagi et al., 2002a). RANKL also evokes 
75 
1. Introduction 
Ca2+ oscillations that lead to calcineurin-mediated activation of NFATcl, and there- 
fore triggers a sustained NFA Tcl-dependent transcriptional program during osteoclast 
differentiation (Takayanagi et al., 2002a). 
1.83 Interferons (IFNs) 
In addition to its positive effects, RANKL also regulates osteoclastogenesis 
through some negative mechanisms so that the osteoclastic bone resorption is well 
controlled. IFN-P signalling has been identified recently as one of these pathways. 
Similar to INF-y, interferon-P (IFN-P) is a negative regulator of osteoclasto- 
genesis. Mice deficient in one of the IFN-cE/P receptor components, IFNARI 
(IFNARI-I-), developed osteoporosis with increased number of osteoclasts 
(Takayanagi et at., 2002b). The fact that RANKL stimulation induced IFN-, B, but not 
IFN-a, expression in osteoclast precursors, suggests that IFN-P is the key factor for 
the regulation of osteoclastogenesis. Similarly, mice lacking IFN-P developed os- 
teopenia with enhanced osteoclastogenesis. The enhanced osteoclastogenesis in 
IFNARI-1- is intrinsic to the osteoclast lineage. Haernatopoietic precursors from 
IFNARI-1- mice exhibited increased osteoclast formation in response to RANKL 
(Takayanagi et al., 2002b). It was shown that IFN-P inhibits RANKL-induced osteo- 
clast formation through ISGF3 (a heterotrimeric complex consisting of Statl, Stat2 
and interferon regulatory factor9 (IRF-9))-mediated gene induction pathway 
(Takayanagi et al., 2002b). 
Surprisingly, it has been identified that there is a signalling cross-talk between 
the RANKL and IFN-P systems. RANKL stimulation in bone marrow precursors 
induces c-fos expression, which binds to DNA and activates the expression of target 
genes including IFN-P. IFN-P then binds to its receptor on osteoclast precursors and 
inhibits osteoclast differentiation by suppressing the synthesis of c-Fos protein. 
Indeed, the inhibitory effect of IFN-P in osteoclast formation could be abrogated by 
overexpression of c-Fos. The fact that RANKL induced c-fos expression induces its 
own inhibitor provides an important negative feedback in regulating osteoclast forma- 




M-CSF exerts its function by binding its receptor, c-Fms, on osteoclast precur- 
sors and mature osteoclasts. Recent studies showed that PI 3-kinase and ERK par- 
ticipate in M-CSF regulated osteoclast proliferation, differentiation and survival. 
Phosphatidylinositol. 3-kinase (P13K) is a heterodimer consisting of a regula- 
tory (p85) and catalytic (pI 10) subunit. It is involved in various cellular functions, 
including mitogenesis, survival, motility and differentiation. P13K stimulates actin 
filament formation and regulates osteoclast attachment, spreading and chemotaxis in 
osteoclasts (Grey et al., 2000; Lakkakorpi et al., 1997). Inhibitors of P13K inhibited 
osteoclastic bone resorption in vitro (Hall et al., 1995a; Nakamura et al., 1995). The 
fact that the activity of P13K is upregulated after M-CSF stimulation, suggests that 
P13K is an essential signalling effector molecule for c-fms (Pilkington et al., 1998). 
Mitogen-activated protein kinases (MAPKs) are serine/threonine kinases that 
transmit signals from extracellular stimuli to multiple substrates involved in cells 
growth, differentiation and apoptosis. There are three MAPK subfamilies: extracel- 
lular signal-regulated kinases (ERKs), JNKs and p38 kinases. The ERK family of 
MAPKs is essential for the survival of osteoclasts (Miyazaki et al., 2000). Inhibiting 
ERK activity rapidly induced osteoclast apoptosis in vitro, while activation of ERK 
remarkably prolonged survival by preventing spontaneous apoptosis. M-CSF 
stimulates ERK activity (Miyazaki et al., 2000) in osteoclasts. Prolonged ERK acti- 
vation leads to enhanced c-Fos expression via phosphorylation-mediated stabilisation 
of the protein (Murphy et al., 2002), suggesting that c-fms mediates osteoclast differ- 
entiation and survival via the ERK/c-Fos pathway. 
1.9 AIMS 
The differentiation and function of osteoclasts are intricately controlled by a 
variety of gencs at different stages, and closely regulated by many hormones and 
cytokines both systemically and locally. Previous studies showed that c-fos knock- 
out mice develop osteopetrosis due to a complete block in osteoclast differentiation. 
Moreover, these mice have a higher number of bone marrow macrophages, suggesting 
that c-Fos is indispensable for osteoclast development and acts at the branch point 
where macrophage and osteoclast differentiation diverge. But it is not clear how c-Fos 
is involved in the regulation of osteoclast development. Determining where the block 
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occurs in the osteoclast lineage is an important first step in understanding the func- 
tion of c-Fos in the differentiation of this lineage. Thus, the first aim of this thesis is 
to map the expression of osteoclast- and macrophage- specific genes in situ, in both 
wild-type and c-fos knockout bones. 
Spleen cells are widely used as a source of haematopoietic precursors in in 
vitro culture systems to analyse the mechanisms involved in osteoclast differentia- 
tion, especially for studies using osteopetrotic animal models as it is difficult to iso- 
late bone marrow precursors from those animals. However, it is likely that spleen 
cells are different from bone marrow precursors, as these cells reside in a local micro- 
environment which is different from that of bone marrow cells, and which may be 
critical for osteoclastogenesis. Thus, in the second aim of this thesis, I will test the 
hypothesis that the haernatopoietic precursors in c-fos knockout long bones, despite 
being reduced in number, have a different osteoclastogenic potential than precursors 
present in c-fos knockout spleens. This will be done by establishing M-CSF- 
dependent bone marrow culture from dissociated osteopetrotic long bones and as- 
sessing osteoclast differentiation and signalling in comparison to spleen populations. 
Previous studies showed that numerous osteoclasts were formed in tumour 
tissues from c-Fos transgenic mice, and that, osteoclasts played an important role in 
tumour progression and tumour remodelling. The hypothesis to be tested in the third 
aim is that overexpression of c-fos in vivo perturbs osteoclast differentiation. This 
will be investigated by mapping the expression of osteoclast marker genes and osteo- 
clastogenic cytokine genes in situ in c-Fos-induced osteosarcomas, and by analysing 
the consequences of c-fos overexpression on osteoclast differentiation and signalling 
from bone marrow precursors in vitro. 
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2.1 General abbreviations 
ot-MEM cc-minimal essential medium + ribonucleosides and deoxyribo- 
nucleosides 
BCIP 5-bromo-4-chloro-3-indolyl phosphate 
bp base pairs 
BMP Bone morphogenetic protein 
BSA Bovine serum albumin 
cDNA complementary DNA 
dATP deoxyadenosine triphosphate 
dCTP deoxycytidine triphosphate 
dGTP deoxyguanosine triphosphate 
DEPC Diethyl pyrocarbonate 
I ý25-(OH)21)3 l, cc25-Dihydroxy Vitamin D3 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
DTT Dithiothreitol 
EDTA Ethylene diarnine tetra-acetic acid 
EtBr Ethidium bromide 
FCS Feotal Calf Serum 
GAPDH Glyceraldehyde Phosphate Dehydrogenase 
dH20 Deionised water 
HCI Hydrochloric acid 
hr hour/s 
kb kilobases 
LiCI Lithium chloride 
min minute/s 
mRNA messenger RNA 
NaAc Sodium acetate 
NaCI Sodium chloride 
NTP nucleotide triphosphate 
PBS Phosphate buffered saline 
PCR Polymerase Chain Reaction 
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PFA Paraformaldehyde 
RNA ribonucleic acid 
RNase ribonuclease 
RNasin ribonuclease inhibitor 
SDS Sodium dodecyl sulphate 
sec seconds 
SSC standard saline citrate 
TAE Tris acetate-EDTA buffer 
TBS Tris-buffered saline 
TBST Tris-buffered saline with Tween 
TE Tris-EDTA buffer 
TESPA 3-aminopropyltriethoxysilane 
TRAP Tartrate Resistant Acid Phosphatase 
Tris Tris(hydroxymethyl)aminomethane 
tRNA transfer ribonucleic acid 
UTP uridine triphosphate 
2.2 Characterisation of mutant mice and histology 
2.2.1 c-Fos transgenic and knockout mice 
Heterozygous c-Fos mutant mice (c-Fos+/-) were intercrossed, and the re- 
sulting c-Fos-/- and their control littertnates were used for this project. c-Fos trans- 
genic mice (H2-c-fos-LTR) were generated previously, where the murine genomic c- 
fos gene was fused to the MHC class I H2-Kb promoter (Grigoriadis et al., 1993). In 
addition, the Y-untranslated region including the polyadenylation site of c-fos was 
replaced with the 3' LTR of the FBJ-MSV to ensure stability of the mRNA. Ilomo- 
zygous H2-c-fos-LTR mice develop osteosarcomas as early as 4 weeks after birth. 
2.2.2 Genotyping 
2.2.2.1 Genomic DNA isolation 
Tails (0.5- 1 cm long) were cut from c-Fos knockout and transgenic litters, and 
digested with 35[d 10mg/ml proteinase K in the 750[d tail buffer (50mM Tris-HCI, 
pH9. O; IOOmM EDTA, 100mM NaCl, 1% SDS) at 55'C overnight. Samples were 
81 
2. Materials and methods 
mixed on Eppendorf Thermomix shaker for 5min. After adding 250[d saturated NaCl, 
samples were spun for 10min at 13,000rpm. 750[d of supernatant was collected, and 
DNA was precipitated by adding 500[d of isopropanol. The mixture was spun at 
13,000rpm for 2min. After washing with 70% ethanol, the DNA pellet was dissolved 
in 200[tl TE at 37*C for 2hr. 
2.2.2.2 PCR genotyping c-fos knockout mice 
Each PCR reaction mixture contained I [d DNA template, 15pM of TonFos 1, 
TonFos2 and TonNeo3 primers, 15MM M902,32.5tiM dNTPs, PCR buffer and 
0.5[d Taq polymerase in 20[d reaction volume. The amplification was performed 
using 1 min denaturation at 94'C, I min annealing at 56*C, and l min extension at 72C, 
for 30 cycles. The PCR product was run on a 1.5% agarose gel with 0.5ttg/ml EtBr. 
The expected PCR product size for the wild-type c-Fos allele is 366bp, and the mu- 
tant c-Fos allele is 276bp. The primer sequences used for PCR genotyping are shown 
in Table 2.1. 
Table 2.1 Primers for genotyping c-fos knockout mice 
Primers Sequence 
TonFosl 5'-agc ttt tat cte cga tga gg-3' 
TonFos2 5'-ctg aca cgg tct tca cca tt-3' 
TonNeo3 5'-tct gtt gtg cce agt cat ag-3' 
2.2.2.3 Southern Blotting 
I Olig of genomic DNA were digested with the appropriate enzyme (Pvu Il for 
c-fos knockouts, BamH I for c-fos transgenics) overnight at 37'C. The reaction con- 
tains 50[d DNA, 6[tI I Ox Buffer (Buffer B for Pvu IT, Buffer E for BamH 1) 40U 
enzyme and d1-120 to a total volume of 60[d. Samples were run on a 0.8% agarose gel 
in TAE at 80V for 30min, then 95V for 3.5hr. The gel was depurinated with 0.25N 
HCI for 20min, denaturated with 0.5M NaOH/1.5M NaCl for 30min, and blotted 
overnight. The blot was set up from bottom to the top as follows: glass plate, 4 
sheets of Whatman 3MM paper, gel upside down, GeneScreen (NEN Life Science 
Products), 4 sheets Whatman 3MM, 3cm. high paper towel, glass plate and weight. 
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The Whatman paper and GeneScreen were presoaked in lOxSSC (2OxSSC stock: 3M 
NaCl, 300mM sodium citrate, pH 7.2). The membrane was then washed with 5OmM 
NaPi (I M NaPi stock: 89g Na2HP04-2H20,3-4ml H3PO4. pH 7.2) for 20min. After 
crosslinking under UV at energy 1200 for 1.5min, the membrane was baked in 80'C 
oven for I hr. 
A 400bp Accl-ApaLl fragment cloned in C54/7 plasmid was used as a probe 
for c-fos knockouts, and a 800bp BamHI fragment cloned in pUMI plasmid was 
used as a probe for c-fos transgenics. Probes for hybridisation were made as follows: 
25-50ng linearised DNA template, in 45[tl dH20 was denatured at IOOT for 5min. 
Denatured DNA was added to the "Ready to GoTm DNA labelling beads" (Amer- 
sham Pharmacia) and 5 ttl 32 P-dCTP, and incubated at 37'C for 30min. The labelled 
probe was then purified by spun through ProbeQuanfrm G-50 Microcolumns (Amer- 
sham Pharmacia) at 30OOrpm for 2min, and denatured with 16.671A of 2N NaOll at 
room temperature for 5min. 
The membrane was prehybridised with Church's buffer (0.5M NaPi, pH7.2, 
7% SDS, ImM EDTA, pH8.0) at 65'C for Ihr in Techne Hybridisation Oven, and 
hybridised with 7-8ml of probe-containing Church's buffer at 65"C overnight. After 
washing with 40mM NaPi/ 1% SDS at 65'C for 3xl5min to remove non-specific 
binding, the membrane was wrapped with Saran Wrap TM and exposed to X-ray film 
(Kodark Scientific Imaging film, X-OMAVm AR) at - 80'C for the appropriate time. 
For c-fos knockouts, the expected size for the wild-type c-fos allele is 1.8kb, and the 
mutant c-fos allele is 1.3kb. For c-fos transgenics, the expected size for the c-fos 
transgene is 6.9kb. 
2.2.3 Tissue preparation 
Mice were killed by cervical dislocation. Bone tissues from c-Fos knockout, 
and c-Fos transgenic mice, and their wild-type littermates, were dissected and fixed in 
fresh 4% paraformaldehyde at 4C for 24hr, and decalcified in 0.5M EDTA at 4C for 
the required time. Bone tissues were paraffin embedded in Hypercentre XP (Ther- 
moshandon) following dehydration and vacuum infiltration in a Histocentre 2 embed- 
ding station (Shandon). Tissue blocks were stored at 40C. 5Rm tissue sections were 
cut from paraffin embedded tissues by using a microtorne (Reichert-Jung 
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1140/Autocut), and mounted on TESPA-treated slides. Sections were dried at 52C 
ovemight and stored at 4C. 
2.2.4 TESPA-treated slides 
Slides were dipped in 10% HCI/ 70% ethanol for 10 sec, then washed in 
dH20 briefly. After dehydrating through 90% and 100% ethanol, slides were baked at 
200'C for 2hr. Sterilised slides were dipped in 2% TESPA (3- 
aminoprophyltriethoxysilane) in acetone for 30sec, and washed twice in 100% ace- 
tone for I Osec. After drying at 40-60T, slides were stored at room temperature. 
2.2.5 Haernatoxylin and Eosin staining 
Paraffin embedded sections were dewaxed twice in histoclear for 15min, and 
rehydrated through decreasing concentrations of ethanol. Sections were stained in 
Haematoxylin for 5min, and washed with tap water for 5min. After destaining in acid 
H20 (10 drops concentrated HCI in 200ml dH20) for a few seconds, sections were 
dehydrated through increasing concentrations of ethanol. Then the sections were 
stained in Eosin for 30sec, dehydrated in 90% and 100% ethanol, and mounted with 
DPX mountant (BDH). 
2.2.6 TRAP (tartrate resistant acid phosphatase) staining on slides 
Slides for TRAP staining were dewaxed and rehydrated as described above. 
The TRAP staining solution was composed of Img/rnI Naphthol-AS-TR-phosphate, 
I OOmM sodium tartrate, N, N-dimethylformamide, acetate buffer (0.2M glacial acetic 
acid, 0.2M NaAc) and lmg/mI Fast Red, buffer pH5.2. The sections were incubated 
in the staining solution at 37 'C for between I Omin to lhr, and washed with dH20, 
counterstained with Haernatoxylin and aquarnounted (BDII). 
2.3 In situ hybridisation 
2.3.1 Amplification of plasmid DNA 
2.3.1.1 Transformation 
20ng of plasmids containing the appropriate DNA fragment were added to 
100[tl of competent bacteria cells (Escherichia coll D115a), and incubated on ice for 
84 
2. Materials and methods 
30min. The bacterial cells were heat shocked at 42C for 90sec, and incubated on ice 
again for 3min. 900[d of LB liquid was added to the bacteria, and incubated at 37'C 
for Mr. 100[tl transformed bacteria were plated out on LB Agar/Ampicillin 
(10ORg/ml) and incubated at 37'C overnight. Several single colonies were picked from 
the plate and inoculated a starter culture of 3ml LB medium/Ampicillin (100[tg/ml). 
Each culture was incubated at 37C overnight with vigorous shaking (300rpm). 
2.3.1.2 Small scale preparation of plasmid DNA 
1.5ml from each culture was spun down. The pellet was resuspended in 100[d 
GTE (5OmM glucose, 25mM Tris-CI pH8.0, lOmM EDTA pH8.0), and incubating 
on ice for 5min. The bacterial cells were lysed with 20ORI TENS (0.2NNaOH, 1% 
SDS) on ice for 5min. Protein was precipitated by addingl50[tl of 3M potassium / 
5M acetate, and incubated on ice for 5min. The lysate was cleared by centrifugation 
at 130OOg for 5min. The supernatant was transfered to a fresh tube, and the plasmid 
DNA was precipitated with 450[d isopropanol. The pellet was spun down and 
washed with 70% ethanol. After air-drying, the pellet was re-dissolved in 50[d 
TE/RNase (20ýtg/ml). 10[tl of each plasmid were mini-digested with appropriate 
enzymes at 37*C for 1hr. The digestion was run on a 0.8% agarose gel to check the 
plasmids, and the correct plasmid was subjected to large scale preparation as de- 
scribed below. 
2.3.1.3 Large scale preparation of plasmid DNA 
100[d of the original culture was inoculated into 200ml LB medium/Ampicillin 
(10ORg/ml), and incubated at 37'C overnight with vigorous shaking (300rpm). Ac- 
cording to the QIAGEN plasmid purification Handbook, the bacterial cells were har- 
vested by centrifugation at 6000xg for 15min at 4C and resuspended in I OMI Buffer 
P 1. The bacterial cells were lysed by adding I Oml Buffer P2 and incubated at room 
temperature for Smin. To clear the lysate, 10ml of prechilled Buffer P3 was added 
and incubated in the barrel of the QIAfilter cartridge at room temperature for 1 Omin. 
The lysate was filtered into a previously equilibrated QlAGEN tip. The QIAGEN 
tip was washed twice with 25ml Buffer QC. DNA was eluted with 15ml Buffer QF 
and precipitated by adding 10.5ml room temperature isopropanol. After spun down 
at 1500g for 30min at VC, the DNA pellet was wasbed with 70Vo ethanol and air- 
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dried. The pellet was re-dissolved in a suitable volume of DEPC-1120 at 37'C for 
30min. 
2.3.1.4 Quantification of DNA 
The concentration of DNA samples was measured by absorbance readings at 
260nm and 280nm wavelength using Light Wave (WPA). The concentration of DNA 
was calculated by the following formula: 
A260XSOxdilution factor--DNA conc ([tl/ml) 
2.3.1.5 Linearisation of plasmids 
Plasmid DNA containing part of the known sequence of a gene of interest was 
digested overnight by appropriate restriction enzymes at 37'C to produce a linearised 
DNA template (Table 2.2), which was then cleaned by phenol/chloroform extraction 
or gel extraction. 
Table. 2.2 List of t)robes 
Probe Restriction enzymes RNA polymerase Hydrolysis time 
Cbfa-I S Xho I T3 
AS Not I/ Xba I T7 
osteocakin S Spe I T7 
AS Pst I T3 
OPG S Sac 11 INco I Sp6 
AS Spe I T7 
RANKL S SacIl1NcoI Sp6 
AS Spe I T7 
MMP-9 S EcoR I Sp6 
AS BamHl T3 
cathepsin K S Spe I T7 
AS NCO I Sp6 
RANK S Xba I T3 25'58" 
AS Hind III T7 
C-fms S Stu I T7 
AS Pst I Sp6 
PB15 S EcoR I T3 11'48" 
AS Sal I T7 
Fra-1 S Xba I T7 
AS EcoR I T3 
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2.3.1.6 PhenoI-chloroform extraction 
DEPC-H20 was added to the overnight digestion so that the final volume is 
300[d. An equal volume (3001d) of phenol was added to the sample, and mixed well 
by shaking. The sample was spun at high speed for 5min, and the aqueous phase was 
removed to a fresh tube. After another phenol extraction, an equal volume of chloro- 
form was added to the aqueous phase. The sample was mixed well by shaking and 
spun at high speed for 2min. The aqueous phase was removed to a fresh tube. DNA 
was precipitated at -20'C overnight with 1/10 volume of IOM NaAc (pH 5.2) (30[d) 
and 2.2 volume of 100% ethanol (726[d). DNA was pelleted and washed with 70% 
ethanol. After air-drying, the pellet was re-dissolved in a suitable volume of TE or 
DEPC- H20 at room temperature for 30min. 
2.3.1.7 Gel extraction 
A 1% (w/v) agarose gel was prepared by adding appropriate amount of aga- 
rose powder (ICN, Genetic Technology Grade Agarose) to TAE buffer (40mM 
Tris-base, lOmM EDTA and 0.1% acetic acid) and boiling to dissolve the agarose. 
The solution was cooled down to about 65*C, and EtBr (10mg/ml) was added to a 
final concentration of 0.5[tg/ml. The agarose was poured into a gel tray and left to 
solidify. After it was set, the gel was put into the electrophoresis tank, and TAE 
buffer was poured into the tank to a level about Imm above the gel surface. DNA 
samples with 6xloading dye (Promega) were loaded onto the gel along with I Kb 
DNA ladder (Promega). Gels were run at 60-IOOV according to the size for the ap- 
propriate time. After electrophoresis the gel was examined under ultraviolet light and 
photograghs were taken by a Kodak video graph printer up 860CE. 
According to the MinElute Handbook, DNA fragment was excised from the 
agarose gel, and weighed. 3 volumes of Buffer QG was added to I volume of gel, and 
incubated at 500C for 10min to dissolve. The sample was applied to the MinElute 
column and spun for I min. 500[il of Buffer QG was added to the spin column and 
spun for Imin. After washed with 750[d of Buffer PE, the MinElute column was 
dried by spun. I O[d of pre-warmed Buffer EB was added to the centre of the mem- 
brane and incubated at 37'C for 5min. DNA was eluted by spun for Imin. 
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2.3.1.8 Quantification of linearised plasmid 
I [d of purified linearised plasmid was run on a 0.7% agarose gel along with 
I [tg Lambda DNAIHind III Markers (Promega). The amount of DNA was evaluated 
approximately by comparing the intensity of bands to that of the ladder fragments 
under ultraviolet light. 
2.3.2. In vitro transcription 
2.3.2.1 Digoxygenin in vitro transcription 
1-2[tg of linearised DNA template were added to the transcription reaction 
along with 2[tl O. lMDTT, 4Ud 5xTranscription Buffer, 2[d lOxDigoxygenin labelling 
mix (Roche), I Id RNasin (40U/[tl) and 2[d RNA polymerase necessary for the tran- 
scription reaction (i. e. T3, T7 or SP6 20U/[tl, Prornega) (Table 2.2) for 2hr at 370C. 
The DNA template was digested with 5ttl RNase-free DNase (IU/ul, Promega) for 
30min at 37C, and the reaction was stopped with 2[d 0.2M EDTA. The probe was 
precipitated overnight with 2[d 5M LiCl and 75 [d 100% ethanol at -200C. The RNA 
probe was pelleted by spun at 13,000rpm 4'C for 20min. The pellet was washed 
with 500[d 70% ethanol. After spinning for 10min at 13,000rpm at 4'C, the pellet 
was resuspended in 100[d DEPC-H20 and I[tl RNasin and dissolved at 370C for 
20min. 3 [d RNA probe was run on a 0.8% agarose gel to check the quality and quan- 
tity of the probe. RNA probes were stored at -20'C. 
2.3.2.2 Radioactive in vitro transcription 
2-3[tg of the DNA template were added to the transcription reaction with 
0.5[tl IM DTT, 1.2gl lOmM GTP, 1.2gl lOmM CTP, 1.2[tl lOmM ATP, Itil 
50[tmM UTP (Promega) and 7 [tl 35 S-labelled UTP (I I OOCi/mmol), 0.5[il RNasin and 
the appropriate RNA polymerase. This was incubated at 37'C for 40min, fresh en- 
zyme was added and incubated for a further hour. The template was digested with 
0.5RI RNase-free DNase, I pl. RNasin, 0.5RI IM DTT and I gI I OmgIffiI tRNA at 37 
'C for I Omin. The RNA probe was precipitated by the addition of 4[d IM DTT, 4[4 
5M NaCl, 20[tl 3M NaAc and 400[d 100% ethanol and 160[d DEPC-H20 at -20'C 
overnight. The RNA probe was pelleted at 13,000 rpm for 10min, and washed twice 
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with 500 [tl lOmM DTT in 70% ethanol. After air-drying, the pellet was resus- 
pended in 50[d 50mM DTT in DEPC-1120. RNA probes were stored at -20'C. 
The counts of probes were measured. I RI probe was added to 2ml of scintil- 
lation fluid in a plastic scintillation vial. The activity of the probe was measured on a 
liquid scintillation counter (EG&G Berthold). 
2.3.2.3 Hydrolysis of riboprobes 
If the probe was longer than 300bp, it was hydrolysed to generate smaller 
fragments. 501AI hydrolysis buffer containing 8OmM NaHC03.120mM Na2C03 
pH 10.2 and I OmM DTT was added to the probe and incubated at 60'C for the re- 
quired length of time according to each probe. The reaction was stopped by adding 
50[tl neutralising buffer (0.2M sodium acetate, 1% glacial acetic acid, lOmM DTT). 
The riboprobe was precipitated with lOmM 3M NaAc pH5.2, l[tl tRNA and 425tAl 
100% ethanol at -200C overnight. The RNA probe was pelleted at 13,000rpm for 
15min. After washing with 5001 [d I OmM DTT in 70% ethanol, the RNA probe was 
resuspended in 50[d 5OmM DTT. Table. 2.2 shows the probes used for in situ hy- 
bridisation. 
The expression of exogenous c-fos was analysed by using a transgene-specific 
probe, named pB 15, as described previously (Grigoriadis et al., 1993). The probe is a 
480bp PCR fragment derived from the FBJ-MSV, coding part of the retroviral enve- 
lope protein pI 5E. 
2.3.3 In situ hybridisation 
2.3.3.1 Digoxygenin-in situ hybridisation 
Paraffin sections were dewaxed, rehydrated and postfixed with 4% parafor- 
maldehyde. Slides were washed in PB S, and immersed in 0.1 M HCI. They were then 
digested with proteinase K (10[tg/ml in 20mM Tris-HCI, 2mM CaC12. pH7.4) at 
37'C for 15 -30min. The tissues were postfixed and acetylated in 0.25% acetic anhy- 
dride in 0.1 M TEA and washed in PBS. 
Tissues were prehybridised using buffer containing 50% formamide, 2xSSC, 
0.5xDenhardts solution and yeast tRNA, for 2hr at room temperature. Digoxygenin 
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labelled probes were added at I OOng/ffil in prehybridisation solution, heated at 1 OOT 
for 3min and cooled on ice. Hybridisation buffer was added to the sections and over- 
laid with parafilm and incubated overnight at 55'C (hot start at 80'Q. Slides were 
then washed in 5xSSC at 550C for 5min, 0.2xSSC for lhr, and cooled to room tem- 
perature in 0.2xSSC. Sections were then washed in lOOmM Tris, 150mM NaCl 
pH7.5 and pretreated with 1% blocking agent for lhr, followed by incubation with 
anti-DIG Fab-fragment for Mr. Colour development was carried out in the presence 
of NBT (4-nitro blue tetrazoliurn chloride) and BCIP (5-bromo-4-cholro-3-indolyl- 
phosphate) and levarnisole for 5min to overnight. Slides were then washed in I OmM 
Tris, ImM EDTA pH8.0, counterstained with Haematoxylin, and mounted with 
aquamount. 
2.3.3.2 35S -radioactive in situ hybridisation 
Sections were dewaxed with xylene, rehydrated with decreasing concentra- 
tions of ethanol, and postfixed with 4% PFA/PBS for 10min. After washing with 
PBS, sections were digested with lOgg/ml proteinase K (37'C, 30min) in PBS and 
postfixed with 4%PFA/PBS for 10min. Sections then were sequentially washed with 
PBS, incubated in 0.2 N HCI for 10min. After washed with PBS, sections were ace- 
tylated with 0.25% acetic anhydride in the presence of O. lM triethanolamine for 10 
min, dehydrated with increasing concentrations of ethanol, and air-dried. Hybridisa- 
tions with 35 S-labelled complementary RNAs were performed in a humidified cham- 
ber in a solution containing 50% formamide, 10% dextran sulphate, 1xDenhardt's 
solution, 600mM NaCl, lOmM Tris-HCI, lmM EDTA, 50mM DTT, 0.25% SDS, 
and 200gg/ml tRNA overnight at 50T. 
After hybridisation, sections were washed with 5xSSC at 50T, with 50% 
formamide/2xSSC at 50'C for 30min, and then with I OmM Tris-HCI (PH7.6), 
5OOmM NaCl, ImM EDTA (TNE) at 37'C for 10min. Sections were treated with 
I OAg/ml ribonuclease A in TNE (3 7'C, 30min). After being washed with TNE, sec- 
tions were incubated once with 2xSSC (50'C, 20min) and twice with 0.2xSSC (50T, 
20min). Sections were dehydrated with increasing concentrations of ethanol and air- 
dried. Slides were then placed on X-ray films (Kodak BioMax MR Film), and autora- 
diographs were obtained after overnight exposure at room temperature. Slides were 
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dipped into emulsion and stored at room temperature or 4'C (after 4 days) for the 
times estimated from the intensity of expression on X-ray film. After developing, 
sections were counterstained with Haernatoxylin and Eosin and mounted with DPX 
mountant. 
2.4 Immunohistochemistry 
Paraffin sections were dewaxed twice in Histoclear for 15 min, and rehydrated 
through decreasing concentrations of ethanol. Sections were trypsinised in I% tryp- 
sin in TBS at 37'C for 15min. To prevent non-specific background, sections were 
blocked with serum in TBS at room temperature for 30min, 20% normal goat serum 
for OPG and 20% normal rabbit serum for RANKL. Sections were incubated with 
primary antibodies, goat polyclonal anti-Mouse RANKL (Santa Cruz) and rabbit 
polyclonal anti-Human OPG (Insight Biotechnology), at room temperature for 2hr or 
at 4'C overnight. After washing with TBS for3x5min, sections were incubated with 
secondary antibodies for lhr, biotinylated rabbit anti-goat IgG (Dako) for RANKL 
and goat anti-rabbit for OPG. After washed with TBS, sections were incubated with 
ABC (StrepABComplex/AP, Dako) for 30min. Colour was developed with Sigma 
Fast Red TR/Napthol AS-MX Tablet set for 2min until visible. Sections were 
washed in TBS, counterstained with haernatoxylin for 45sec and mounted with 
aquamount. 
For F4/80 staining, after dewaxed and rehydrated, sections were incubated in 
0.42% 11202/methanol for 40min to block the endogenous hyperoxidase, and washed 
twice with PBS. To prevent non-specific background, sections were blocked with 
1: 100 rabbit serum for 3 Omin. Primary F4/80 antibody was added to the sections and 
incubated at room temperature for 90min. After washing three times in PBS, sections 
were incubated with secondary antibody (1: 100 biotinylated rabbit anti-rat IgG) for 
45min. ABC (Vectastain) was made by adding one drop A and one drop B to 2.5 H 
PBS at 30min. After washing three times in PBS, sections were incubated with ABC 
for 45min, and washed twice with PBS. Colour was developed with DAB (Vectas- 
tain) for 2-5min until visible. Sections were counterstained with Haematoxylin and 
dehydrated through increasing concentrations of ethanol. After dipped in Histoclear, 
sections were mounted with DPX mountant. 
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2.5 Cell culture 
2.5.1 Bone marrow cultures 
Mice were killed by cervical dislocation, and the tibias and femurs were re- 
moved and dissected free from adhering soft tissues. Long bones isolated from c-Fos 
transgenic mice either had no turnours, or had small turnours not affecting most part 
of the bone marrow space. To make sure that exogenous c-Fos was expressed in 
transgenic bone marrow cells, RT-PCR for the c-Fos transgene was performed in each 
experiment, as described below in table 2.3. 
The bone marrow was flushed with a-MEM (Sigma) containing 10% FCS ei- 
ther from Gibco BRL (Paisley, UK) or Summit (Denver, CO, USA) using a IOMI 
syringe attached to a 25-gauge needle. For the newborn mice and adult c-Fos knock- 
out mice, bone tissues were chopped by using a sterilized scalpel blade. The bone 
marrow suspension was carefully agitated with a plastic Pasteur pipette to obtain a 
single cell suspension, and filtered through a cell strainer (70[tm Nylon, BD Fal- 
conTm). The bone marrow cells were spun down at 1200rpm for 5min, resuspended 
in 15ml ot-MEM containing 10% FCS and 25ng/ml recombinant murine M-CSF (Ge- 
netics Institute), and incubated overnight in a 75cm2 flask (TPP) at 37'C. The next 
day, non-adherent cells were harvested and haernatopoietic cells were counted. 90[d 
trypan blue in 2% glacial acetic acid was added to 10gl cell suspensions. Two times 
10[d mixture was added into a haemocytometer, cells not stained blue were counted. 
The concentration of the cell suspension was calculated as follows: 
(No. I+ No. 2)/2x IOXI04 = Cell conc (cells/ml) 
The appropriate volume of cell suspension was spun down at 1200rpm for 
5min. Cells were plated into 96-well tissue culture plates (TPP) at a cell density of 
5x 104 cell/well in 2001tl a-MEM-10% FCS medium supplemented with 25ng/ml M- 
CSF and either 5ng/ml recombinant mouse sRANKL (AMGEN) or 30ng/ml of re- 
combinant human sRANKL (Autogen Bioclear/Santa Cruz). Cells were fed every 3 
days with 200[tl fresh medium. For c-Fos transgenic bone marrow culture, cells were 
cultured with different concentrations of M-CSF (0,10,30 and lOOng/ml) and 
RANKL (0,1,5,10,50,100ng/ml). Cells were fixed on day 5 to day 7 for TRAP 
staining, and day 8 to day 10 for analysis of resorption pits. 
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2.5.2 SPleen cultures 
Spleens were removed, mashed and filtered through a cell strainer. Cells were 
spun down and resuspended in a-MEM containing 10% FCS, and incubated over- 
night in M-CSF (25ng/ml) in a 75cm 2 flask. The next day, non-adherent cells were 
harvested and spun down. Cells were plated into 96-well plates at a cell density of 
5xlO5cells/welI in 200[tl (x-MEM-10% FCS supplemented with M-CSF and 
RANKL. Cells were fed every 3 days with 200pl fresh medium. 
2.5.3 TRAP staining 
After culture for 5-7 days, cells were washed in PBS, fixed in 4% parafortnal- 
dehyde/ PBS for 15min at room temperature. After washing with Ix PBS, cells were 
stained for acid phosphatase at 37C at the presence of 0.05M sodium tartrate using 
the Leukocyte Acid Phosphatase kit (SIGMA) for the appropriate time. TRAP posi- 
tive cells containing at least three nuclei were counted. 
2.5.4 Analysis of resorption pit formation 
Ivory dentine slices cut to 5mm diameter wafers were cleaned by ultrasonica- 
tion in distilled water, washed, sterilised by immersion in 100% ethanol overnight, 
and stored dry at room temperature. Cells were plated the same as on plastic. On day 
5 to 7, concentrated HCI was added to the medium (82[tl per 100ml medium). Cells 
were fixed on day 8 to 10, and stained for TRAP activity. After cells were removed 
by brushing with a toothbrush, the dentine slices were stained with 1% Toluidine 
Blue for 10sec. The resorption pits were displayed on the screen by using a micro- 
scope (Leica) and video camera (Sony), and the number of pits was quantified using 
the point-counting method. The screen was divided into 10mmx I Omm squares, and 
the pits overlying each grid intersection were counted. The percentage of resorption 
was quantified as the number of counted pits divided by the whole area of the slice. 
2.5.5 Statistics 
All the experiments were repeated at least three times. Values presented are 
the mean±SE of triplicate cultures from a representative experiment. The differences 
between different groups were analysed by unpaired Students west. 
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2.5.6 Apoptosis assay 
The apoptosis of cells was analysed by TUNEL (TdT-mediated dUTP nick 
end labelling) staining using the In Situ Cell Death Detection, POD kit (Roche). Cells 
grown on glass coverslips were fixed with PFA for lhr at room temperature and 
rinsed in PBS. The cells were permeabilised (0.1% Triton X-100 in 0.1% sodium 
citrate) for 2min on ice, and rinsed twice in PBS for 5min. Cells were incubated with 
TUNEL reaction mixture (1: 10 dilution of terminal transferase solution in label solu- 
tion) at 37"C for Mr. Coverslips were rinsed three times in PBS for 5min. After 
mounted with Vectashield (VECTOR), the apoptotic cells were observed under fluo- 
rescence microscope. 
2.6 R-NA manipulation 
2.6.1 Total RNA isolation from cultured cells 
Nonadherent cells were spun down at 1200rpm, and lysed with 300ýtl solu- 
tion D (4M guanidinium, 25mM sodium citrate, I OOmM P-mercaptoethanol, 0.5% 
lauroylsarcosine). Cells grown in 6-well plates were lysed with 300gl solution D and 
scraped with a rubber scraper and transferred to a falcon tube. After 30ýd 2M sodium 
acetate (pH 4.0), 300pl saturated phenol and 76ptl chloroform were added, samples 
were mixed thoroughly by vortexing for 10sec, and incubated on ice for 15min. The 
samples were spun at 10,000rpm for 20min at 4'C, the aqueous phase were trans- 
ferred to a fresh tube and 300ýd isopropanol was added and precipitated overnight at 
-20'C. Samples were then spun at 10,000rpm for 20min at 4C, the supernatant was 
removed and the pellet was dissolved in 300gl solution D. This solution was trans- 
ferred to an eppendorf tube and precipitate with 600ýtl ethanol overnight at -20'C. 
The samples were then pelleted by spun at speed 13,000rpm for 10min at 4'C. After 
washed with 75% ethanol and air-dricd, the pellet was redissolved in 20 to 50[tl of 
DEPC-H20 and stored at -80'C. 
Total RNA was also isolated using RNeasy Mini Kit (Qiagen). Cells were 
lysed with 35ORI Buffer RLT (10[d P-mercaptoethanol per Iml Buffer RLT). The 
lysate was homogenized by spinning through a QlAshredder spin column for 2min at 
13,000rpm. 350ttl 70% ethanol was added to the homogenized lysate and mixed well 
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by pipetting. Samples were applied to an RNeasy mini column, and spun for l5sec at 
13,000rpm. The flow-through was discarded. The RNeasy column was washed by 
adding 700[tl Buffer RWI and spun for l5sec at 13,000rpm. Contaminants were 
removed by adding 500[tl Buffer RPE to the column and spun for l5sec at 
13,000rpm. Another 500[d Buffer RPE was added, and the column was spun for 
2min at 13,000rpm. To make sure there was no ethanol contamination, the RNeasy 
column was placed in a fresh 2ml collection tube and spun for another minute. RNA 
was eluted with 30-50[d RNase-free H20 and spun for Imin at 13,000rpm. RNA 
samples were stored at -80'C. 
2.6.2 Isolation of total RNA from tissues 
Limbs from c-fos knockouts and their littermates, tumour tissues from c-Fos 
transgenic mice, were dissected free of soft tissues and put in 8ml solution D (4M 
Guanidine thiocyanate, 25mM sodium citrate, IOOmM P-mercaptoethanol. 0.5% 
lauroylsarcosine, 0.1% antifoam A). Sample was homogenized in Polytron for 45sec 
at speed 6.0.8ml 2M NaAc (pH 4.0), 8. OmI phenol and 1.6ml chloroform were added 
to the sample, and mixed well by vortexing 20sec. After incubating on ice for 15min, 
each sample was spun at speed 10,000rpm for 15min at 4*C. The supernatant was 
transferred to a fresh tube, and RNA was precipitated by adding 7ml isopropanol at - 
20'C overnight. RNA pellet was spun down at speed 50OOrpm for 15min at 4'C. 
After washed with 70% ethanol, RNA was dissolved in a suitable volume of DEPC- 
H20. 
2.6.3 Quantification RNA 
The concentration of RNA samples was measured by absorbance readings at 
260nm and 280nm wavelength using Light Wave (WPA). The concentration of RNA 
was calculated by the following fon-nula: 
A260 x40 xdilution factor--RNA conc ([d/ml) 
2.6.4 Northern blotting 
The gel tank, tray and combs were washed with 0. IN NaO11, and rinsed thor- 
oughly with d1120. The gel was made of 3.6g agarose, 8. Oml 50xMOPS (1M MOPS, 
0.25M NaAc, 0.05M EDTA, pH 7.0) and 325ml 1120. After the mixture was boiled 
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and cooled down to 65'C, 67ml formaldehyde was added. For the samples, 20[tg 
RNA in 20[d DEPC-H20 were mixed with 20[d formamide, 7[d formaldehyde, I [d 
50xMOPS and 2[d bromophenol blue, and heated at 70'C for 5min and cooled down 
on ice. The RNA samples were run on the gel in lxMOPS at 100V for 30min, then 
120V for 4hr with pumping. The gel was washed in I OxSSC for 20min with shaking, 
and blotted with Genescreen (presoaked in lOxSSQ overnight (see protocol for 
Southern blotting). The blot was washed in 50mM NaPi for 10min, and shaking for 
another I Omin. After crosslinking under UV at energy 1200 for 1.5min, the blot was 
baked in 80'C oven for Mr. Hybridisation was performed the same way as Southern 
Blotting. The blot was rehybridised with different probes after stripped in stripping 
buffer (2mM EDTA, 1% SDS) at 80'C for 30min. 
2.6.5 RT-PCR (Reverse Transcription Polymerase Chain Reaction) 
I gg of total RNA was used to synthesise cDNA. The RNA was heated to 
70'C for 5min together with 0.5ýtg oligo-dT primer. After cooling down to VC, 5PLI 
M-MLV RT Buffer, 1.25ptl lOmM dNTPs, IgI M-MLV RT (RNase H-) (Qiagen) 
and 3.75gl DEPC-1120 were added to each reaction and heated to 40'C for 60min. 
The enzyme was inactivated by heating to 700C for 15min. 3111 of RT product was 
used for PCR. Each PCR reaction mixture contained I OpM of reverse and forward 
primers, 3ýd MgC12 (25mM), 1.25[tl dNTPs (lOmM), 5gl lOxPCR buffer and 0.5[tl 
Taq polymerase (Promega) in a final volume of 50pl. The amplification was per- 
formed for indicated cycles shown in Table 2.3 using I min denaturation at 940C, l min 
annealing at indicated temperature, and 1 min extension at 72'C. PCR product was run 
on a 2% agarose gel with EtBr staining. Where indicated RT-PCR gels were scanned 
by densitometry using SigmaGel software. 
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Table. 2.3 List of primers 
Wý 01 
Primers Sequence 51-3' ATM Length Cycles 
TRAP For age age caa gga gga. cta cgt t 56"C 238bp 28 
Rep tcg ttg atg tcg cac; aga gg 
CTR For gtc ttg caa, cta ctt ctg gat gc: 58'C 255bp 28 
Rev aag aag aag ttg ace ace aga gc 
RANK For aca cct gga atg aag aag ata. aat g 60T 448bp 26 
Rev ctt cat ctc tgt ggt agt agt ggc t 
C-fms For aac aag ttc tac; aaa, ctg gtg aag g 60*C 753bp 22 
Rev gaa, gee tgt agt cta age atc; tgt c 
F4180 For gaa. ttc tec ttg tat atc ate age 56*C 157bp 26 
Rev gaa, tct tgg cca aga aga gac 
FOS-tg For ace tgg tgc tgg att gta tct agt gc 60T 188bp 28 
Rev gcg gta gtc cct gtt ccc act C 
fra-I For cgc agg ccc tgc gag cag ate 60T 279bp 40 
Rep gcc aga, ace ace tgg gtc ctt 
fra-2 For aag tgt egg aac cgt cgc egg gag 60T 539bp 40 
Rev ttc aag gag tct gat gac tgg We 
IFN-fi For cca cag ccc tct cca tca act ata age 60T 372bp 30 
Rev age tet tca agt gga gag cag ttg agg 
TRAF6 For gca agt atg agt gtc cca tct g 60T 353bp 35 
v Rev cct ggg aca ate ctc aat aat g 
GAPDH For ace aca gtc cat gcc ate ac: 60T 452bp 24 
Rev tcc ace ace ctg ttg ctg ta 
Abbreviation: ATM, annealing temperature; For, forward; Rev reverse. 
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Chapter 3 
In situ expression studies in c-Fos knockout and transgenic 
mice 
98 
3. In vivo studies 
3.1 Introduction 
Initial experiments were performed to investigate the extent to which osteo- 
clasts and osteoblasts were affected when c-Fos levels were altered in vivo. Thus, the 
first part of my thesis was to examine the expression of osteoclast, osteoblast and 
macrophage marker genes in situ, in bones of mutant mice that either lack c-Fos, or in 
bone tumours of transgenic mice that overexpress c-Fos. 
Although it has been known for a long time that c-fos knockout mice develop 
osteopetrosis due to a complete absence of osteoclasts, it's still not completely clear 
at which point osteoclast development is blocked. To investigate this, the expression 
of marker genes which represent different stages of osteoclast and macrophage differ- 
entiation were analysed by in situ hybridisation and immunohistochemistry. 
3.2 Expression of osteoclast and macrophage marker genes in c-fos 
knockout long bones 
Histochcmical staining for TRAP activity showed that there were many 
TRAP positive multinucleated osteoclasts and mononuclear precursors present in 
regions distal to the growth plate and along the periosteal and endosteal bone surfaces 
of wild-type mice (Fig. 3.1.1 A, C). TRAP positive cells were completely absent in c- 
fos knockout long bones (Fig. 3.1.1 B, D). As previously reported (Grigoriadis et al., 
1994), this suggests that in the c-Fos knockouts, fully differentiated osteoclasts as 
well as their post-mitotic mononuclear precursors are absent. This was now con- 
firmed by in situ hybridisation for Cathepsin K, which is also expressed at the same 
stages of osteoclast differentiation as TRAP. Strong expression of Cathepsin K was 
observed in multinucleated osteoclasts and mononuclear precursors in wild-type 
mice, but no expression was observed in knockout mice (Fig. 3.1.2 A-D). 
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Fig. 3.1.1 TRAP-staining of long bones from wild-type and c-fos knockout mice. TRAP- 
positive multinucleated and mononuclear cells are observed adjacent to bone surfaces in wild- 
type long bones (A, C), whereas c-fos knockout bones lack TRAP-positive cells (13,13). Origi- 
nal magnification: A, Bx 10; C, D x40. 
In situ hybridisation for MMP-9, which is an early marker of the osteoclast 
lineage, showed strong expression in multinucleated osteoclasts and mononuclear 
precursors of wild-type mice, and interestingly, expression was also observed in 
mononuclear osteoclast precursors of the knockouts (Fig. 3.1.3 A-D). Similarly, 
RANK was expressed in multinucleated osteoclasts and mononuclear precursors of 
wild-type mice, and was only expressed in mononuclear precursors of the knockouts 
(Fig. 3.1.4 A-F). These observations suggest that the MMP-9- and RANK-positive 
lop 
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3. In vivo studies 
mononuclear cells in c-fos knockout mice represent an osteoclast progenitor popula- 
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Fig. 3.1.2 Digoxygenin in situ hybridisation of Cathepsin K expression in long bones of 
wild-type and c-fos knockout mice. Cathepsin K is expressed in multinucleated osteoclasts 
and mononuclear precursors of wild-type long bones (A, C, arrow), but is absent in c-fos 
knockout bones (13, D). E and F show sense controls. Original magnification: A, Bx 10; C, D 
x40; E, F x20. 
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Fig. 3.1.3 Digoxygenin in situ hybridisation of MMP-9 expression in long bones of wild- 
type and c-fos knockout mice. AIMP-9 is strongly expressed in multinucleatcd osteoclasts 
(arrows) and mononuclear precursors (arrowheads) of wild-type long bones (A, C), but is only 
expressed in mononucicar cells (arrows) of mutant bones (13, D). E and F show sense controls. 
Original magnification: A, B x5; C, D x40; E, F x20. 
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Fig. 3.1.4 Radioactive in situ hybridisation of RANK expression in long bones of wild-type 
and c-fos knockout mice. RANK is strongly expressed in i-nultinuclcated osteociasts (arrows) 
and mononuclear precursors (arrowheads) in wild-type bones (A, C, E). More mononuclcar 
cells (arrow) express RANK in mutant bones (13,13, F). G and H show sense controls. A, B, E, 
F, bright field; C, D, G, H, dark field. Original magnification: A-D, G, H x5; E, IF x40. 
FKO 
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3. In vivo studies 
Analysis of c-fms expression showed strong expression in multinucleated 
osteoclasts and mononuclear cells not only on the bone surfaces but also in the bone 
marrow of wild-type mice (Fig. 3.1.5 A, C, E). This probably reflected the presence of 
both osteoclasts and macrophages, since c-fms is expressed in both these cell types. 
In the absence of c-fos, however, c-fms expression was observed in a greater number 
of mononuclear cells but in no multinucleated cells which were absent (Fig. 3.1.5 




Fig. 3.1.5 Radioactive in situ hybridisation of c-fms expression in long bones of wild- 
type and c-fos knockout mice. c-Fms is expressed in multinucleated and mononuclear cells 
in wild-type bones (A, C, E). More mononuclear but no multinucleated cells express c-fms in 
mutant bones (B, D, F). G and H show sense controls. A, B, E, F bright field; C, D, G, H 
dark field. Original magnification: A-D, G, H x5; E, F x40. 
kF 
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3. In vivo studies 
Since there were no osteoclasts in c-fos knockout mice, these results suggested 
that there was an increase in macrophages and this was examined further using a 
macrophage-specific marker. Immunostaining for F4/80 antigen showed positive 
staining cells in the wild-type bone marrow, while a greater number of F4/80-positive 
cells were observed in the knockouts (Fig. 3.1.6 A-D). This confirms the increase in 
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Fig. 3.1.6 Immunostaining of F4/80 antigen expression in long bones from wild-type 
and c-fos knockout mice. F4/80-positive cells are observed in the wild-type bone marrow 
spaces (A, C). More F4/80-positive macrophage-like cells are present in mutant bones (13, D). E 
and F show negative controls. Original magnification: A, Bx 10; C, D x40; E, F x20. 
105 
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3.3 Expression of osteoblast marker genes in c-fos knockout long 
bones 
Previous data in c-fos knockouts implied that osteoblasts were normal 
(Grigoriadis et al., 1994). However, this was based only on their ability to support 
osteoclast differentiation, as the expression of marker genes had not been analysed. 
Thus, in order to further rule out the possibility that the defect in osteoclasts in the 
absence of c-fos is due to osteoblasts, in situ hybridisation and immunohistochemis- 
try of osteoblast marker genes and genes that are critical for osteoclast differentiation 
were performed. 
Analysis of Cbfa-I expression showed strong expression in osteoblasts, pre- 
hypertrophic chondrocytes and some bone marrow cells of the wild-type long bones 
(Fig. 3.2.1 A, C). Similarly, in c-fos knockout long bones, despite the altered bone 
architecture, strong expression of Cbfa-I was observed in osteoblasts and some bone 
marrow cells (Fig. 3.2.1 B, D). In situ hybridisation of osteocalcin showed strong ex- 
pression in osteoblasts of both wild-type and c-fos knockout long bones (Fig. 3.2.2 
A-D). These results confirm the previous notions, but not yet published, that os- 
teoblasts lacking c-fos do not show any obvious phenotype. 
Although it has been established that c-fos knockout ostcoblasts could sup- 
port osteoclast differentiation (Grigoriadis et al., 1994), these data were based on in 
vitro studies with no molecular analyses. Thus, in the next experiments, the expres- 
sion of two osteoblast-derived. factors that regulate osteoclastogenesis, RANKL and 
OPG, were analysed in situ. In situ hybridisation of RANKL showed strong expres- 
sion in osteoblasts and prehypertrophic chondrocytes of the wild-type long bones 
(Fig. 3.2.3 A, C), and immunolocalisation of RANKL comfirmed strong protein ex- 
pression in osteoblasts (Fig. 3.2.3 E). The majority of osteoclasts didn't express 
RANKL (Fig. 3.2.3 C), although some multinucleated osteoclasts occasionally ex- 
pressed low levels of RANKL (data not shown). In c-fos knockout long bones, strong 
expression of RANKL was observed in osteoblasts and prehypertrophic chondro- 
cytes, at both the RNA and protein levels (Fig. 3.2.3 B, D, F, ). 
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Fig. 3.2.1 Digoxygenin in situ hybridisation of Cbfa-I express 
i 
ion in long bones of wild-type 
and c-fos knockout mice. In wild-type long bones, CNa-l is expressed in ostcoblasts and 
prehypertrophic chondroeytcs (A, C). Cbfa-I mRNA is also similarly detected in the mutant 























Fig. 3.2.2 Digoxygenin in situ hybridisation of osteocalcin expression in long bones of 
wild-type and c-fos knockout mice. In wild-type long bones, strong expression of 
osteocalcin is observed in osteoblasts (A, C). Osteocalcin mRNA is also strongly expressed in 
ostcoblasts in mutant long bones (13,13). E and F show sense controls. Original magnification: 
A, B x5; C and D x40; E, F x20. 
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Fig. 3.2.3 Digoxygenin in situ hybridisation and immunolocalisation of RANKL expression 
in long bones of wild-type and c-fos knockout mice. Strong expression of RANKL mRNA 
(A) and protein (E) is observed in osteoblasts of wild-type long bones. RANKL mRNA (B) and 
protein (F) are also highly expressed in the mutant osteoblasts. C, D and G, H show sense and 
negative controls for the in situ hybridisation and immunolocalisation studies, respectively. 




3. In vivo studies 
In situ hybridisation of OPG, the potent inhibitor of osteoclast differentia- 
tion, showed a similar expression pattern to RANKL strong RNA expression was 
observed in osteoblasts and prehypertrophic chondrocytes of both the wild-type and 
c-fos knockout long bones, and immunolocalisation studies confirmed the expression 


















Fig. 3.2.4 In situ hybridisation and immunolocalisation of OPG expression in long 
bones of wild-type and c-fos knockout mice. In wild-type long bones, strong expression of 
OPG mRNA (A) and protein (E) is observed in osteoblasts. OPG mRNA (B) and protein (F) 
are also strongly expressed in the mutant osteoblasts. C, D and G, H show sense and negative 
controls for the in situ hybridisation and immunolocalisation. studies, respectively. Original 
magnification: A, B, E, F x40; C, D, G, H x20. 
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3. In vivo studies 
As the in situ and immunohistochemical analyses are not quantifiable, semi- 
quantitative RT-PCR of RANKL and OPG were performed with total RNA isolated 
from c-fos +/+, +/- and -/- limbs. The expression levels of both RANKL and OPG 
were upregulated in c-fos knockout limbs. Additionally, the expression of OPG was 
upregulated to a lesser extent than that of RANKL (Fig. 3.2.5). Taken together, it is 
suggested that the defects in osteoclast differentiation are unlikely to be caused by 
gross alterations in the production of RANKL and OPG by osteoblasts. 








Fig. 3.2.5 Semi-quantitative RT-PCR analysis of RANKL and OPG expression in C-fos 
+/+, +/- and -/- mouse limbs. Total RNA was isolated from 5-month old limbs from the 
indicated genotypes. Both RANKL and OPG levels are upregulated in the knockout limbs 
relative to +/+ limbs. GAPDH was used as a loading control. The relative expression levels 
of RANKL and OPG were analysed by densitometry, normalised to GAPDH. 
3.4 Expression of osteoclast and macrophage marker genes in c-fos 
transgenic osteosarcomas 
In the next series of experiments, I investigated the status of osteoclasts and 
macrophages in mice overexpressing c-fos, which develop osteosarcomas (Grigoriadis 
et al., 1993). This was done because previous data from our laboratory showed that 
osteoclasts were present in c-fos-induced osteosarcomas predominantly during the 
phase of rapid turnour growth (EI-Emir and Grigoriadis, unpublished). Moreover, 
ostcosarcomas in double c-fosk-jun transgenic mice develop faster and have more 
osteoclasts, while c-fos transgenic mice crossed with c-fos knockout mice have virtu- 
ally no tumours (Wang ct al., 1995). These results suggest an important role for c-Fos 
ill 
RANXL OPG 
3. In vivo studies 
for not only tumour development, but perhaps also for osteoclast-mediated remodel- 
ling within growing osteosarcomas. 
Figure 3.3.1 characterises the basic features of osteosarcomas from c-fos 
transgenic mice. These turnours contain large amounts of neoplastic bone which often 
invades into the bone marrow spaces (Fig. 3.3.1 B, C), and which is actively remod- 








Fig. 3.3.1 Radiographic and histological analysis of osteosarcomas in c-Fos transgenic 
mice. X-ray shows calcified tumours in c-Fos transgenic skeleton (A, arrows). Haematox- 
ylin+Eosin staining shows that tumours contain large amounts of bone (B) which often 
invade into the bone marrow space (C). Detailed histological analysis shows active bone 
remodelling with numerous cuboidal osteoblasts (D, arrows) and multinucleated osteoclasts 
(E, arrows). Original magnification: B, C x5; D, E x40. 
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In all the following in situ studies, the expression of the relevant marker genes 
was examined in two basic areas of the tumours: areas containing bone, and areas in 
the periphery of the turnours which are more fibroblastic in nature, although the exact 
characteristics of the cell types present in the fibrous regions are not known. 
Histochernical staining for TRAP activity showed that many TRAP positive 
multinucleated and mononuclear cells were present in the turnours, mostly situated in 
lacunae on bone surfaces (Fig. 3.3.2 A, C). In addition, many TRAP-positive mononu- 
clear cells were observed in fibroblastic areas without any evidence of bone present 
(Fig. 3.3.2 B, D). 
bone 
Air 
3. In vivo studies 
This was surprising as osteoclasts normally form in areas adjacent to bone 
surfaces. In order to further characterise those TRAP-positive cells, the expression of 
other osteoclast maker genes was investigated. Analysis of Cathepsin K and MMP-9 
expression showed very strong expression in all multinucleated osteoclasts and many 
mononuclear precursors in bone-containing areas within the tumours, and, as ob- 
served with TRAP staining, mononuclear cells in fibroblastic areas also expressed 
these two osteoclast marker genes (Figs. 3.3.3 A-D, and 3.3.4 A-D). 
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Fig. 3.3.3 Digoxygenin in situ hybridisation of cathepsin K expression in tumour tissues 
from c-Fos transgenic mice. Cathepsin K is expressed by numerous multinucleated and 
mononuclear cells which are present adjacent to bone (A, C), but also in fibroblastic areas of 
the tumour margin not containing any bone (B, D). E and F show sense controls. Original 















Fig. 3.3.4 Digoxygenin and radioactive in situ hybridisation of MMP-9 expression in 
tumour tissues from c-Fos transgenic mice. MMP-9 is strongly expressed by numerous 
multinucleated and mononuclear cells which are present adjacent to bone (A, C), but also in the 
fibroblastic areas of the tumour margin not containing any bone (B, D). E and F show sense 
controls. Original magnification: A, Bx 10; C, D x40; E, F x20. 
Analysis of RANK expression also showed high expression in both 
multinucleated and mononuclear cells, with an apparent higher basal level of expres- 
sion in fibroblastic areas (Fig. 3.3.5 A-F). The c-fins expression pattern also indicated 
high expression in osteoclasts, but also in a high proportion of mononuclear cells 
(Fig. 3.3.6 A-D). Immunostaining for F4/80 antigen showed large numbers of F4/80- 
positive macrophages were present in bone tumours, while multinucleated osteoclast 
were negative (Fig. 3.3.7 A, B). 
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Fig. 3.3.5 Radioactive in situ hybridisation of RANK expression in tumour tissue from 
c-Fos transgenic mice. Strong expression of RANK is observed in numerous multinucleated 
osteoclasts (A, C, arrows) and mononuclear precursors (A, C, arrowheads). RANK is also ex- 
pressed by cells in the fibroblastic areas of the tumour margin not containing any bone (E, 
arrows). G (bone areas) and H (fibroblastic areas) show sense controls. A, C, E bright field; 
B, D, F-H dark field. Original magnification: A, B, G x5; C-F, H x40. 
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Fig. 3.3.6 Radioactive in situ hybridisation of c-fms expression in turnour tissues from c-Fos 
transgenic mice. c-Fms is expressed by numerous multinucleated cells (A, C, arrows) and 
mononuclear cells (A, C, arrowheads). E and F show sense controls. A, C, E, bright field; B, D, F 
dark field. Original magnification: A, B, F x5; C, D x40; E x20, 
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Fig. 3.3.7 Immunostaining of F4/80 antigen expression in tumour tissues from c-Fos 
transgenic mice. Numerous F4/80-positive macrophages are present in the turnours (A, B), 
while multinucleated osteoclasts are F4/80-negative (B, arrow). C shows a negative control. 
Original magnification: A x10; B x40; C x20. 
3.5 Expression of osteoblast marker genes in c-fos transgenic 
tumours 
In order to identify further the phenotype of the cells in the fibroblastic areas 
of the turnours, and to find out the possible reasons for osteoclast formation in these 
areas, in situ hybridisation of osteoblast marker genes and genes that are critical for 
osteoclast differentiation were performed in turnour tissues. 
In situ hybridisation of Cbfa-I showed strong expression not only in trans- 
formed osteoblasts, but also in fibroblastic cells present at the tumour margins 
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(Fig. 3.4.1). Hybridisation of adjacent sections with osteocalcin showed that while 
osteocalcin was strongly expressed in definitive cuboidal osteoblast-like cells, it was 
not expressed in fibroblastic cells (Fig. 3.4.1 C, D). These data suggested that the cells 
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Fig. 3.4.1 Digoxygenin in situ hybridisation of Cbfa-I and osteocalcin expression in 
tumour tissues from c-Fos transgenic mice. Cbfa-1 is expressed in transformed ostcoblast- 
like cells (A) and fibroblastic cells (C), while osteocalcin is only expressed in osteoblast-like 
cells (B) and not in fibroblastic cells (D). E and F show negative controls. Original magnifica- 
tion: A-D x40; E, F x20. 
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To investigate whether these cells were capable of supporting osteoclast dif- 
ferentiation, RANKL and OPG expression were analysed in adjacent sections. In situ 
hybridisation of RANKL showed strong expression not only in transformed os- 
teoblast- like cells but also in fibroblastic cells present within the turnours at sites not 
in close proximity to bone (Fig. 3.4.2 A-D). Similarly, OPG was strongly expressed 
not only in osteoblast- like cells but also in fibroblastic cells present at the tumour 
margins (Fig. 3.4.3 A-D). Thus, these results suggest that the cells within fibroblastic 
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Fig. 3.4.2 Digoxygenin in situ hybridisation of RANKL expression in tumour tissues 
from c-Fos transgenic mice. RANKL is highly expressed in transformed osteoblast-like cells 
(A, C), and also in fibroblastic cells present within turnours at sites distant from bone tissues 
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Fig. 3.4.3 Digoxygenin in situ hybridisation of OPG expression in tumour tissues from 
c-Fos transgenic mice. OPG is highly expressed in transformed osteoblast-like cells (A, C) 
and fibroblastic cells present within the turnours at sites distant from bone tissue (B, D). E 
and F show sense controls. Original magnification: A, Bx 10; C, D x40. E, F x20. 
3.6 Expression of c-fos andfra-I in c-fos knockout and transgenic 
mice 
As mentioned in the Introduction (section 1.7.4), the c-fos-related gene, fra- 1, 
is a downstream target gene of c-fos, and is also extremely important in osteoclast 
differentiation. Thus, in this section, the expression offra-I and c-fos, were investi- 
gated in situ in the context of osteoclast differentiation. 
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I first investigated the expression of fra-1 in c-fos knockout mice. In wild- 
type littermates, fra-I was expressed in cells along some surfaces of trabecular bone 
as well as in cells along the distal growth plate (Fig. 3.5.1 A, C). Additional double 
staining for TRAP activity showed that those cells were TRAP-positive 
multinucleated osteoclasts and mononuclear precursors (Fig. 3.5.1 E). Thus, it ap- 
pears thatfra-1 was expressed predominantly in osteoclasts. In c-fos knockout long 
bones, there was overall a greater number of cells expressingfra-I (Fig. 3.5.1 13,13,17). 
Since there are no osteoclasts; in c-fos mutants, these cells are most likely osteoblasts 
and perhaps other bone marrow cells expressing high levels of fra-1 to compensate 
for the lack of c-fos. 
In c-fos transgenic mice, expression of c-fos was analysed using a transgene- 
specific probe (see section 2.3.2.2 in Materials and Methods). Consistent with pre- 
vious data, exogenous c-fos was strongly expressed in many cells, including trans- 
formed osteoblastic cells lining the bone surfaces, in addition to fibroblastic tumour 
cells (Fig. 3.5.2 A, B). Interestingly, additional double staining for TRAP activity 
showed strong c-fos transgene expression in some TRAP-positive cells, although the 
majority of TRAP-positive multinucleated cells did not express exogenous c-fos 
(Fig. 3.5.2 C, D). However, there were always many TRAP-positive mononuclear 
cells expressing the c-fos transgene present next to multinucleated osteoclasts, which 
probably represent osteoclast precursors (Fig. 3.5.2 C, D). 
Strongfra-I expression was observed in cells along the bone surface of tu- 
mour tissues, and in contrast to c-fos expression (Fig. 3.5.3 A, B), additional double 
staining for TRAP activity showed thatfra-I was strongly expressed by TRAN 
positive multinucleated osteoclasts and mononuclear precursors (Fig. 3.5.3 C, D). This 
suggests that exogenous c-fos affects osteoclast formation by upregulatingfra-I ex- 
pression. 
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Fig. 3.5.1 Radioactive in situ hybridisation offra-I expression in long bones of wild-type 
and c-fos knockout mice. Fra-I is strongly expressed in cells along the bone surfaces in wild- 
type bones (A, C). More cells expressfra-I in mutant bones (13,13). Additional double staining 
for TRAP activity shows cells expressing fra-I in wild-type bones arc TRAP-positive 
multinucleatcd and mononuclear cells (E, arrow), while in mutant bones thefra-I positive cells 
arc TRAP-ncgative mononuclcar cells (F). G and H show sense controls. A, B, E, F bright field; 
C, D, G, H dark field. Original magnification: A-D x5; E, F x40; G, H x20. 
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Fig. 3.5.2 Radioactive in situ hybridisation of c-fos transgene expression in turnour tissues 
from c-Fos transgenic mice. Ostcoblasts (A, B) and transformed fibroblastic cells (C, D) 
express high levels of the c-fos transgcne. Additional doublc staining for TRAP activity shows 
, 
fos transgenc express on n some TRAP (+) cells (E, arrows), a though the m ority of strong c- III aj 
TRAP 0 multinuclcatcd cells are negative (F, arrows). G (bone areas) and H (fibroblastic 
areas) show sense controls. A, C, E, F, bright field, B, D, G, H, dark field. Original 
magnification: A, B, D, G, H x5; C, E, F x40. 
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Fra-I 








Fig. 3.5.3 Radioactive in situ hybridisation of fra-I expression in turnour tissues from c- 
Fos transgenic mice. High fra- I expression is observed in cells adjacent to bone (A, B). 
Additional double staining for TRAP activity showsfra-I is strongly expressed by TRAP- 
positive mononuclcar and multinucleatcd cclls (C, D, arrows). E and F show sense controls. 
A, C, D, E, bright field; B, F dark field. Original magnification: A, B, F x5; C x10; D x40; E 
x20. 
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3.7 Discussion 
3.7.1 Inactivation of c-Fos affects osteoclast but not osteoblast gene expression 
As described in the Introduction (section 1.7), c-Fos is crucial for osteoclasto- 
genesis and affects both osteoclast and macrophage differentiation. Therefore I first 
investigated the expression of osteoclast- and macrophage-specific genes in situ, in 
both wild-type and c-fos knockout bones. Consistent with previous published data 
(Grigoriadis et al., 1994), there are no TRAP positive osteoclasts cells present in c- 
fos knockout mice. Here, I have confin-ned that mature osteoclasts and their immedi- 
ate precursors are absent using an additional marker, cathepsin K, which is expressed 
at the same stages of osteoclast differentiation as TRAP. In addition, since c-fos 
knockout mice express MMP-9 in a subpopulation of cells, an additional marker for 
early osteoclast lineage cells was used, RANK, and the results clearly indicated that 
RANK-positive mononuclear precursors were present in the absence of c-fos. These 
markers can now be added to a lineage diagram indicating the proposed position 
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Fig. 3.6.1 The role of c-Fos in osteoclast differentiation 
Among the osteoclastic genes, MMP-9 is known as the earliest marker for the 
osteoclast lineage (Roodman, 1999). During endochondral bone development, MMP- 
9 is indispensable for the migration of preosteoclasts to the future bone marrow cav- 
ity (Engsig et al., 2000; Reponen et al., 1994). MMP-9 is first expressed by cells 
outside perichondrium at E15, earlier than TRAP and c-fms expression at the same 
site (Jerntland et al., 1998). At later developmental stages, MMP-9 expression was 
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most intense at the chondro-osseous margin, while TRAP and c-fms expression were 
more uniform throughout the bone. The distinct expression pattern may represent 
different osteoclast subpopulations or stages of osteoclastogenesis. MMP-9 positive 
mononuclear cells are present at the c-Fos mutant growth plate, suggesting that these 
are osteoclast precursors, and that in the absence of c-Fos, they were unable to fur- 
ther differentiate into TRAPIcathepsin K positive multinucleated osteoclasts. 
Similar expression of RANK at the growth plate further confirmed that these 
cells are osteoclast precursors. RANK, the receptor for RANKL, is widely expressed 
in the body, but is highly expressed by osteoclasts and their precursors in bone (Hsu 
et al., 1999). During osteoclastogenesis, RANKL binds RANK on osteoclast precur- 
sors, and leads to the activation of NFicB, JNK and c-Fos/AP-1 (Damay et al., 1998; 
Kim et al., 1999; Matsuo et al., 2000), which are important signalling molecules and 
transcription factors for osteoclast differentiation. However, in the absence of c-Fos 
these other signalling pathways downstream of RANKURANK could not rescue 
osteoclast differentiation, confirming the importance of c-Fos. Nevertheless, the 
presence of RANK expression in the absence of c-Fos strongly suggests that 
RANKL-responsive osteoclasts are present, and that c-Fos acts downstream of this 
point to regulate osteoclast differentiation. 
Inimunocytochemical staining for F4/80 antigen also indicated that c-fos 
knockout mice have a higher number of F4/80-positive bone marrow macrophages 
than wild-type controls, confirming previous data (Grigoriadis et al., 1994). Addi- 
tionally, more mononuclear cells expressing c-fms were present in the mutant long 
bones. However, the expression pattern of F4/80 and c-fms in long bones is different: 
In wild-type mice, F4/80, a mature macrophage marker, was expressed mainly in the 
bone marrow space, while c-fms, the receptor of M-CSF was expressed predomi- 
nantly in metaphyseal trabecular bone which is similar to osteoclast markers 
(Hofstetter et al., 1995). In mutant mice, there was an increase in the number of 
F4/80 positive cells in the marrow space, but this time, c-fms expression was also 
expressed in the bone marrow space, rather than in the metaphysis, suggest that these 
cells were of the macrophage lineage. Although the number of mature macrophages in 
c-Fos knockout long bones was increased, there was no difference in the number of 
ER-MP58-expressing cells, which represent M-CSF-responsive macrophage progeni- 
tors (Grigoriadis et al., 1994). Therefore, the different expression pattem of c-fms and 
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F4/80 may suggest that in c-Fos mutant long bones, it is possible that more M-CSF- 
responsive osteoclast precursors are generated to compensate for the deficiency of 
osteoclasts, however, in the absence of c-Fos, these cells cannot differentiate further 
along the osteoclast lineage and may divert to macrophage phenotype instead. 
With the exception of c-Fos, other transcription factors, like PU. 1, NF-KB 
and Mitf as well as the production of RANKL and M-CSF by stromal cells, are re- 
quired for osteoclast/macrophage lineage development. As described in the introduc- 
tion, PU. 1 knockout mice have cell-autonomous effects in the myeloid /monocyte 
lineage; they do not form osteoclasts or macrophages and develop severe osteopetro- 
sis (Tondravi et al., 1997). The majority of PU. I-/- monocytic precursors detected 
were at the pre-late marker stage of development, expressing only MOMA-2, ER- 
MP12, ER-MP58 and ER-MP20 (Henkel et al., 1999). Thus, PU. 1 is recognized as 
the earliest gene controlling osteoclast differentiation. 
Regarding NFKB, mice deficient in both the p5O and p52 subunits developed 
severe osteopetrosis (Franzoso et al., 1997; lotsova et al., 1997) as they fail to gener- 
ate mature osteoclasts and B cells. Occasionally, one or two TRAP positive cells 
were seen in the osteopetrotic limbs, but the intensity of the TRAP staining was 
very weak. On the other hand, the number of macrophages in bone marrow was in- 
creased, which is similar to the c-Fos mutants. In addition, during osteoclastogenesis, 
both NFKB and c-fos are activated by M-CSF and RANKL stimulation (Darnay et 
al., 1999; Matsuo et al., 2000), suggesting that these two transcription factors may 
share downstream signalling pathways and act similarly in osteoclast lineage, al- 
though they are mutually exclusive since one transcription factor cannot compensate 
for the absence of the other. Furthermore, it has been reported c-fms and RANK 
expressing osteoclast progenitors were present in NFKB double knockout spleens 
(Xing et al., 2002), which I have now shown is similar to the in situ results in c-Fos 
knockout long bones. 
Mice deficient in the mi (microphthalmia) gene, another transcription factor, 
developed osteopetrosis with dysfunctional immature mononuclear osteoclasts pre- 
sent. By RT-PCR, Roundy et al. showed that RANK expression was dramatically 
enhanced in mi n*e (Roundy et al., 2003), which suggests that mi acts downstream 
of c-fos and NFKB (Luchin et al., 2000). 
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Mice lacking functional M-CSF, named oplop mice, have severe deficiency of 
osteoclasts, monocytes, and mature macrophages in various tissues (Naito et al., 
1991; Wiktor-Jedrzejczak et al., 1992). Mice with a disruption of RANKL gene de- 
veloped severe osteopetrosis due to complete absence of TRAP-positive mature 
multinucleated osteoclasts and immature preosteoclasts (Kong et al., 1999). RANK 
knockout mice developed a similar phenotype as the RANKL knockouts, where the 
formation and function of dendritic cells and macrophages were unaffected. The dis- 
tribution of macrophages in mutant spleen was also non-nal (Dougall et al., 1999). 
Taken together, in the cascade of osteoclast differentiation c-fos is down- 
stream of PU. 1, c-fins and RANK, upstream of mi, and similar as NFKB, acts at the 
branch point where osteoclast and macrophage differentiation diverge 
(Fig. 3.6.2)(Karsenty and Wagner, 2002). 
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Fig. 3.6.2 Genetic regulation of osteoclast differentiation 
Analysis of the expression of osteoblast marker genes and genes that are criti- 
cal for osteoclast differentiation was performed in order to investigate the conse- 
quences of lacking c-Fos on osteoblasts in situ. This was important as previous ex- 
periments only examined osteoblast-mediated osteoclastogenesis in vitro (see below). 
Osteoblasts are derived from mesenchymal stem cells, to date, only three osteoblast- 
specific transcripts have been identified: Cbfa-1, its downstream gene Osx and osteo- 
calcin (Karsenty, 1999; Nakashima et al., 2002). In situ hybridisation showed that 
both genes were strongly expressed by osteoblasts in c-fos knockout long bones. 
Cbfa-I is the transcription factor controlling osteoblast development and regulating 
the expression of bone matrix proteins. Mice lacking Cbfa-I developed cartilaginous 
skeletons due to complete absence of osteoblast differentiation (Komori et al., 1997). 
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The similar expression of Cbfa-I in c-fos mutant and wild type long bones suggests 
that early osteoblast differentiation and function are not affected in the absence of c- 
fos. Osteocalcin is a gene expressed only in terminally differentiated osteoblasts, and 
the secreted molecule it encodes inhibits osteoblast function (Ducy et al., 1996). 
Previous studies showed that in oplop, tlltl osteopetrotic rat mutations, osteocalcin 
mRNA levels were significantly decreased (Shalhoub et al., 1991). In c-fos knockouts, 
the level of osteocalcin expression was only slightly lower than that of wild type. 
Since bone formation is coupled with osteoclastic bone resorption, active osteoblast 
differentiation and function are likely to be retarded in the absence of osteoclasts. 
Hence, the decreased osteocalcin expression may be secondary to the defect of bone 
remodelling in the absence of c-Fos. 
Previous studies have shown that the pathogenic defect of osteopetrosis may 
be intrinsic either to the osteoclast lineage or to the osteoblasts/stromal cells that 
constitute the bone marrow microenvironment supporting the development and acti- 
vation of osteoclasts. It has been proven that the defect in osteoclastogenesis in the 
absence of c-Fos resides within osteoclast lineage, and c-Fos knockout osteoblasts 
can fully support osteoclast formation both in vivo and in vitro (Grigoriadis et aL, 
1994). However, the expression of genes that are essential for osteoclast differentia- 
tion has never been mapped using in situ techniques. It is widely accepted that 
RANKL and M-CSF are the two key factors produced by osteoblast/stromal cells 
for osteoclastogenesis. M-CSF is important not only for the development of osteo- 
clast, but also for macrophages, stimulating the proliferation and differentiation of 
bipotential precursors. In the absence of RANKL, M-CSF can stimulate even late- 
stage RANW osteoclast precursors into macrophages (Arai et aL, 1999). Since mice 
lacking M-CSF have a severe deficiency of both osteoclasts and macrophages, the 
fact that more macrophages are present in c-Fos mutant long bones suggests that the 
production and function of M-CSF are not affected. 
RANKL is essential for osteoclast development and T cell differentiation in 
vivo. RANKL deficient mice developed osteopetrosis with no osteoclasts (Kong et 
al., 1999). In vitro, RANKL is necessary and sufficient to support osteoclast differ- 
entiation from haematopoietic precursors in the presence of M-CSF (Quinn et al., 
1998a). OPG acts as a decoy receptor for RANKL and inhibits osteoclast differentia- 
tion both in vitro and in vivo, and the ratio of RANKL and OPG levels in the bone 
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microenvironment is critical for the regulation of osteoclast formation (Hofbauer et 
al., 2000). The expression of RANKL and OPG was investigated in c-fos mutant long 
bones and in situ hybridisation showed that RANKL and OPG were strongly ex- 
pressed in osteoblasts and prehypertrophic chondrocytes of wild-type 
(Kartsogiannis et al., 1999) and c-fos knockout mice. As mRNA levels do not always 
correlate with secreted proteins, the in situ results were further confirmed by immu- 
nohistochernistry. Roundy et al. reported that RANKL transcription was upregu- 
lated in bone marrow from osteopetrotic mice, including oplop, c-fos-1- and mi 
(Roundy et al., 2003), which may represent a compensatory mechanism for osteo- 
clast deficiency. 
In conclusion, osteoblasts appear to be normal in c-fos knockout long bones. 
The defects in osteoclast differentiation in the absence of c-Fos are therefore unlikely 
to be caused by dysfunction of osteoblasts. 
3.7.2 Overexpression of c-Fos affects both osteoclasts and osteoblasts in 
transgenic osteosarcomas 
In this thesis, I also investigated the effect of overexpression of c-Fos on os- 
teoclast differentiation, since osteoclasts appeared to play an important role in the 
turnour phenotype in these transgenic mice (see also section 1.7.3.2). The expression 
of osteoclast- and macrophage- specific genes were investigated in c-Fos-induced 
osteosarcomas, and the results showed that large amount of osteoclasts and macro- 
phages were present in the active bone remodelling area within osteosarcomas, and 
surprisingly, osteoclastic cells were also present in fibroblastic areas at the margin of 
osteosarcomas not containing any bone. 
High levels of MMP-9, RANK and cathepsin K expression, which are osteo- 
clastic marker genes, were observed in fibroblastic areas of osteosarcomas suggesting 
that these cells belong to the osteoclast lineage and arc functional. It is well known 
that MMP-9 plays an important role in tumour invasion and metastasis due to their 
ability to degrade basement membrane collagens (Himelstein et al., 1994). MMP-9 is 
not only expressed in tumour cells at the margins adjacent to the tumour-stroma in- 
terface, but also stromal cells surrounding tumours (Ueda et al., 1996). The MMP-9 
secreting human fibrosarcoma cell line HT1080 also invaded a basement membrane in 
vitro. Transfection of HT1080 genomic DNA into non-invasive cells resulted in se- 
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cretion of MMP-9 and cell invasion, while non-invasive control DNA transfectants 
did not secrete MMP-9 (Kubota et al., 1991). Despite the high expression of MMP- 
9 in different invasive cell types, the expression in c-fos-induced osteosarcomas ap- 
parently remained confined to osteoclast-like cells, as in situ hybridisation and immu- 
nostaining of adjacent sections showed that these cells also expressed other osteoclast 
marker genes, such as TR, 4P, RANK and cathepsin K. 
RANK, the receptor for RANKL, mediates the signalling of RANKL and is 
critical for osteoclast differentiation. The expression of RANK, not only in 
multinucleated cells adjacent to bone, but also in the fibroblastic areas, further con- 
finned that these cells are committed to the osteoclast lineage. Cathepsin K is consid- 
ered to be restricted to osteoclasts and osteoclastic bone resorption, but it has been 
reported that cathepsin K also plays an important and direct role in the infiltration 
and growth of turnours. Haeckel et al. reported that cathepsin K was strongly ex- 
pressed in chondromas with enhanced immunoreactions at the infiltrative tumour 
margins. Osteoclastic giant cells were present between tumour tissues and adjacent 
bone trabeculae, which expressed high levels of cathepsin K (Haeckel et al., 2000). In 
c-fos osteosarcomas, the fibrous regions also expressed cathepsin K, further sup- 
porting the hypothesis that osteoclast-like cells are present in ectopic areas within 
the tumours. 
it is widely accepted that osteoclasts are normally found only in bone tissues. 
The fact that cells expressing osteoclastic marker genes are present in fibroblastic 
areas of the tumour margin in c-Fos-induced osteosarcomas, in areas not adjacent to 
bone tissue, suggests that there is ectopic formation of bone-resorbing cells in the 
tumours which may precede the formation of bone forming cells during tumour pro- 
gress, which is different from the normal physiological condition. The presence of 
ectopic osteoclast-like cells may not be unique to this model, as there are other re- 
ports showing that functional osteoclastic cells are present in different bone-related 
pathologies. For example, the soft tissue tumour, malignant fibrous histiocytoma 
(MFH) contains functional osteoclasts within the tumour surrounded by muscle 
(Flanagan and Chambers, 1989). Recently, Riminucci et al. reported that osteoclasts 
occurred ectopically in fibrous tissues in fibrous dysplasia (FD), which may be due 
to overexpression of IL-6 (Riminucci et al., 2003). 
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Osteoclasts are required not only for bone destruction but previous data from 
our laboratory has suggested that they were also required for bone tumour growth. 
Wang et al. reported that osteosarcomas developed in Fos-Jun double transgenic mice 
contained more osteoclasts than c-Fos transgenic mice, and were more remodelled 
(Wang et al., 1995). Additionally, transgenic mice overexpressing c-fos in osteoclasts 
using a TRAP promoter develop large bone lesions and turnours, which contained 
numerous osteoclasts, (Beedles et al., 1999). On the other hand, tumour formation 
was almost absent in c-fos-1- mice expressing c-Fos transgene (Wang et al., 1995), 
which suggests that c-Fos-induced tumorigenesis may be gene dose-dependent, or 
alternatively, that osteoclasts are necessary for osteosarcoma development. Similarly, 
mi mice lacking osteoclasts were resistant to fibrosarcoma cell (from an osteolytic 
sarcoma tumour, NCTC clone 2472) induced tumorigenesis (Clohisy and Ramnaraine, 
1998). However, these mice developed turnours and osteolysis after the osteoclast 
deficiency was rescued by bone marrow transplantation (Clohisy and Ramnaraine, 
1998). On the other hand, injection of tumour cells into oplop mice stimulated osteo- 
clastogenesis and tumorigenesis, which was abolished by OPG treatment (Clohisy et 
al., 1995; Clohisy et al., 2000). Finally, conditioned medium from oplop tumour ex- 
plants contained M-CSF, suggesting that tumour cells secreted the factor that oplop 
lacked and rescued the defect of osteoclast deficiency which then led to tumour for- 
mation (Clohisy et al., 1995). Taken together, bone resorbing cells are indispensable 
for bone turnour development. 
It has been well established that macrophages and osteoclasts are derived from 
same bipotential monocyte/macrophage progenitors, and in vitro studies showed that 
mature macrophages and macrophage cell lines are able to differentiate into osteo- 
clasts in the presence of M-CSF and RANKL. Macrophage infiltration is commonly 
found in inflammatory diseases including primary and metastatic bone turnours, how- 
ever, the role of macrophages in tumour development and bone resorption is unclear 
(Quinn et al., 1998b). It has been reported that human mesenchymal tumour- 
associated macrophages differentiated into functional osteoclasts when cultured with 
osteoblastic cells or with RANKL and M-CSF (Quinn et al., 1998b; Yang et al., 
2002), and the differentiation of these cells into osteoclasts played an important role 
in osteolytic metastasis of carcinomas. In order to study the role of macrophages in 
the growth of c-Fos-induced osteosarcomas, macrophage marker genes expression 
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was investigated. In situ hybridisation of c-fms, and immunostaining for F4/80, one of 
the macrophage-specific surface antigens which has been widely used as a mature 
macrophage& marker (Hattersley and Chambers, 1989b), showed strong expression in 
numerous macrophage-like mononuclear cells throughout turnour tissues. These re- 
sults suggest that a large amount of macrophages are present in c-Fos-induced os- 
teosarcomas, and although their function is not entirely clear, it is possible that they 
could switch to the osteoclast lineage in the presence of appropriate stimuli 
(Miyamoto et al., 2001). 
Taken together, a large amount of multinucleated and mononuclear cells with 
osteoclast and macrophage phenotypes are present in c-Fos-induced osteosarcomas, 
not only in bone area but also in fibroblastic areas of the tumour margin not contain- 
ing any bone, which may play an important role in tumour progress. 
Subsequent experiments addressed the reasons for the large number of osteo- 
clasts in c-Fos transgenic tumours, in particular, in the fibroblastic areas. There are 
two possible explanations: (1) osteoblasts or tumour cells in transgenic mice have a 
higher potential to support osteoclast differentiation. (2) Overexpression of c-Fos 
acts directly on osteoclast precursors promoting them to differentiate into mature 
osteoclasts by certain mechanisms (see also below). In situ hybridisation of os- 
teoblast marker genes and ostcoblast-derived genes that are critical for osteoclast 
differentiation were first performed in tumour tissues. As expected, the two os- 
teoblastic genes, Cbfa-I and osteocalcin were strongly expressed in transformed os- 
teoblasts along the surface of neoplastic bones. Interestingly, fibroblastic cells at the 
edge of turnours also expressed high level of Cbfa-1, the transcription factor essential 
for osteoblast lineage, but not osteocalcin, the mature osteoblastic marker gene, sug- 
gesting that these cells might be immature osteoblasts. 
As shown before, the local bone marrow microenvironment is critical for os- 
teoclast development in vivo. Osteoblasts/stromal cells produce M-CSF and 
RANKL, which are indispensable for osteoclastogenesis, in response to osteotropic 
stimuli. At the same time, these cells also secrete OPG, a negative regulator for osteo- 
clastogenesis, and the ratio of RANKL: OPG determines the generation and function 
of osteoclasts (Hofbauer et al., 2000). To further investigate whether overexpression 
of c-Fos affected the ability of transformed osteoblasts and fibroblasts to support 
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osteoclast differentiation, the expression of RANKL and OPG were investigated at 
different sites in the osteosarcomas. Besides the expected high expression of these 
cytokines in osteoblastic cells lining neoplastic bone, high levels of RANKL and 
OPG expression were also observed in turnour fibroblastic cells, suggesting that these 
transformed fibroblasts/pre-osteoblasts are capable of supporting osteoclast differen- 
tiation, and this may explain the presence of osteoclast-like cells in these regions. 
Similar work has been done on giant cell tumour (GCT) tissues. GCT, also named 
osteoclastoma, is a rare primary osteolytic tumour of bone. Unlike most other lytic 
bone tumors, however, GCT contains osteoclast-like cells within the tumour stroma 
(Atkins et al., 2000). RT-PCR of fractionated GCT tissues showed that GCT stro- 
mal cells expressed high level of RANKL and OPG mRNA (Atkins et al., 2000; Huang 
et al., 2000). Other studies have shown that in addition to their induction of RANKL 
expression in bone marrow stromal cells, turnour cells, such as mycloma cells, pros- 
tate cancer cells and squamous cell carcinoma cells, directly produced RANKL (Nagai 
et al., 2000; Sezer et al., 2003; Zhang et al., 2001 a), and have the potential to support 
osteoclast formation in vitro. As during bone remodelling, bone formation generally 
follows bone resorption, in malignant turnours, it appears that other transformed cell 
types apart from osteoblastic cells can also support osteoclast formation and this 
may be the cellular mechanism responsible for stimulating osteolysis, as in breast 
cancer metastases or myeloma, or the bone remodelling seen in primary bone tu- 
mours. 
Taken together, osteoblastic marker genes and key genes for osteoclastogene- 
sis are strongly expressed not only by tumour osteoblasts but also by transfon-ned 
fibroblasts and/or pre-osteoblasts, which may account for the ectopic osteoclastic 
cells present in fibroblastic areas. 
3.7.3 Altered expression offra-1 in c-fos knockout and transgenic mice 
As mentioned in the Introduction (see section . 1.7.4), the c-fos-related gene, 
fra- I is now quite well-established as a c-Fos target gene. Thus, to further investigate 
the potential role offra-1 in the signalling pathway downstream of c-fos in osteoclast 
and osteoblast differentiation, fra-I was analysed in c-fos knockout long bones, and 
c-Fos transgenic osteosarcomas. 
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Fra- I is the transcriptional target of c-Fos in osteoclast progenitors, and over- 
expression of Fra- I rescued the defect of osteoclastogenesis from c-fos knockout 
spleen cells more efficiently than c-Fos (Fleischmann et al., 2000; Matsuo et al., 
2000). Furthermore, RANKL-inducedfra-I expression in haernatopoietic precursors 
is dependent on the presence of c-fos (Matsuo et al., 2000). Here, in situ hybridisa- 
tion analysis demonstrated clearly thatfra-1 is specifically and highly expressed by 
both osteoblasts and osteoclasts in wild-type bones. While it may have been ex- 
pected thatfra-1 is expressed in osteoclasts, this has never been demonstrated by 
any in situ techniques until now. Surprisingly, in c-fos knockout bones, numerous 
mononuclear cells expressed high levels offra-1. These cells could be osteoblasts, 
which express fra- I and would be found throughout the osteopetrotic bone marrow 
space, or alternatively, they could represent a population of osteoclast precursors. It 
is possible that in the absence of c-fos, fra-] transcription is upregulated by RANKL 
through another unknown pathway(s) in order to compensate for the deficiency of c- 
Jos in osteoclastogenesis. However, the endogenous level is not high enough to rescue 
the defect of osteoclast differentiation compared with exogenous Fra-1 (Matsuo et 
al., 2000). In fact, Owens et al. have reported that Fra-1 plays a role in osteoclast 
differentiation distinct from that of c-Fos. In their studies, infection of bipotential 
osteoclast/macrophage precursor cell lines with retroviruses expressing Fra- I but not 
c-Fos caused a dramatic increase in osteoclast differentiation and function in the pres- 
ence of stromal cells (Owens et al., 1999). Moreover, in vivo loss-of-function and 
gain-offunction experiments showed that Fra- I is dispensable for osteoclastogenesis. 
Fra-1 knockout mice generated by injection of Fra-l-/- ES cells into tetraploid wild 
type blastocysts have TRAP positive osteoclasts present in the long bones at birth 
(Schreiber et al., 2000). Moreover, Fra-1 transgenic mice developed osteosclerosis 
due to enhanced bone formation, while osteoclasts were not affected (Jochum et al., 
2000). Thus, in vivo, the importance of Fra-I as "the" target gene that mediates the 
function of c-Fos is still not established. 
Finally, previous data showed that osteoblasts are target cells of c-Fos trans- 
gene (Grigoriadis et al., 1993). With respect to osteoclasts, previous reports have 
generally concluded that differentiated, multinucleated osteoclasts don't express high 
levels of c-fos, or only a small proportion of osteoclasts do (Oyama et al., 1998). 
However, the expression of endogenous c-fos or the c-fos transgene in the osteoclastic 
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lineage hasn't been looked at. In situ hybridisation showed the expected high expres- 
sion of the c-fos transgene in osteoblasts and other mononuclear cells within the tu- 
mour fibroblastic stroma, as this was observed previously (Grigoriadis et al., 1993). 
However, additional double staining for TRAP activity and in situ hybridisation for 
exogenous c-fos showed that only a few TRAP positive multinucleated cells ex- 
pressed the transgene, while there were many TRAP positive mononuclear cells that 
expressed high levels of the transgene, which could represent osteoclast precursors. 
These data suggest that the c-Fos transgene might regulate the differentiation of os- 
teoclast precursors directly. Furthermore, a high level of fra-I expression was ob- 
served in osteoclasts and their mononuclear precursors in the turnours. Taken to- 
gether, these results imply that in the context of the transgenic osteosarcomas, c-fos 
may control osteoclast development throughfra-I signalling, whereas in the absence 
of c-fos, alternative signalling pathway(s) may regulate the expression offra-1. 
Having mapped the expression patterns of osteoclast and osteoblast marker 
genes in situ in c-Fos knockout and transgenic tissues, I focussed in the next chapters 
on investigating the role of altered levels of c-Fos on osteoclast differentiation using 
in vitro assays and molecular analyses. 
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Chapter 4 
In vitro osteoclast differentiation from c-Fos knockout and 
transgenic precursors 
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4.1 Introduction 
As shown in the previous chapter, M-CSF- and RANKL-responsive cells are 
present in both c-fos mutant mouse strains, the c-fos transgenics and, despite the 
absence of osteoclasts, in the c-fos knockouts. To investigate further the possible role 
of c-Fos using these mutants, in vitro studies were performed to determine the osteo- 
clastogenic potential of osteoclast precursors in each model system. 
As shown in the previous chapter, M-CSF and RANKL responsive cells are 
still present in c-fos knockout long bones, studies were performed to find out 
whether these precursors have the potential to form osteoclast under in vitro condi- 
tion. This was done using a stroma-free culture system containing non-adherent M- 
CSF-dependent bone marrow cells as a source of osteoclast precursors. This might be 
difficult in the c-fos knockout animals which have a much reduced bone marrow space 
due to the osteopetrosis, however, there are significant numbers of marrow cells 
within these bones, particularly in younger animals. The reason for doing these ex- 
periments was based on the hypothesis that the haernatopoietic precursors which 
will differentiate into osteoclasts, and which are blocked in the absence of c-Fos, are 
different in the bone marrow versus the spleen, i. e. that they may represent the 
"true" precursors, and that the age of the animal may affect the osteoclast potential. 
After the publication of the c-fos knockout phenotype where it was clearly shown 
that c-fos knockout spleen cells failed to differentiate into osteoclasts (Grigoriadis et 
al., 1994), all subsequent work by Wagner and co-workers was performed using 
spleen cell-derived haematopoietic cells as a source of osteoclast precursors (Matsuo 
et al., 2000). While this was a very informative approach, I will investigate in this 
chapter, the osteoclast potential of haernatopoietic cells derived from c-fos knockout 
bone marrow, and compare it with normal precursors and precursors isolated from c- 
fos-overexpressing mice. 
4.2 Establishment of a stroma-free cell culture system for osteoclast 
differentiation 
Experiments were performed first to optimise the conditions for osteoclast 
generation. This was done using bone marrow cells from male CD I adult mice, which 
were incubated with M-CSF overnight, and non-adherent cells harvested one day 
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later and being used as a starting cell population. For plating density studies, M-CSF- 
dependent precursors were plated at cell densities ranging from 102 to 5x 105 
cells/6mm well and cultured with 25ng/ml of M-CSF and 5ng/ml of RANKL. The 
results showed there was an increase in osteoclast formation with increasing cell den- 
sity, which reached a peak at 5x 104 cells/well and decreased at higher densities 
(Fig. 4.1.1). Based on this, all subsequent experiments were perfon-ned at a plating 
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Fig. 4.1.1 The effects of cell density on the formation of TRAP positive multinucleated 
cells. M-CSF-dependent bone marrow cells from CDl mice were plated at different cell densi- 
ties in 96-well-plates. Cells were cultured with RANKL (5ng/ml) and M-CSF (25ng/ml) for 5 
days, then fixed and stained for TRAP activity. The numbers of TRAP positive multinucleated 
cells were counted. Values are the mean ± SE of triplicate cultures from a representative experi- 
ment. 
I next investigated the dose-dependency of the two major osteoclastogenic cy- 
tokines, M-CSF and RANKL. Culture of M-CSF-dependent precursors at a fixed 
dose of RANKL (25ng/ml) and increasing concentrations of M-CSF showed that M- 
CSF was essential for osteoclast differentiation, and caused a dose-dependent in- 
crease in osteoclast fori-nation (Fig. 4.1.2 A). For the RANKL dose-response, M- 
CSF-dependent cells cultured in a fixed dose of M-CSF (25ng/ml) and different con- 
centrations RANKL also showed that RANKL necessary for inducing osteoclasts 
and that this response was dose-dependent with concentrations as low as 3ng/nil 
significantly stimulating osteoclast differentiation (Fig. 4.1.2 B). Based on these stud- 
ies, and unless otherwise stated, all subsequent experiments were performed using 
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concentrations of M-CSF at 25ng/ml and R-ANKL at 5ng/ml, for both bone marrow 
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Fig. 4.1.2 M-CSF and RANKL stimulate osteoclast formation in a dose-dependent man- 
ner. Bone marrow cells from CDI mice were cultured at 5x 104 cells/well in 96-well-plates. 
Cells were treated with 5ng/ml of RANKL and different concentrations of M-CSF (A), or 
25ng/ml of M-CSF and different concentrations of RANKL (B) for 5 days. Cells were then 
fixed and stained for TRAP activity. The numbers of TRAP positive multinucleated cells were 
counted. Values are the mean ± SE of triplicate cultures from a representative experiment. 
Finally, dose-response studies were performed to examine the effects of two 
additional cytokines which are important for osteoclast differentiation, TGF-P and 
TNF-oc, and which were used in the c-Fos studies. In the presence of M-CSF and 
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RANKL, TGF-P caused a dose-dependent increase in osteoclast number and size, 
starting from a concentration as low as O. Olng/ml (Fig. 4.1.3). This is consistent with 
recently published data (Fuller et al., 2000). With respect to TNF-CC, this cytokine 
has been reported to be able to substitute for RANKL in M-CSF-dependent cultures 
(Azuma et al., 2000). However, under our experimental conditions, TNF-oC in the 
absence of RANKL caused only a very small increase in osteoclast number, and only 
at high concentrations (100ng/ml) (Fig. 4.1.4). Subsequent TNF-ot experiments were 
therefore performed in the presence of RANKL, and this is consistent with the re- 
port that low levels of PANKL may be necessary to "prime" osteoclast precursors 
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Fig. 4.1.3 TGF-P augments osteoclast formation in a dose-dependent manner in the 
presence of RANKL and M-CSF. M-CSF-dependent bone marrow precursors from CDI 
mice were treated with RANKL (5ng/mI), M-CSF (25ng/mi) and different concentrations of 
TGF-P for 5 days. Cells were then fixed and stained for TRAP activity (A). The numbers of 
TRAP positive multinucleated cells were counted (B). Values are the mean ± SE of triplicate 
cultures from a representative experiment. Original magnification: Ax 10. 
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Fig. 4.1.4 TNF-a induces osteoclast formation at high concentrations in the absence of 
RANKL. M-CSF-dependent bone marrow precursors from CDl mice were treated with M- 
CSF (25ng/ml) and different concentrations of TNF-(x for 5 days. Cells were then fixed and 
stained for TRAP activity (A). The numbers of TRAP positive multinucleated cells were 
counted (B). Values are the mean ± SE of triplicate cultures from a representative experiment. 
Original magnification: A xI0. 
4.3 In vitro osteoclast differentiation from c-fos knockout mice 
4.3.1 Osteoclast differentiation from adult mice 
I first investigated the differentiation of spleen-derived haematopoictic cells 
under our experimental conditions. Spleen cells from 2-3 month old c-fos +/+, +/-, and 
-/- male mice were incubated with 25ng/ml of M-CSF overnight. M-CSF-dependent, 
non-adherent precursors were then plated at different cell densities and cultured with 
25ng/ml of M-CSF and 5ng/ml of RANKL for 8 days. The results showed efficient 
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osteoclast formation which increased with cell density, reaching a peak at 5x 105 and 
106 cells/well in wild-type cultures, then decreasing dramatically. Consistent with 
published data (Grigoriadis et al., 1994), no TRAP-positive multinucleated cells were 
induced from c-jbs -/- spleen cultures (Fig. 4.2.1). Interestingly, there was also an 
apparent gene-dosage effect, as at each cell density the number of TRAP-positive 
multinucleated cells induced from c-jbs +/- spleen cells was much less than that from 
c-fos +/+ (Fig. 4.2.1). 
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Fig. 4.2.1 TRAP positive multinucleated cells are not induced from c-fos -/- adult 
spleens. M-CSF-dependent spleen cells from 2-months old male c- s +/+, +/- and -/- mice J6 
were plated at different cell densities in 96-well plates. Cells were cultured under standard 
conditions for 8 days, then fixed and stained for TRAP activity. The numbers of TRAP 
positive multinucleated cells were counted. Values are the mean ± SE of triplicate cultures 
from a representative experiment. *** P<0.00 1. 
I next attempted to isolate cells from bone marrow of adult c-fbs mutant mice. 
This was difficult as the osteopetrosis generally worsens with age (Fig. 4.2.2), and the 
number of marrow cells decreases. Nevertheless, enough M-CSF-dependent non- 
adherent cells could be derived from chopped adult c-fos knockout bones to perform 
an osteoclast differentiation assay. After treatment with RANKL for different days, 
there were no TRAP-positive cells, either multinucleated or mononuclear, induced 
from adult c-fos mutant bone marrow cultures (Fig. 4.2.3 A), whereas +/+ and +/- 
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cultures showed a time-dependent increase in osteoclast number, starting from day 5- 
6. Accordingly, there was no resorption pit forination (Fig. 4.2.3 B). As also observed 
with the spleen cultures, the number of TRAP-positive multinucleated cells and re- 
sorption pits induced from c-fos +/- bone marrow cells at each time point was less 






Fig. 4.2.2 Haematoxylin+Eosin staining of long bones from E16.5, postnatal days I 
(PI), 15 (P15) and 2 month old (21M) c-fos knockout mice. The bone marrow space was 
clearly present in the E16.5 c-fos mutant long bone (A), but was gradually reduced in PI (B) 
and P 15 (C) mutant long bones, and was hardly evident in the adult (2M) mutant long bone 
(D). Original magnification: A x20; B-D x 10. 
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Fig. 4.2.3 TRAP positive cells and resorption pits are not induced from c-fos -/- adult 
bone marrow culture. M-CSF-dependent bone marrow cells from 2-month old male c-/bs 
+/+, +/- and -/- mice were cultured under standard conditions in 96-well plates and on 
dentine slices. Cells were fixed on different days for analysis of TRAP and resorption. The 
numbers of TRAP positive multinucleated cells were counted (A), and the percentage of 
resorbed area on dentine slices was quantified (B). Values are the mean :E SE of triplicate 
cultures from a representative experiment. * P<0.05; *** P<0.001. 
4.3.2 Osteoclast differentiation from newborn and young mice 
To investigate the osteoclast potential of younger mice, where histologIcal 
evidence showed that the osteopetrosis is not as severe as in adults, osteoclast differ- 
entiation assays were performed using cells from young (2-3 week-old) and newborn 
mice. 
Figure 4.2.4 A shows the time course of osteoclast formation from bone mar- 
row precursors of 2-3 week-old mice. In c-fos +/+ cultures, there was an increase in 
the number of TRAP-positive multinucleated cells from day 4 and reached a peak on 
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day 7, then decreased. Wild-type cells also made numerous resorption pits (Fig. 4.2.4 
B, 4.2.5). As before, the number of osteoclasts induced at each time point and pits 
formed in c-fos +/- cultures were less than that from c-fos +/+. In c-fos -/- cultures, 
there were no multinucleated cells formed, although there were several TRAP- 
positive mononuclear cells. This is interesting because in adult cultures, there are no 
TRAP-positive cells at all, either multinucleated or mononuclear. Moreover, there 
was clear resorption pit formation in mutant cultures, which were probably formed 
by these mononuclear cells, although the number was significantly less than that from 
either +/+ or +/- cultures (Fig. 4.2.4,4.2.5). These results show for the first time any 
functional resorptive activity from cells derived from c-fos knockout mice. 
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Fig. 4.2.4 Functional TRAP positive mononuclear cells are induced from 2-3 week old C- 
fos -/- bone marrow cultures. M-CSF-dependent bone marrow cells from postnatal 18-day 
old c-fos +/+, +/- and -/- rnice were cultured under standard conditions in 96-well plates and 
on dentine slices. Cells were fixed on different days, stained for TRAP activity and the nurn- 
bers of TRAP positive multinucleated cells were counted (A). Cells on dentine slices were 
fixed on day 10 and the percentage of resorbed area was quantified (B). Values are the mean 
SE of triplicate cultures from a representative experiment. ** P<0.01; *** P<0.001. 
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Fig. 4.2.5 TRAP positive mononuclear cells and resorption are induced from 2-3 week 
old c-fos -/- bone marrow cultures. M-CSF-dependent bone marrow cells from postnatal 18- 
day old c-fos +/+, +/- and -/- mice were cultured under standard conditions in 96-well plates 
and on dentine slices. Cells were fixed on day 6 and stained for TRAP activity. Cells on 
dentine slices were fixed on day 10 and the resorption pits were stained with Toluidine Blue. 
Original magnification: x 10. 
To further investigate the osteoclast potential of knockout haernatopoietic 
cells, and to see whether the age of the cells is important, I next performed experi- 
ments with newborn mice. Surprisingly, a significant number of TRAP-positive 
multinucleated cells were fon-ned from newborn c-fos mutant bone marrow precursors 
(Fig. 4.2.6 A, 4.2.7), and these cells fonned resorption pits as well (Fig. 4.2.6 B, 
4.2.7), although the number of TRAP-positive multinucleated cells and pits was 
much less than that from the wild-type or +/- bone marrow (Fig. 4.2.6). This is the 
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first observation showing the generation of TRAP-positive multinucleated osteo- 
clasts with the ability to make resorption pits from c-fos knockout cells. 




















Fig. 4.2.6 Functional TRAP positive multinucleated cells are induced from newborn c-fos 
bone marrow cultures. M-CSF-dependent bone marrow cells from newborn c-f6s 
and -/- mice were cultured under standard conditions in 96-well plates and on dentine slices. 
Cells were fixed on day 10, stained for TRAP activity and the numbers of TRAP positive 
multinucleated cells were counted (A). Cells on dentine slices were fixed on day II and the 
percentage of resorbed area was quantified (B). Values are the mean ± SE of triplicate cultures 
from a representative experiment. ** P<0.01; *** P<0.001. 
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Fig. 4.2.7 TRAP positive multinucleated cells and resorption are induced from newborn 
c-fos bone marrow cultures. M-CSF-dependent bone marrow cells from newborn c-fos 
+/+, and -/- mice were cultured under standard conditions in 96-well plates and on dentine 
slices. Cells were fixed on day 10 and stained for TRAP activity. Cells on dentine slices were 
fixed on day II and the resorption pits were stained with Toluidine Blue. Original magnifica- 
tion: x 10. 
4.3.3 Effects of TGF-P and TNF-ct on osteoclast differentiation from c-fos 
knockout mice 
As mentioned in the Introduction (section 1.5.3.5,1.5.3.7), it has been well 
established that TGF-P and TNF-oc can augment osteoclast formation in the presence 
of M-CSF and RANKL (Fuller et at., 2000; Zhang et al., 2001 b). Thus, it was inter- 
esting to examine whether these cytokines could enhance or rescue the block in osteo- 
clast differentiation in bone marrow or spleen cells derived from c-fos knockout mice. 
M-CSF-dependent non-adherent bone marrow and spleen precursors from newborn, 
2-3 week-old and 2-3 month-old c-fos +/+, +/- and -/- mice were cultured with TGF-P 
or TNF-a in the presence of M-CSF and RANKL. 
Newborn bone marrow precursors from c-fos +/+, +/- and -/- were cultured 
with TGF-P or TNF-a for 5 or 9 days. On day 5, the number of TRAP-positive 
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multinucleated cells induced from c-fos +/+ and +/- cells were significantly increased 
by adding TGF-P or TNF-ot (Fig. 4.3.1 A). No TRAP-positive cells were formed in 
c-fos -/- bone marrow cultures. However, after 9 days, there was still an increase in 
the number of TRAP-positive multinucleated cells formed in TGF-p-treated cultures, 
but there was no difference in the number of TRAP-positive multinucleated cells 
formed between TNF-(x-treated cultures and controls (Fig. 4.3.1 B). 




























Fig. 4.3.1 TGF-P stimulates TRAP positive multinucleated cell formation from newborn C- 
fos -/- bone marrow cultures. M-CSF-dependent bone marrow cells from newborn c-fos +/+, 
+/- and -/- rnice were cultured with RANKL only, or together with TGF-P (I ng/ml) or TNF-ct 
(100ng/ml). Cells were fixed on day 5 (A) and day 9 (B), stained for TRAP activity and the 
numbers of TRAP positive multinucleated cells were counted. Values are the mean ± SE of 
triplicate cultures from a representative experiment. ** P<0.0 1. 
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More importantly in day 9 cultures, although TRAP-positive multinucleated 
cells hadn't fon-ned from c-fos -/- cells in control cultures, there was a slight but sig- 
nificant increase in the number of TRAP-positive mononuclear cells and some 
multinucleated cells induced by addition of TGF-P (Fig. 4.3.1 B, 4.3.2). TNF-a failed 
to stimulate forrnation of multinucleated cells by day 9 (Fig. 4.3.1 B), although many 
faintly TRAP-positive mononuclear cells were observed (Fig. 4.3.2). The resorption 
assays which were performed in parallel showed that there was no significant in- 
crease in pit formation by TGF-P or TNF-cc treatment in c-fos +/+ or +/- bone mar- 
row culture, whereas resorption pit formation in c-fos -/- bone marrow cultures was 
significantly increased by TGF-P (Fig. 4.3.3,4.3.4). 
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Fig. 4.3.2 TGF-P and TNF-a stimulate TRAP positive multinucleated and mononuclear 
cell formation from newborn c-fos -/- bone marrow cultures, respectively. M-CSF- 
dependent bone marrow cells from newborn c- fibs and -/- mice were cultured with 
RANKL only, or together with TGF-P (I ng/ml) or TNF-cc (100ng/ml). Cells were fixed on day 
9 and stained for TRAP activity. Arrows show TRAP positive multinucleated cells formed in 
newborn c-fos -/- bone marrow cultures treated with TGF-P. Original magnification: x 10. 
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Fig. 4.3.3 TGF-A stimulates resorptive activity of osteoclasts from newborn c-fos -/- bone 
marrow cultures. M-CSF-dependent bone marrow cells from newborn C-fos +/+, +/- and -/- 
mice were cultured with RANKL only, or together with TGF-P (I ng/ml) or TNF-(x (I OOng/ml). 
Cells were fixed on day II and the percentage of resorbed area on dentine slices was quantified. 












Fig. 4.3.4 TGF-A stimulates resorption in newborn c-fos -/- bone marrow cultures. M-CSF- 
dependent bone marrow cells from newborn c-fos +/+, +/- and -/- mice were cultured with 
RANKL only, or together with TGF-P (I ng/ml) or TNF-a (I OOng/ml). Cells on dentine slices 
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Similar to bone marrow cultures, the number of TRAP-positive 
multinucleated cells induced from newborn c-fos +/- spleen cultures was significantly 
increased by adding TGF-P. However, in contrast to bone marrow cultures, no 
TRAP-positive cells were formed from c-fos -/- spleen cultures and TGF-P could not 
restore osteoclast formation or resorptive activity in these cultures (Fig. 4.3.5). 
































Fig. 4.3.5 TRAP positive cells and resorption pits are not induced from newborn C-fos -/- 
spleen cultures. M-CSF-dependent spleen cells from newborn c-fos +/- and -/- mice were 
cultured with RANKL only, or together with TGF-P (I ng/ml) or TNF-a (I OOng/ml) in 96-well 
plates and on dentine slices. Cells were fixed on day 9, stained for TRAP activity and the 
numbers of TRAP positive multinucleated cells were counted (A). Cells on dentine slices were 
fixed on day II and the percentage of resorbed area was quantified (B). Values are the mean 
SE of triplicate cultures from a representative experiment. ** P<0.01. 
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I next investigated the TGF-P and TNF-a effects on the differentiation of 
bone marrow and spleen cells derived from young and adult mice. Bone marrow and 
spleen precursors from 2-3 week old c-fos +/+ and -/- mice were cultured with TGF- 
P or TNF-(x (10 or I OOng/ml) for 4,5,6 and 9 days. Under normal conditions, 
TRAP-positive multinucleated cells were formed in wild-type bone marrow and 
spleen cell cultures from day 4, their numbers reached a peak on day 5 and decreased 
thereafter to day 9 (Fig. 4.3.6,4.3.7 and 4.3.10 A). The number of TRAP-positive 
multinucleated cells was increased by adding TGF-P in both bone marrow and spleen 
cultures, and this increase was more prominent with longer culture time (Fig. 4.3.6 and 
4.3.10 A). Treatment with TNF-a caused an increase in the number of TRAP- 
positive multinucleated cells and this was generally observed early during the time 
course (day 4-5), but the number decreased rapidly thereafter, although there was 
greater number of osteoclast-like cells surviving with high concentrations of TNF-oC 
(Fig. 4.3.6). Analysis of resorption pit formation showed that in both bone marrow 
and spleen-derived precursors, TGF-P and TNF-oc enhanced the resorptive activity 
of wild-type cells (Fig. 4.3.8,4.3.9,4.3.10,4.3.11). 
























Fig. 4.3.6 TGF-P and TNF-a fail to induce TRAP positive multinucleated cell formation 
from 2-3 week old c-fos -/- bone marrow cultures. M-CSF-dependent bone marrow cells 
frorn postnatal 17-day old c-fos +/+ and -/- mice were cultured with RANKL only, or together 
with TGF-P (I ng/ml) or TNF-a (10 or I OOng/mI). Cells were fixed on days 4,5,6 and 9, 
stained for TRAP activity and the numbers of TRAP positive multinucleated cells were 
counted. Values are the mean ± SE of triplicate cultures from a representative experiment. 
P<0.01; *** P<0.001. 
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With respect to c-fos knockout cells, there were, as expected, no TRAP- 
positive multinucleated cells fon-ned in c-fos -/- bone marrow and spleen cultures 
(Fig. 4.3.6). Addition of either TGF-P or TNF-ct failed to rescue the formation of 
TRAP-positive multinucleated cells, although the number of TRAP-positive mono- 
nuclear cells was increased (Fig. 4.3.7). Analysis of resorption pit formation showed 
no resorption from spleen cultures (Fig. 4.3.10 B), but a few pits formed under con- 
trol conditions in bone marrow cultures, presumably due to mononuclear osteoclast- 
like cells (Fig. 4.3.8 B, 4.3.9). Addition of TGF-P and to a lesser extent TNF-Ct, en- 
hanced bone resorption slightly in c-fos -/- bone marrow cultures (Fig. 4.3.8 B). In 
contrast, there was no rescue of resorption by either TGF-P or TNF-cc in mutant 
spleen cultures (Fig. 4.3.10 B). 
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Fig. 4.3.7 TRAP positive multinucleated cells are not induced from 2-3 week old c-fos -/- 
bone marrow cultures with TGF-P or TNF-cE. M-CSF-dependent bone marrow cells from 
postnatal 17-day old c-jbs +/+ and -/- mice were cultured with RANKL only, or together with 
TGF-P (I ng/ml) or TNF-a (10 or I OOng/ml). Cells were fixed on days 4 and 9, and stained 
for TRAP activity. Original magnification: x 10. 
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Fig. 4.3.8 TGF-P and TNF-a enhance the resorptive activity from 2-3 week old c-fos -/- 
bone marrow cultures. M-CSF-dependcnt bone marrow cells from postnatal 17-day old c-fos 
+/+ and -/- mice were cultured with RANKL only, or together with TGF-Ii (I ng/ml) or TNF-Q 
(10 or lOOng/mI). Cells were fixed on day II and the percentage of resorbed area was quantified 
(A). The data for the c-jbs-1- bone marrow cultures were replotted on a larger scale in (B). 





















Fig. 4.3.9 TGF-P and TNF-(x enhance osteoclastic resorption from 2-3 week old c-fos -/- 
bone marrow cultures. M-CSF-dependcnt bone marrow cells from postnatal 17-day old c-fos 
+/+ and -/- mice were cultured with RANKL only, or together with TGF-P (I ng/ml) or TNF-a 
(10 or I 00ng/ml). Cells were fixed on day II and the resorption pits were stained with 
Toluidinc Blue. Original magnification: x 10. 
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Fig. 4.3.10 TGF-P and TNF-a fail to induce functional TRAP positive cells from 2-3 week old 
c-fos -/- spleen cultures. M-CSF-dependent spleen cells from postnatal I 7-day old c-fi)s +/+ and - 
/- mice were cultured with RANKL only, or together with TGF-fi (I ng/ml) or TNF-U (10 or 
I OOng/mI). Cells were fixed on day 4,5,6 and 9, stained for TRAP activity and the numbers of 
TRAP positive multinucleated cells were counted (A). Cells on dentine slices were fixed on day II 
and the percentage of resorbed area was quantified (B). Values are the mean :: SE of triplicate 

















Fig. 4.3.11 TGF-P and TNF-a enhance functional TRAP positive cell formation from 2-3 
week old c-fos +/+ spleen cultures. M-CSF-dependent spleen cells from postnatal 17-day old 
c-fos +/+ mice were cultured with RANKL only, or together with TGF-P (Ing/ml) or TNF-(X 
(10 or 100ng/ml). Cells were fixed on day 4 and 9, and stained for TRAP activity. Cells on 
dentine slices were fixed on day II and the resorption pits were stained with Toluidine Blue. 
Original magnification: x 10. 
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Finally, the effects of TGF-P were investigated on bone marrow and spleen 
cell precursor populations derived from 2-month old c-fos knockout mice. The num- 
ber of TRAP-positive multinucleated cells induced from c-fos +/+ and +/- bone mar- 
row and spleen culture were significantly increased by adding TGF-P (Fig. 4.3.12). 
This correlated well with increased resorptive activity (Fig. 4.3.13), although the lack 
of a stimulatory effect in wild-type spleen cells is not clear at this time. More impor- 
tantly, no TRAP-positive cells have ever been observed in c-fos -/- adult bone mar- 
row and spleen cultures cultured in the absence or presence of TGF-P, and accord- 
ingly, there was no corresponding resorption pit formation in c-fos mutant cultures 
(Fig. 4.3.12 and 4.3.13). These results suggest that in haernatopoietic precursors de- 
rived from older mice, TGF-P does not have the ability to rescue TRAP-positive 
multinucleated cell fon-nation and resorption under these experimental conditions. 
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Fig. 4.3.12 TGF-ft fails to induce TRAP positive cell formation from c-fos -/- adult bone 
marrow and spleen cultures. M-CSF-dependent bone marrow (A) and spleen cells (B) ftom 
2-month old male c-fos +/+, +/- and -/- mice were cultured with RANKL only, or together 
with TGF-P (Ing/ml). Cells were fixed on day 9, and stained for TRAP activity and the num- 
bers of TRAP positive multinucleated cells were counted. Values are the mean ý: SE of tripli- 
cate cultures from a representative experiment. ** P<0.001; *** P<0.0001. 
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Fig. 4.3.13 TGF-ft fails to induce resorptive activity in c-fos -/- adult bone marrow and 
spleen cultures. M-CSF-dependent bone marrow (A) and spleen cells (B) from 2-month old 
male c-jbs +/+, +/- and -/- mice were cultured with RANKL only, or together with TGF-P 
(I ng/ml) on dentine slices. Cells were fixed on day 10 and the percentage of resorbed area was 
quantified. Values are the mean ± SE of triplicate cultures from a representative experiment. 
*** P<0.001. 
4.3.4 Summary 
Taken together, the data presented in this section demonstrate that c-fos 
knockout cells can, under the appropriate conditions, differentiate into functional, 
osteoclast-like cells. This appears to be age-related, with newborn cells having a 
greater potential than adult cells. Moreover, the c-fos-independent differentiation 
potential appears to be restricted to bone marrow-derived cells, suggesting that there 
may be differences in the properties of M-CSF-dependent haernatopoietic cells de- 
rived from bone marrow and spleen. Finally, TGF-P can partially rescue osteoclast 
differentiation in c-fos mutant cells, but only in young animals, suggesting that not 
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only the basal differentiation potential, but also the TGF-P responsiveness is lost 
with, increasing age. 
4.4 In vitro osteoclast differentiation from c-fos transgenic mice 
The previous section clearly demonstrated that c-fos is important for the 
differentiation of osteoclasts, and that there may be a c-fos-independent mechanism 
for osteoclast differentiation. In this section, I will investigate the consequences of c- 
fos overexpression on osteoclasts, using the c-fos transgenic mice. As mentioned in 
the Introduction (section 1.7.2.1), these mice develop osteosarcomas due to expres- 
sion of the c-fos transgene in osteoblastic cells, which become transformed, leading to 
tumour formation. However, in view of the potential role of osteoclasts in tumour 
growth and remodelling (see section 3.3), it is possible c-fos overexpression may have 
a direct effect on osteoclasts. 
Before using the c-fos transgenic mice as a model system, it was necessary to 
check whether the c-fos transgene was expressed in osteoclasts, which was never 
investigated in the original characterisation of this strain. However, since it was dem- 
onstrated that c-fos transgenic mice could rescue the cell autonomous block in osteo- 
clast differentiation in c-fos knockout mice in vivo (Matsuo et al., 2000), it was in- 
ferred that the c-fos transgene must be expressed in the osteoclast lineage. As shown 
in Fig. 5.4, RT-PCR analysis of bone marrow-derived haernatopoietic precursors 
confirmed that the c-fos transgene is expressed in the osteoclast lineage (see also 
chapter 5). 
As described in the previous chapter, there were numerous osteoclasts pre- 
sent in tumour tissues from c-fos transgenic mice. In order to find out whether exoge- 
nous; c-fos has direct effect on osteoclast differentiation, bone marrow cells from c-fos 
transgenic mice and their littermates were cultured in vitro. 
4.4.1 Effects of exogenous c-fos on M-CSF and RANKL responsiveness during 
osteoclast differentiation 
Since the c-Fos and AP- I transcription factor lie downstream of both M-CSF 
and RANKL signalling (see Introduction, section 1.8.1,1.8.3), initial experiments 
were to investigate whether c-fos transgenic osteoclast precursors showed a differen- 
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tial responsiveness to these osteoclastogenic cytokines. M-CSF-dependent non- 
adherent bone marrow cells from c-fos transgenic mice and their wild-type littermates 
were cultured with different concentrations of M-CSF and RANKL. The effects of 
different concentrations of RANKL in the Presence of a fixed concentration of M- 
CSF showed a2 to 3-fold increase in the number of TRAP-positive multinucleated 
cells generated from transgenic bone marrow cells compared to wild-type cells at 
RANKL concentrations greater than 5ng/ml (Fig. 4.4.1 A). Similarly, M-CSF dose- 
response experiments in the presence of a fixed RANKL concentration showed an 
approximately 2-fold increase in TRAP-positive multinucleated cells from transgenic 
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Fig. 4.4.1 Osteoclast precursors overexpressing c-fos exhibit increased responsiveness to 
M-CSF and RANKL. M-CSF-dependent bone marrow cells from adult male c-fos transgenic 
mice and their wild-type littennates were cultured in 96-well plates. Cells were treated with M- 
CSF (25ng/ml) and different concentrations of RANKL (A), or with RANKL (5ng/ml) and 
different concentrations of M-CSF (B) for 6 days. Cells were then fixed, stained for TRAP 
activity and the numbers of TRAP positive multinucleated cells were counted. Values are the 
mean ± SE of triplicate cultures from a representative experiment. * P<0.05; ** P<0.01; 
P<0.001. 
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The increase in the number of osteoclasts correlated well with an increase in 
resorption pit formation, with c-fos transgenic precursors showing a higher amount of 
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Fig. 4.4.2 Osteoclasts induced from c-fos transgenic bone marrow cultures exhibit higher 
resorptive activity with different concentrations of RANKL and M-CSF. M-CSF- 
dependent bone marrow cells from adult inale (--Jb. v transgenic mice and their wild-type litter- 
mates were cultured on dentine slices. Cells were treated with 25ng/ml M-CSF and different 
concentrations of RANKL (A), or with 5ng/ml RANKL and different concentrations of M- 
CSF (B). Cells were fixed on day 10 and the percentage of resorbed area was quantified. 
Values are the mean ± SE of triplicate cultures from a representative experiment. * P<0.05; 
P<0.001. 
Thus, these data suggest that c-fos transgenic haematopoietic precursors show 
a greater sensitivity to the two essential osteoclast cytokines, M-CSF and RANKL. 
The effects of c-fos transgene expression in osteoclasts and resorption pit formation 
165 
5 10 50 
RANKL (ng/ml) 
4. In vitro studies 
under the standard culture conditions of 25ng/ml M-CSF and 5ng/ml RANKL are 














Fig. 4.4.3 Overexpression of c-fi)s enhances functional TRAP positive multinucleated cell 
formation in response to RANKL and M-CSF. M-CSF-dependent bone marrow cells from 
. 
16s transgenic inice and their wild-type littennates were cultured in 96-well plates adult inale c- 
and on dentine slices with 25ng/ml M-CSF and 5ng/ml RANKL. Cells were fixed on day 6 
and stained for TRAP activity. Cells on dentine slices were fixed on day 10 and the resorption 
pits were stained with Toluidine Blue. Original magnification: x 10. 
4.4.2 Effects of exogenous c-fos on TGF-P and TNF-a responsiveness during 
osteoclast differentiation 
In view of the effects of TGF-P and TNF-(x on osteoclast differentiation in c- 
fos knockout mice shown in the previous chapter, I next investigated whether over- 
expression of c-fos affects the responsiveness of osteoclast precursors to these cyto- 
kines. M-CSF-depcndent non-adherent bone marrow cells from c-fos transgenic mice 
and their wild-type littermates were cultured with Ing/ml of TGF-P in addition to 
M-CSF and RANKL for 5 to 8 days. At each time point, TGF-P increased the num- 
ber of TRAP-positive multinucleated cells induced from both wild-type and c-jbs 
transgenic bone marrow cultures (Fig. 4.4.4 A). Although the overall numbers of os- 
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teoclasts were greater in c-fos transgenic cultures, the stimulatory effects of TGF-P 
appeared to be similar between wild-type and transgenic cells (Fig. 4.4.4 A). Analy- 
sis of resorption paralleled the osteoclast numbers, and showed that there was an 
increase in resorptive activity in both TGF-P treated wild-type and c-fos transgenic 
bone marrow cultures (Fig. 4.4.4 B). 
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Fig. 4.4.4 TGF-P enhances TRAP positive multinucleated cell and resorption pit forma- 
tion in both wild-type and c-fos transgenic bone marrow cultures. M-CSF-dependent 
bone marrow cells from adult male c- jbs transgenic mice and their wild-type littermates were 
cultured with RANKL only, or together with TGF-P (I ng/ml) in 96-well plates or on dentine 
slices. Cells were fixed from day 5 to 9, stained for TRAP activity and the numbers of TRAP 
positive multinucleated cells were counted (A). Cells on dentine slices were fixed on day 9 
and the percentage of resorbed area was quantified. Values are the mean ± SE of triplicate 
cultures from a representative experiment. * P<0.05; ** P<0.01; *** P<0.001. 
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M-CSF-dependent non-adherent bone marrow cells from c-fos transgenic mice 
and their wild-type littermates were also cultured with TN F-ot and 25ng/mI of M- 
CSF in the absence of RANKL to find out whether overexpression of c-fos affects 
the responsiveness of osteoclast precursors to TNF-oc. Interestingly, no TRAP posi- 
tive multinucleated cells were formed in the absence of RANKL from both wild-type 
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Fig. 4.4.5 TNF-a fails to induce TRAP positive multinucleated cell formation from wild 
type and c-fos transgenic bone marrow cultures in the absence of RANKL. M-CSF- 
dependent bone marrow cells from adult male c-lbs transgenic mice and their wild-type litter- 
mates were cultured with 25ng/ml M-CSF and 100ng/ml TNF-(x. Cells were fixed on day 6 
and stained for TRAP activity. Original magnification: x 10. 
4.4.3 Effects of exogenous c-fas on apoptosis of osteoclast precursors 
The previous sections showed that osteoclast differentiation in the presence 
of exogenous c-fos was increased. Together with the increased sensitivity to M-CSF 
and RANKL, which are not only important for differentiation but also for osteoclast 
survival, it was of interest to investigate whether c- fibs overexpression affected the 
survival of osteoclast precursors. To this end, a TUNEL (TdT-mediated dUTP nick 
end labelling) assay was performed on c- . 
16s transgenic and wild-type bone marrow 
precursors which have been induced to apoptose by withdrawal of serum, M-CSF 
and R-ANKL. The results showed that after 2 days culture, withdrawal of factors for 
a further 24 hours caused a significant increase in the number of TUNEL-positive 
cells, but there were no obvious differences between wild-type and transgenic cul- 
tures (Fig. 4.4.5). These results suggest that increased survival of osteoclast lineage 
cells is unlikely to be the main reason for the enhanced osteoclast differentiation seen 
in c-fos-overexpressing cells. 
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Fig. 4.4.6 No differences in the amount of apoptotic cells between c-fos transgenic and 
wild-type precursors. M-CSF-dependent bone marrow cells from adult male c. 16s transgenic 
mice and their wild-type littermates were cultured with M-CSF and RANKL (30ng/mI) in 24- 
well plates on coverslips for 2 days. Serum and growth factors were then withdrawn for 24 
hours, and cells were fixed and stained for TRAP and TUNEL activity. Original rnagnifica- 
tion: x 10. 
4.4.4 Effects of exogenous c-fos on RANKL and OPG expression 
Finally, since in primary bone marrow cultures, there may be some contami- 
nating stromal cells remaining in the cultures, it was important to confirm that the 
effect of exogenous c-fos on osteoclast differentiation is not secondary to the effect 
on osteoblasts. This was done by isolating stromal cells from c-jbs transgenic mice 
and wild-type littermates, and examining the expression of RANKL and OPG. First, 
analysis of transgene expression carried out by RT-PCR, showed that exogenous c- 
fos was expressed in transgenic stromal cells, but was absent in the wild-type stromal 
cells (Fig. 4.4.7 A). The transgene levels were quite low and could not be detected 
readily by Northern blotting. Analysis of RANKL and OPG expression by Northern 
blot analysis showed that in wild-type mice, addition of 1,25(OH)2D3 and Dex- 
amethasone stimulated the expression of RANKL but inhibited OPG expression, as 
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expected (Fig. 4.4.7 B). In c- er , 
fos-overexpressing stromal cells, there were no diff - 
ences in either basal or hon-none-induced expression of RANKL or OPG (Fig-4.4.6). 
This suggests that c-fos transgenic stromal cells do not have altered levels of osteo- 
clastogenic cytokines and this is unlikely to explain the effects of c-fos on osteoclast 
differentiation. 
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Fig. 4.4.7 Expression of RANKL and OPG in c-Fos transgenic stromal cells. Stromal 
cells were isolated from c-fos transgenic mice and their wild-type littermates. Cells were 
treated with or without 10-'M 1,25 (OH)2D, and Iff"M Dexamethasone for three days. 'Me 
expression of c-fos transgene was investigated by RT-PCR (A), and the expression of 
RANKL and OPG was investigated by Northern blot (B). GAPDH was used as a loading 
control. 
4.5 Discussion 
The results of this chapter must be viewed in the context of the molecular 
data provided in the next chapter. Therefore, the results of both chapters will be 
discussed in one section at the end of chapter 5 (see section 5.7). 
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Chapter 5 
Gene expression during osteoclast differentiation in c-fos 
knockout and transgenic cultures 
171 
5. Gene expression 
5.1 Introduction 
The previous chapter used tissue culture experiments to show that c-fos 
knockout precursors can, to a limited extent, differentiate into functional osteoclasts, 
and that overexpression of c-fos can increase the sensitivity of osteoclasts precursors 
to M-CSF and RANKL. In order to investigate the possible mechanism by which c- 
fos affects osteoclast differentiation, the expression of osteoclast marker genes and 
signalling factors for osteoclast differentiation was analysed by semi-quantitative RT- 
PCR in c-fos knockout and transgenic cell cultures, both before differentiation in M- 
CSF-dependent precursors, and after induction of differentiation by M-CSF and 
RANKL. 
5.2 Expression of osteoclast marker genes in c-fos knockout bone 
marrow and spleen cultures 
Total RNA was isolated before and after differentiation from newborn, 2-3 
week-old and adult c-fos +/+ and -/- male bone marrow and spleen cultures. RT-PCR 
of the osteoclast marker genes TRAP and CTR showed that TRAP was expressed at 
lower levels in c-fos -/- cultures, especially in newborn cultures which can form func- 
tional osteoclasts (Fig. 5.1 A-C), although the expression was quite variable. Since 
TRAP expression in vitro can be an inconsistent marker, especially at the RT-PCR 
level, I also analysed the expression of CTR, which is the best marker of osteoclasts. 
First, CTR was expressed in all wild-type samples only after differentiation, vali- 
dating the use of this as a good marker. CTR expression was clearly observed in c-fos 
mutant newborn cultures, and this was at a lower level than in wild-type controls 
(Fig. 5.1 A), which correlated well with their differentiation capacity shown in the 
previous chapter. In post-natal day 18 cultures, CTR was not easily detectable in 
mutant bone marrow cultures after differentiation, which is expected since only a low 
number of mononuclear TRAP-positive cells were observed in these cultures (Fig. 5.1 
B; see also Fig. 4.2.3,4.2.4). In 2 month-old cultures, no CTR expression was de- 
tccted either in bone marrow or spleen-derived precursors (Fig. 5.1 Q, consistent 
with their lack of ability to form functional osteoclasts. Thus, in newborn c-fos -/- 
cultures which formed functional osteoclasts, this was confirmed at the molecular 
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5. Gene expression 
Analysis of the receptors for RANKL and M-CSF, RANK and c-fms, respec- 
tively, showed that both genes were upregulated after differentiation of wild-type 
cells (Fig. 5.1). However, in c-fos -/- cultures, whereas no significant changes in c-fMS 
expression were observed, RANK expression was reduced in c-fos mutant cells when 
compared with c-fos +/+ cells (Fig. 5. I A-C). The fact that RANK expression was still 
observed in c-fos knockout cells suggests that putative osteoclast precursors still 
exist in the absence of c-fos. Finally, analysis of a definitive macrophage marker, 
F4/80, showed that at all ages tested, F4/80 expression was increased in c-fos mutant 
cultures (Fig. 5.1), confirming previously published results that there are more macro- 
phages in mice lacking c-fos (Grigoriadis et al., 1994). 
5.3 Expression of c-Fos-related genes and signalling molecules in c- 
fos knockout bone marrow and spleen cultures 
To investigate the expression of genes which may lie downstream of, or are 
associated with c-fos during ostcoclast differentiation, RT-PCR was performed for 
genes encoding other c-fos family members and signalling molecules important for 
osteoclast differentiation. In wild-type cultures, the expression of fra-1, which is a 
well-established c-Fos target gene, increased after differentiation in both bone marrow 
and spleen cultures at all ages (Fig. 5.2). In the absence of c-Fos, however, some inter- 
esting changes were observed: in adult-derived c-fos -/- cells, fra- I expression was not 
induced following differentiation, and levels were lower after differentiation compared 
with wild-type cells, consistent with the fact that it is a c-Fos target gene (Fig. 5.2 C). 
This supports previous data that adult c-fos knockout spleen cells have decreased 
fra-I expression (Matsuo et al., 2000), and this is now also shown here with adult 
bone marrow-derived cells, which also do not form osteoclasts. In contrast, however, 
in newborn and young c-fos knockout cells, fra-I expression was stimulated during 
differentiation, and the levels were higher than wild-type controls following differen- 
tiation (Fig. 5.2 A, B). This was only observed in bone marrow cells, which form os- 
teoclasts, but not in spleen cells, which do not form osteoclasts. The other c-fos- 
related gene, fra-2, did not show any significant changes in either bone marrow or 
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S. Gene expression 
The expression of TRAF-6, which is downstream of RANK receptor signal- 
ling, was generally reduced after differentiation of c-fos knockout cultures compared 
to wild-type cells, and this was most prominent in newborn and young cultures 
(Fig. 5.2A-C). This also correlates well with the reduced RANK expression at this 
stage (Fig. 5.1 A). The expression of 1FN-, 8, another c-Fos target gene, was down- 
regulated in mutant spleen cultures, consistent with recently published results 
(Takayanagi et al., 2002b), and this was also observed now in adult bone marrow- 
derived cultures (Fig. 5.2 Q. In newborn knockout bone marrow cultures, which form 
osteoclasts, there was a slight upregulation of IFN-, o expression after differentiation, 
which was not observed in spleen cultures (Fig. 5.2 A). Finally, preliminary analysis 
of NFAM expression, which has recently been shown to be downstream of RANKL 
signalling in a c-Fos-dependent manner (Takayanagi et al., 2002a), showed that there 
were no significant changes in newborn mutant bone marrow and spleen cultures. 
Thus, these results show some unique gene expression patterns specifically in 
newborn bone marrow cultures which have retained osteoclastic potential, and which 
are not found in knockout cell populations which have lost the ability to form osteo- 
clasts. 
5.4 Expression of osteoclast marker genes in c-fos transgenic bone 
marrow and spleen cultures 
I next investigated whether overexpression of c-fos resulted in altered gene 
expression patterns which correlated with the differentiation effects observed in 
chapter 4. Before this, however, it was important to demonstrate that the c-fos trans- 
gene was expressed in osteoclast precursors. RT-PCR analysis using transgene- 
specific primers indicated that the c-fos transgene was indeed expressed both before 
and after osteoclast differentiation, although the levels were apparently lower in dif- 
ferentiated cultures (Fig. 5.4). Analysis of the osteoclast marker genes TRAP, cathep- 
sin K and CTR showed that all these genes were expressed at slightly higher levels 
after differentiation of bone marrow cells derived from c-fos transgenic mice com- 
pared to wild-type littermate controls (Fig. 5.3). This is consistent with the increased 
number of osteoclasts seen in the differentiation experiments shown in chapter 4. 
Interestingly, the expression of the receptor RANK showed higher levels in transgenic 
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cultures both before and after differentiation (Fig. 5.3). This may explain the increased 
sensitivity of transgenic ostcoclast precursors to RANKL treatment which was 
shown in chapter 4 (Fig. 4.4.1 A), and raises the possibility that RANK expression 
may be regulated, either directly or indirectly, by c-Fos. In contrast, no changes in c- 
fins expression were observed betwccfl transgcnic and wild-typc cultures (Fig. 5.3), 
suggesting that the increases responsiveness to M-CSF observed earlier (Fig. 4.4.1 B) 












Fig. 5.3 Expression of osteoclast and inacrophage marker genes in differentiation cul- 
tures of c-Fos transgenic haeniatopoictic cells. M-CSF-dependeni boric marrow ccll.,, iso- 
fated from adult male c-Fos-transgenic mice and their wild-lype littermates were culture(] 
under standard osteoclast differentiation conditions. Total RNA was isolated From M-('SF- 
dependent non-adherent precursors prior to file addition of' RANKI. (before dillerentialion) 
and from cells cultured for 5-6 days in the presence of' RANKI, (, It'tCl- differentiation). RT- 
PCR analysis of TRAP, cathepsin K, CTR, RANK and c-. 1ins expression was perl'ormcd. 
GAPDH was used as a loading control. 
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5.5 Expression of c-Fos-related genes and signalling molecules in c- 
fos transgenic bone marrow and spleen cultures 
Analysis of the c-Fos target gene, fi-a-1, demonstrated that the expression of 
fi-a-1 was upregulatcd in transgcnic M-CSF-dependent precursors before differentia- 
tion, and this increase was maintained after osteoclast differentiation (Fig. 5.4). This 
irnplicatcs fi-a- I as a downstream gene which may explain why c- . 
/bs-overex press ion 
causes enhanced osteoclast differentiation, and is consistent with the previously 
published data that ovcrcxprcssion offi-a-1 can stimulate ostcoclast differentiation 
(Owens ct al., 1999). In contrast, fi-a-2 expression was not altered signif icantly in 









Fig. 5.4 Expression of osicocia, " and c- I os- 1 clated menes in differen- 
tiation cultures of c-Fos transgenic hacillatoPoictic cells. M-CSF-dcpcndcw honc marrow 
cells isolated From adult 11WIC C-FOS-11-alisgellic mice and their wild-typc lijjcrjjý, jc,, were 
cultured Linder standard osteoclast differciltiation conditions. Total RNA was isolated From M- 
CSF-dependent non-adherent precursors prior to the addilion of' RANKL (hcl'orc diflerentia- 
Lion) and From cells cultured for 5-6 days in the present ot'RANKI. Of-ter differentiation). RT- 
PCR analysis of c-. /bs-transgene,. fi-a-I. fi-a-2, TRAF-6, IFV-13 and NFATcl expres-sion was 
perfonned. GAPDH was used as a loading control. 
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Analysis of TR, 4F-6 expression also showed significant increases in expres- 
sion in c-fos-overexpressing cultures both before and after differentiation (Fig. 5.4), 
and this was consistent with the increased expression of the receptor RANK observed 
earlier (Fig. 5.3). On the other hand, no significant changes were observed in the ex- 
pression of IFN-P and NFA Tcl (Fig. 5.4). 
5.6 Time course of fra-I expression in osteoclast precursors after 
RANKL stimulation 
Finally, to further analyse the role offira-1 in the context of varying c-fos lev- 
els, and to compare with previous published data, I analysed the induction of fra- I 
expression following RANKL treatment of M-CSF-dependent bone marrow and 
spleen cells derived from different c-fos mutant mice. First, M-CSF-dependent non- 
adherent cells from c-fos +/- and -/- newborn and postnatal day 18 bone marrow and 
spleens, were stimulated with M-CSF and RANKL for the indicated times, and the 
expression offira-1 was analysed by RT-PCR. As expected, and confirming previous 
reports (Matsuo et al., 2000), the induction offra-1 was markedly reduced in cells 
lacking c-Fos, and this was observed in the spleen cultures and young bone marrow 
cultures which do not make multinucleated osteoclasts (Fig. 5.5). In contrast, how- 
ever, in newborn knockout bone marrow cultures which can differentiate into func- 
tional osteoclasts, there was no reduction in RANKL-stimulatedfra-I expression in 
the absence of c-fos (Fig-5.5 A). 
Similar experiments were done with bone marrow cells from c-fos transgenic 
and wild-type mice to investigate the effects of exogenous c-fos onfra-I induction by 
RANKL. Starting as early as 30min after RANKL addition, the expression of fra-I 
was upregulated in c-fos-overexpressing bone marrow cultures compared to wild- 
type cultures at all time points, and reached a peak at about I hour (Fig. 5.5 Q. These 
results clearly suggest that the increase in osteoclastic potential in c-fos- 
overexpressing cells may be due to enhanced RANK receptor expression, which lead 
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5.7 Discussion 
5.7.1 Establishment of an in vitro culture system 
Many in vitro model systems have been established so far to study the 
mechanisms of osteoclast differentiation and activation. Among all the methods, the 
coculture system, which combines bone marrow haernatopoietic precursors and sup- 
portive stromal cells (Takahashi et al., 1988a), historically is the most widely em- 
ployed, since the osteoclasts induced in this system more closely resemble the in 
vivo circumstances. However, after the discovery of RANKL, it is possible to gener- 
ate osteoclasts from bone marrow precursors in the absence of stromal cells, which 
provides a model system to study the events in osteoclastogenesis without the addi- 
tional effects of other cells (Udagawa et al., 1999). Because of the difficulties in iso- 
lating bone marrow cells from osteopetrotic bones, most studies involving os- 
teopetrotic animals have used spleen cells as a source of haematopoietic precursors 
(Takahashi et al., 1991). Spleen is one of the secondary lymphoid organs, which 
contains numerous red blood cells, lymphocytes, macrophages and monocytes that 
can differentiate into osteoclasts given the proper stimulation. 
In this thesis, only stroma-free differentiation cultures of osteoclasts were 
performed, thus initial experiments were set up in order to establish the optimal con- 
ditions for differentiation, which can vary according to different serum batches, 
mouse strain and source/activity of M-CSF and RANKL. Cell plating density ex- 
periments and dose-response analyses for M-CSF and RANKL identified the ideal 
parameters for obtaining functional. Moreover, TGF-P dose response experiments 
showed a dose-dependent increase in both osteoclasts number and size, consistent 
with published data (Fuller et al., 2000). However, although it has been reported that 
TNF-cc could substitute for RANKL in supporting osteoclast differentiation in the 
presence of M-CSF, only very few TRAP positive multinucleated cells were gener- 
ated at the highest concentration in the absence of RANKL. Thus, it is likely that 
under our experimental conditions, some RANKL is required to observe any TNF-(x 
effects (Lam et al., 2000; Zhang et al., 2001b). 
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5.7.2 In vitro studies of c-fos knockout mice 
5.7.2.1 Osteoclast precursors lacking c-Fos have a limited potential to differen- 
tiate into functional osteoclasts 
To date, all in vitro differentiation assays for studying the mechanism of the 
osteoclastogenesis deficiency in osteopetrotic animals have used spleen cells as the 
source of haernatopoietic precursors, because of the difficulty in obtaining sufficient 
numbers of bone marrow precursors. Clearly, the splenic precursors have proven to 
be very valuable in understanding the role of c-Fos in osteoclast differentiation 
(Matsuo et al., 2000; Takayanagi et al., 2002b), however, as it has been hypothesised 
in this thesis, it is possible that the monocyte/macrophage precursors isolated from 
bone marrow are different from that of the spleen. As described before, RANKL and 
M-CSF are essential and sufficient for osteoclast formation. RANKL was first identi- 
fied as a product of activated T cells, and T cells also produce M-CSF and other 
cytokines that stimulate osteoclastogenesis, such as IL-1, IL-6, and TNF-a, which 
play an important role in pathological bone loss (Theill et al., 2002). However, no 
osteoclasts, but only macrophages are formed in the spleen, even under inflammatory 
conditions, even though these two cell types are derived from the same mono- 
cyte/macrophage precursors, and abundant T cells are present in the spleen. Thus, 
the absence of osteoclastogenesis in spleen tissues suggests that the local spleen mi- 
croenvironment is different from that in the bone marrow, and/or different precursor 
populations or precursors at different differentiation stages are present in the spleen 
versus the bone marrow. 
In order to study the effect of the absence of c-Fos on osteoclastogenesis 
from precursors derived from different sources, I systematically compared the osteo- 
elastic potential of cells derived from bone marrow and spleen tissues at different 
ages of c-Fos mutant and wild-type mice. Surprisingly, several TRAP positive 
multinucleated cells were formed from newborn mutant bone marrow cells, and these 
cells formed resorption pits as well, although the number of TRAP-positive 
multinucleated cells and pits were much less than that from the wild-type bone mar- 
row and the formation time was much delayed (10 days). Nevertheless, these data 
showed for the first time that bone marrow precursors from newborn rnice lacldng c- 
Fos have a limited potential to differentiate into mature, functional osteoclasts. On 
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the other hand, spleen cells from the mutant newborn mice were unable to generate 
TRAP positive multinucleated cells, supporting the hypothesis that the M-CSF- 
dependent mononuclear precursors derived from spleen are different from bone mar- 
row precursors. 
During haematopoiesis in bone marrow, granulocyte-monocyte progenitors 
differentiate into promonocytes, which leave the bone marrow and enter the blood- 
stream. While circulating in the bloodstream, they further differentiate into mono- 
cytes, and then migrate into the various tissues and differentiate into specific tissue 
macrophages. Thus, the resident bone marrow macrophages are different from those 
in the spleen, skin and brain, which are specifically designated as Kupffer cells, den- 
dritic cells and microglia, respectively, and each of these populations have different 
functions specific to each of those tissues. Thus, in the case of c-Fos deficiency, one 
interpretation is that early stage osteoclast progenitors in bone marrow have an in- 
trinsic ability, at least in part, to differentiate into osteoclasts, while those in spleen 
couldn't. The possible mechanisms for this are discussed below in section 5.7.4. 
Alternatively, another explanation for the inability of newborn mutant spleen cells to 
form osteoclasts, in vitro is that the number of progenitors in the mutant spleen is too 
low to form osteoclasts, compared to those in the bone marrow. Indeed, it was 
shown in wild-type spleens (e. g. Fig. 4.2.1), where, compared to bone marrow cells, 
ten-fold more spleen cells were needed for osteoclast formation. 
The other significant observation was that the osteoclastic potential in pre- 
cursors lacking c-Fos was age-dependent. While newborn knockout bone marrow 
cells could clearly form multinucleated. osteoclasts, only a few TRAP positive mono- 
nuclear cells were generated from 2-3 week old mutant bone marrow precursors, but 
they were nevertheless functional. In contrast, no TRAP positive cells or resorption 
pits were induced from c-Fos mutant adult bone marrow culture or from mutant 
spleen cells. These results suggest that the potential of c-Fos knockout bone marrow 
precursors to differentiate into later stage osteoclasts is diminished in adult animals. 
These data therefore provide a possible explanation for the histological observation 
that the osteopetrosis in c-Fos knockouts becomes progressively worse with age, 
with a clear evidence of a partial bone marrow space in embryonic and newborn ani- 
mals, in contrast to older animals which are heavily osteopetrotic (Fig. 4.2.2). The 
reasons for this are not entirely clear. In embryos and young growing mice, bone 
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formation and remodelling occur at a rapid rate, which might lead to the active and 
continuous generation of osteoclast progenitors. In contrast, bone remodelling is sig- 
nificantly reduced in adults and consequently, osteoclast progenitors may not be 
required at a high frequency and their turnover is reduced. Therefore, in the absence 
of c-Fos, the very low number of early progenitors would result in the inability to 
form osteoclasts. The diminished differentiation ability of precursors in the mutant 
mice is also consistent with the previous observations that transplantation of wild 
type bone marrow cells rescued the osteopetrosis in newborn c-Fos knockout mice 
when active bone remodelling was still occurring, but couldn't rescue the osteopetro- 
sis in adult mutant mice (Okada et al., 1994). 
An unexpected observation was that the number of TRAP positive 
multinucleated cells induced from c-Fos heterozygous precursors (c-Fos+/-) was 
significantly decreased than that from the wild-type precursors (c-Fos+/+). This 
occurred in both bone marrow and spleen cultures from newborns to the adults. This 
has not been reported before, and suggests that c-fos affects osteoclast formation in a 
gene dose-dependent manner. This is similar to the situation with NFicB, where lot- 
sova et al. reported that the number of osteoclasts was slightly reduced in single 
NFKB knockout mice, p50-l'p52-/-, and osteoclast differentiation was arrested before 
fusion in p50-l-p52-/+ mice which contained only mononuclear immature osteoclasts 
but exhibited a normal bone phenotype (lotsova et al., 1997). Although the differen- 
tiation potential was significantly reduced in c-Fos heterozygous precursors in vitro, 
the mice developed a normal bone marrow cavity, which suggests that there are 
mechanism(s) in vivo that could compensate for the deficiency of c-Fos. 
Although I showed in this thesis that TRAP-positive cells could be induced 
from newborn and young c-fos mutant bone marrow cells in vitro, it is clear that there 
are no TRAP-positive cells present in vivo at any age (Grigoriadis et al., 1994). This 
apparent inconsistency could be explained in several ways. First, although the in situ 
hybridisation results and previously published data showed that osteoblasts are ca- 
pable of supporting osteoclast differentiation (Grigoriadis et al., 1994), it is not clear 
how efficient this process is in vivo vs in vitro. Other cell types, such as lympho- 
cytes, and many systemic and local factors, which play important roles in osteoclast 
formation, are not present in vitro, but are present in vivo, where the balance of 
stimulatory and inhibitory factors may be altered in the absence of c-fos. Also, the in 
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vitro system, which uses maximal concentrations of purified RANKL and M-CSF 
proteins, may be more efficient in inducing osteoclast differentiation from c-fos -/- 
precursors than in an in vivo environment where the "real" concentrations are not 
known. Second, Udagawa et al. reported that c-Fos affects the proliferation of osteo- 
clast precursors (Udagawa et al., 1996). One cannot rule out, therefore, that cell pro- 
liferation in the relatively pure cell populations and high plating cell densities used in 
vitro might not accurately reflect the proliferation of similar populations in vivo. 
Third, although there are no identifiable TRAP positive cells in c-fos mutant bones in 
vivo, the current hypothesis is that the partial resorption which occurs in these mice 
is performed by the mononuclear MMP-9 positive cells, which are probably osteo- 
clast precursors. It is possible that in vitro, a small proportion of these cells may 
progress further in the osteoclast lineage and express subsequent markers such as 
TRAP and CTR. Finally, it should be noted that with the increasing number of 
knockout animals being generated for many genes, that there are often slight discrep- 
ancies in cell behaviour in in vivo vs ex vivolin vitro cultures, which yield important 
information regarding gene function, rather than being interpreted as just in vitro arti- 
fact. Regarding osteoclast biology, the recent analysis of osteoclast differentiation in 
JNKI knockout mice in vivo vs in vitro provides one such example, although there 
are several others concerning other AP- I genes (David et al., 2002). 
Taken together, the in vitro data have provided valuable novel information in 
understanding the role of c-fos regulates osteoclast formation. Clearly, osteoclasts can 
form in the absence of c-Fos, although at very low levels, and therefore, the existing 
notion that c-Fos is an essential gene for osteoclast differentiation, may need to be re- 
evaluated. 
5.7.2.2 Osteoclastic marker genes are expressed in newborn and young c-fos 
knockout bone marrow cultures 
To verify the in vitro results using molecular markers, and to try and investi- 
gate a possible mechanism to explain the low levels of osteoclast differentiation in the 
absence of c-Fos, detailed expression analyses were performed. Consistent with 
tissue culture results, RT-PCR analysis showed that the osteoclast markers TRAP 
and, most importantly, CTR, were expressed in newborn mutant bone marrow cul- 
tures, although the expression levels were much lower than the wild type, which was 
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expected due to their reduced numbers. However, the RT-PCR data for TRAP was 
not always consistent, showing some expression in adult mutant cultures, which is 
inconsistent with the absence of TRAP staining in vitro. Moreover, TRAP mRNA 
was detected even before differentiation in all cultures, which suggests that for meas- 
uring TRAP expression, RT-PCR may not be so reliable, or alternatively, in spite of 
transcription, there was no protein produced or the protein level was too low to be 
detected. On the other hand, CTR is the most specific marker for mature osteoclasts 
in bone (Hattersley and Chambers, 1989a), and CTR expression pattern paralleled 
exactly the appearance of osteoclasts in vitro. Unfortunately, CTR expression was 
not detected in mutant 2-3 week-, old cultures which formed TRAP positive mono- 
nuclear cells that fortned pits. However, this was not surprising, as it is unlikely that 
CTR message could be detected from the very few TRAP positive mononuclear cells 
that were present in these cultures. Thus, these data definitely confirmed at the mo- 
lecular level that mature osteoclasts were generated in the absence of c-Fos. 
As expected, RANK mRNA was expressed in c-Fos mutant cells, although 
the level was much lower than in the wild type, which confirms the in situ hybridisa- 
tion results shown in Chapter 3, and is consistent with published data (Matsuo et al., 
2000). Additionally, the expression level was upregulated after differentiation both in 
the wild type and mutant cultures, which is consistent with previous experiments 
that M-CSF stimulates RANK expression on early-stage osteoclast precursors (Arai 
et al., 1999). As shown before, precursors isolated from c-Fos mutant spleen have 
less differentiation potential in vitro than those from bone marrow, however, para- 
doxically, the RT-PCR data showed higher RANK expression in mutant spleen cul- 
tures than in bone marrow. Although RANK is expressed primarily on osteoclastic 
cell lineage in bone, it is also expressed in T and B cells that are abundant in spleen 
(Anderson et al., 1997). Besides developing osteopetrosis, RANK knockout n-&e 
also lack peripheral lymph nodes and had defective B cell and T cell maturation (Li et 
al., 2000). Therefore most cells expressing RANK in spleen cultures could be lym- 
phocytes, which could explain the RT-PCR results. 
The mature macrophage marker, 174/80, was highly expressed in the mutant 
cultures, which correlates well with the in vivo expression pattern, and further sup- 
ports the notion that bipotential precursors differentiated into the macrophage lineage 
in the absence of c-Fos. In contrast to the in situ expression data, there was no differ- 
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ence in c-fms expression, which is present on both osteoclasts and macrophages, 
between mutant and wild-type cultures at all ages tested. However, high levels of c- 
fms expression could perhaps be expected in the in vitro cultures, as the cells are 
selected in the presence of maximal doses of M-CSF, thus any differences between 
mutant and wild-type cultures may not be evident. 
Taken together, semi-quantitative RT-PCR analysis of osteoclast and 
macrophage genes further confirmed that M-CSF and RANKL responsive progeni- 
tors are present in c-Fos mutant mice, and that these cells have a limited potential to 
differentiate into mature osteoclasts in an age-dependent manner. 
5.7.2.3 Altered expression of signalling molecules in c-fos knockout cultures 
During osteoclast differentiation, RANKL binds to RANK, the receptor on 
osteoclast precursors, which mediates signal transduction via TNF receptor- 
associated factor (TRAF) proteins, especially TRAF-6 (Naito et al., 1999; Wong et 
al., 1998). TRAF-6 knockout mice developed osteopetrosis due to the defect in os- 
teoclast differentiation and activation (Lomaga et al., 1999; Naito et al., 1999). In the 
experiments with c-fos knockout mice, semi-quantitative RT-PCR showed that 
TRAM expression was upregulated after differentiation in wild type cultures, while 
in mutant cultures, the expression remained unchanged after differentiation. This is 
consistent with low level of RANK expression in the same cells, and implies that the 
signalling pathway downstream of RANKURANK is attenuated in the absence of c- 
Fos. 
With respect to other c-Fos-related genes, some interesting observations 
were made. Fra-1 is a transcriptional target of c-Fos in osteoclast progenitors, and 
overexpression offra-1 rescued the differentiation of c-fos deficient osteoclast pre- 
cursors both in vivo and in vitro (Fleischmann et al., 2000; Matsuo et al., 2000). 
Semi-quantitative RT-PCR analysis offra-1 expression in osteoclast cultures at dif- 
ferent ages showed upregulation offra-1 expression after differentiation in the wild- 
type cultures, which coincides with osteoclast formation. Interestingly, although the 
expression level was low before differentiation, fra-1 mRNA was strongly expressed 
in mutant newborn and 2-3 week old bone marrow cultures after differentiation, and 
the level appeared approximately two fold higher than the wild-type, although this 
was not quantified by densitomctry. This increase could provide one possible cxpla- 
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nation for the osteoclastogenesis which occurred in these mutant cultures. Matsuo et 
al. reported that RANKL induces transcription offra-1 in a c-Fos-dependent manner 
(Matsuo et al., 2000). In their studies, fra-I expression in c-Fos-/- spleen cells was 
lower than in the wild type, and no induction was observed 0.5-2 hours after 
RANKL treatment. Similarly in the experiments shown here, fra-1 expression was 
not upregulated in all the mutant spleen cultures, but also not in the adult bone mar- 
row culture after differentiation. The fact that TRAP positive multinucleated and 
mononuclear cells were only formed in newborn and 2-3 weeks old mutant bone mar- 
row culture, wherefra-I was strongly induced by RANKL, suggests that in mutant 
progenitors from young mice, fra- 1 is upregulated by some unknown, c-Fos- 
independent mechanism in response to osteoclastogenic stimuli, perhaps to compen- 
sate the deficiency of c-Fos. These results also suggest that Fra-1 may support os- 
teoclast differentiation by a mechanism different from c-Fos, which is consistent with 
previous experiments thatfra-I knockout mice developed normal bone structure with 
apparently normal numbers of TRAP positive osteoclasts present (Schreiber et al., 
2000). 
Fra-2 is another Fos family protein. In fibroblasts, expression of Fra-2 after 
growth stimulation is later than that of c-Fos, suggesting that it's a transcriptional 
target of c-Fos in this cell type (Suzuki et al., 1991), although this has not been 
shown directly. The reasons why this c-Fos-related gene has become interesting with 
respect to osteoclasts, is that it has recently been suggested thatfra-2 is a negative 
regulator of osteoclastogenesis. Recent preliminary data from Wagner and co-workers 
have demonstrated thatfra-2 knockout mice have an increased number of osteoclasts 
and developed osteoporosis (Karsenty and Wagner, 2002). In the experiments with c- 
fos knockout cells shown here, RT-PCR analysis offra-2 showed expression in bone 
marrow and spleen cultures both before and after differentiation, and there was no 
apparent differences between the wild-type and knockout cultures, which suggests 
that the regulation of fra-2 transcription in osteoclast progenitors may be c-Fos- 
independent. 
IFN-P has recently been identified as an inhibitor of osteoclastogenesis, 
playing an important role in c-Fos-mediated osteoclast differentiation. It is expressed 
and secreted by the osteoclast itself Mice lacking IFN-P receptors developed osteo- 
porosis with increased osteoclastic bone resorption, and IFN-P knockout rnice had a 
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similar defect (Takayanagi et al., 2002b). In osteoclast precursors, RANKL induces 
the expression of IFN-P in a c-Fos-dependent manner, as the induction was absent in 
c-Fos deficient splenocytes. IFN-P then inhibits osteoclast differentiation by inter- 
fering with the RANKL-induced expression of c-Fos (Takayanagi et al., 2002b), 
which represents an important negative feedback regulation for osteoclastogenesis. 
Thus, IFN-P is both a c-Fos target gene, and is involved in negatively regulating c- 
Fos. It was therefore an interesting candidate gene for investigating in the differentia- 
tion of osteoclasts in c-fos knockout mice. Surprisingly, however, semi-quantitative 
RT-PCR showed that IFN-P was expressed in newborn and 2-3 week old mutant 
cultures both before and after differentiation. It was also expressed in adult cultures 
after differentiation, although before differentiation the expression levels were only 
detectable in adult mutant precursors, which is consistent with the results of Ta- 
kayanagi et al. (Takayanagi et al., 2002b). Since in their experiments, IFN-P induction 
was absent in c-Fos deficient splenocytes after 2 and 24 hours RANKL stimulation, 
our results suggests that in long term culture, some mechanisms may substitute for c- 
Fos in mediating RANKL-induced expression of IFN-P. One candidate could be Fra- 
1, although it is not yet known whether Fra-1 can regulate IFN-P transcription. In 
addition, the expression of IFN-, 6 in mutant bone marrow cultures was similar to that 
of wild-type cultures, while in mutant spleen cultures the expression was lower than 
in wild-type cultures, which further supported one of the hypotheses in this thesis 
that the precursors in spleen are different from those in bone marrow, at least in their 
response to RANKL. 
Taken together, semi-quantitative RT-PCR analysis confirmed the tissue 
culture results that mature osteoclasts were formed in c-Fos-mutant newborn bone 
marrow cultures. Alternative signalling pathways, particularly in younger animals, 
including upregulation offra-1, may compensate for the deficiency of c-Fos. 
5.7.2.4 TGF-P and TNF-4x can not fully rescue osteoclastogenesis in the ab- 
sence of c-fos 
RANKL-induced osteoclastogenesis is regulated by various hormones and 
growth factors. TGF-P is one of the growth factors that act directly on osteoclast 
precursors and strongly promoted their differentiation (Fuller et al., 2000). Interest- 
ingly, it has been reported that TGF-P might facilitate osteoclast differentiation 
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through its role as a macrophage deactivator. Antibodies against TGF-P significantly 
inhibited osteoclast formation in vitro (Fox et al., 2000; Kaneda et al., 2000). Thus, 
the effect of TGF-P on osteoclastogenesis in the absence of c-Fos was investigated. 
Consistent with previous data (Fuller et al., 2000), TGF-P strongly stimu- 
lated osteoclast formation and survival in the presence of RANKL and M-CSF in 
wild-type bone marrow cultures, however, the effect of TGF-P on resorptive func- 
tion was much less significant. The possible explanation is that the culture time was 
prolonged slightly (I I days) in order to obtain measurable and reliable levels of bone 
resorption from mutant precursors. Therefore, in the corresponding wild-type cul- 
tures, the percentage of resorption was very high even in the absence of TGF-P, 
which may conceal the stimulatory effect of TGF-P. Interestingly, the number of 
TRAP positive multinucleated and mononuclear cells generated from newborn c-Fos 
mutant bone marrow cultures and their ftinction were significantly increased by TGF- 
P. In addition, the number of TRAP positive multinucleated cells induced from TGF- 
P-treated heterozygous cultures was similar to that of wild-type cultures, which 
suggests that TGF-P may also partially rescue the reduction in differentiation caused 
by the absence of one c-fos allele. 
The molecular mechanisms by which TGF-P stimulates osteoclast differen- 
tiation and survival are still not clear. TGF-P signals through Smad-2 and 3, which 
form heteromeric complexes with the co-Smad, Smad-4. These complexes are translo- 
cated into the nucleus, and regulate the transcription of target genes in co-operation 
with other transcription factors, e. g. AP-1 family, coactivators and corepressors (ten 
Dijke et al., 2000). It was reported that TGF-P synergistically increased RANKL- 
induced translocation of NFO, an important transcription factor for osteoclastogene- 
sis, into nuclei in osteoclast progenitors (Kaneda et al., 2000). In vitro binding studies 
showed that both Smad3 and Smad4 bind all three Jun family members: c-Jun, JunB, 
and JunD (Liberati et al., 1999). It is well established that c-Fos heterodimerises with 
Jun proteins, mainly c-Jun, exerting transcription activities. Furthermore, c-Jun co- 
operates with c-Fos in osteoclastogenesis (Wang et al., 1995). Koseki et al. showed 
that although TGF-P had no effect on JNK activity, it enhanced JunB expression 
(Koseki et al., 2002), which is reported to affect c-Jun-mediated transactivation and 
transformation. Hence, in the absence of c-Fos, TGF-P may enhance osteoclast for- 
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mation through NFxB and c-Jun signalling but this remains to be investigated. 12-0- 
tetradecanoyl-13-acetate (TPA)-responsive gene promoter elements (TREs) are in- 
volved in the transcriptional responses of several genes to TGF-P. c-Jun and c-Fos, 
bind to TREs as an AP- I complex and act together with Smad3 and Smad4 to activate 
transcription in response to TGF-P. However, Smad3 and Smad4 can also activate 
TGF-p-inducible transcription from the TRE in the absence of c-Jun and c-Fos 
(Zhang et al., 1998). This suggests that in the absence of c-fos, TGF-P may enhance 
osteoclast differentiation by some alternative mechanisms. However, TGF-P failed to 
rescue the defect of osteoclast formation in newborn spleen cultures, and in 2-3 week 
old and adult bone marrow and spleen cultures. Furthermore, although osteoclasto- 
genesis from heterozygous precursors in adult cultures was enhanced after TGF-P 
treatment, it was still much lower than that from the wild type precursors. 
In conclusion, the partial rescue effect of exogenous TGF-P in the absence of 
c-Fos is restricted to the early progenitors and is RANKL-dependent. Exogenous; 
TGF-P can not fully substitute for c-Fos in osteoclastogenesis. 
TNF-a is a pro-inflammatory cytokine, which plays an important role in 
pathological bone resorption. In addition to its stimulatory effects on RANKL- 
induced osteoclastogenesis (Lam et al., 2000), TNF-a has been reported to be able to 
induce osteoclast formation independently of RANKL (Azurna et al., 2000; Fuller et 
al., 2002). Under our experimental conditions, TNF-a failed to induce osteoclasts in 
the absence of RANKL, supporting other reports by Lam et al. that basal levels of 
RANKL are required to "prime" the precursors for osteoclastogenesis (Lam et al., 
2000). Thus, I also investigated the effect of TNF-cc on osteoclast differentiation in 
the absence of c-Fos. 
As expected, TNF-a enhanced RANKL-induced osteoclast formation in 
wild-type cultures and this appeared to occur over a shorter time course. Ilowcver, 
the number of TRAP positive multinucleated cells decreased dramatically in long- 
term TNF-a culture more rapidly than in wild-type cultures, suggesting either that 
TNF-a induces osteoclast apoptosis, or that osteoclasts undergo their normal pro- 
gramme of apoptosis earlier than wild-type cells since they form earlier. The function 
of TNF-cc is mediated by two receptors: TNF receptorl (TNF-Rl) and 2 (TNF-R2). 
TNF-et binding to TNF-RI leads to activation of NFKB, ERKs and JNK, which are 
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important signalling molecules for osteoclast formation (Zhang et al., 2001b). How- 
ever, binding of TNF-cc to TNF-RI also induces the recruitment of FADD and 
caspase-8 which leads to apoptosis (Barkett and Gilmore, 1999). TNF-(x didn't res- 
cue the osteoclastogenesis defect in c-Fos deficient precursors from newborn and 2-3 
week old mutant mice, but it nevertheless had a significant effect as many more 
TRAP positive mononuclear cells were generated in mutant bone marrow cultures, 
though the staining was faint. These results suggest that in the presence of RANKL, 
TNF-a may indeed enhance the differentiation of precursors towards the osteoclast 
pathway, however, in the absence of c-Fos, these cells fail to differentiate further into 
mature osteoclasts. This is consistent with previous experiments in which transgenic 
mice overexpressing TNF-(x, which develop rheumatoid arthritis-like symptoms, 
were intercrossed with c-Fos knockout mice. The resulting TNF-a Tg/c-Fos-/- mice 
still developed osteopetrosis but with a non-destructive arthritis (Redlich et al., 
2002), suggesting that exogenous TNF-a could not rescue the block in osteoclast 
differentiation in vivo. 
The inability of TNF-a to rescue the defect of osteoclastogenesis in the ab- 
sence of c-Fos is perhaps not surprising, since both TNF-(x and RANKL belong to 
the TNF ligand superfamily, and their signalling pathways are considerably overlap- 
ping (Zhang et al., 2001b). Moreover, TRAF-6 is also critical for TNF-a-induced 
osteoclastogenesis, and osteoclast formation in the presence of M-CSF and TNF-a 
was abolished in spleen cell cultures derived from TRAF-6 deficient n*e (Kaji et al., 
2001). Together with the fact that TNF-a induces AP-1 activity (Brenner, nature 
1989), the tissue culture results suggest that c-Fos is indispensable for TNF-a in- 
duced osteoclastogenesis. 
Taken together, TGF-P and TNF-cE stimulate RANKL-induced osteoclasto- 
genesis in a c-Fos-dependent manner, and TGF-P can enhance osteoclast formation in 
early c-Fos mutant progenitors. 
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5.7.3 In vitro studies of c-fos transgenic mice 
5.7.3.1 Osteoclast precursors overexpressing c-Fos have an enhanced potential 
to differentiate into functional osteoclasts 
The experiments described in this thesis also demonstrated a novel role for c- 
Fos as a positive regulator of osteoclast differentiation, using the c-Fos transgenic 
mice as a model system. Exogenous c-Fos may enhance osteoclastogenesis through 
several mechanisms: (1) exogenous c-Fos could increase the ratio of RANKL: OPG in 
local environment, hence exerting its effect indirectly via osteoblasts/stromal cells; (2) 
high levels of c-Fos in osteoclast precursors could substitute for the requirement of 
RANKL and M-CSF in osteoclast differentiation; (3) overexpression of c-Fos in 
osteoclast precursors could increase their responsiveness to osteotropic factors; and 
(4) exogenous c-Fos could prolong the survival of osteoclasts and their precursors. 
It was important to check whether c-Fos affects osteoclast differentiation 
indirectly through osteoblasts/stromal cells, because osteoblastic cells are target cells 
for c-fos in these mice, leading to osteosarcoma. formation (Grigoriadis et al., 1993). 
Osteoblasts from newborn mouse calvaria, are widely used for supporting osteoclast 
generation in vitro. However, in the c-Fos transgenic mice, the expression of exoge- 
nous c-fos starts from 2-3 weeks after birth in bone tissues although primary cultures 
of stromal cells were never investigated (Grigoriadis et al., 1993). Additionally, pre- 
vious experiments showed that osteoblasts of adult mouse calvarial bone expressed 
decreased level of RANKL and didn't readily support osteoclast fortnation 
(Kartsogiannis et al., 1999), whereas stromal cells from adult bone marrow were able 
to support osteoclast formation in vitro (Hattersley and Chambers, 1989c; Takahashi 
et al., 1988b; Udagawa et al., 1990). 
Northern blot analysis of RANKL and OPG expression using RNA isolated 
from c-Fos transgenic and wild-typc stromal cells, showed that stromal cells cx- 
pressed very low basal levels of RANKL and OPG, which were increased and de- 
creased, respectively, by treatment with 1,2501403 and dexamethasone, consistent 
with previous studies (Horwood et al., 1998; Udagawa et al., 1999). Furthermore, the 
levels of RANKL and OPG were similar in both transgenic and wild-type cells. Ex- 
amining whether the c-Fos transgenic stromal cells actually expressed the transgene 
using transgene-specific primers, revealed that strornal cells from c-Fos transgenic 
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mice expressed very low levels of the transgene. These results suggest that it is un- 
likely that exogenous c-Fos affects osteoclastogenesis through osteoblastic cells. 
The question of whether overexpression of c-Fos has direct effects on osteo- 
clasts is still not well understood. As mentioned in the Introduction (section 1.7.3.2), 
previous data from our and Wagner's laboratories examining the osteoclasts within c- 
Fos transgenic turnours, and the generation of TRAP-c-fosLTR mice, provided cir- 
cumstantial evidence supporting a direct role for c-Fos in stimulating osteoclasts 
(Grigoriadis et al., 1993; Wang et al., 1995; Beedles et al., 1999). An effect of c-fos 
has also been implicated in the differentiation of chick osteoclasts, as overexpression 
of c-Fos directly enhanced osteoclastogenesis in vitro (Miyauchi et al., 1994). In 
contrast, however, Owens et al. reported that infection of immortalised osteo- 
clast/macrophage precursor cell lines and spleen cells with a c-Fos expressing retrovi- 
rus had no effects on osteoclast formation when cultured with stromal cells (Owens 
et al., 1999). Finally, Takayanagi et al. recently reported that bone marrow mono- 
cytc/macrophage precursors infected with a c-Fos retrovirus differentiated into 
TRAP positive cells in the absence of RANKL, although the efficiency was very low 
(7%) (Takayanagi et al., 2002a). The reasons for these inconsistencies are not very 
clear, but may be due to the different culture systems employed. In this thesis, the 
role of exogenous c-Fos was investigated in an ax vivo system, by examining M-CSF- 
dependent nonadherent bone marrow cultures from c-Fos transgenic mice compared 
to wild type littermates. 
First, these experiments were feasible only after confirming that the c-fos 
transgene was expressed in M-CSF-dependent nonadherent bone marrow cells from 
c-Fos transgenic mice, which suggests that the transgene may act directly on osteo- 
clast precursors. This was also consistent with the in situ hybridisation results that 
the transgene was expressed in TRAP positive mononuclear cells within the turnours 
and was downregulated after differentiation. 
No TRAP positive cells were formed from c-Fos transgenic bone marrow 
precursors cultured with RANKL or M-CSF alone, suggesting that exogenous c-Fos 
is unable to substitute the requirement of RANKL and M-CSF signalling in osteo- 
clast formation. Nevertheless, overexpression of c-fos had a clear effect on the re- 
sponsiveness of osteoclast precursors to M-CSF and RANKL. The results clearly 
showed that the number of TRAP positive multinucleated cells was greater in c-fos- 
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overexpressing cells at all doses of M-CSF and RANKL tested, and this correlated 
well with resorptive activity. 
Taken together, these results suggested that overexpression of c-fos indeed 
has the potential of promoting osteoclastogenesis by directly acting on osteoclast 
precursors and increasing their sensitivity to M-CSF and RANKL, independently of 
any effects on osteoblasts/stromal cells. 
In view of the TGF-P and TNF-a effects discussed above, the possibility 
that high levels of c-Fos might have effects on TGF-P and TNF-(x responsiveness 
was also investigated. Although TGF-P significantly increased the number of osteo- 
clasts and stimulated resorption in all experiments, these stimulatory effects were 
similar in both c-Fos transgenic and wild type bone marrow cultures, suggesting ex- 
ogenous c-Fos in osteoclast precursors has no effect on TGF-P responsiveness. 
Similarly, c-Fos transgenic precursors cultured with M-CSF and TNF-ot gave rise to 
some TRAP positive mononuclear cells, but no multinucleated cells, suggesting that 
high levels of c-Fos had no effect on the responsiveness of precursors to TNF-a. 
Additionally, these results fit with the previous observation that, under our experi- 
mental conditions, TNF-a requires some additional RANKL in order to see its ef- 
fects. It would therefore be interesting to see whether TNF-oc, in the presence of 
RANKL, has different effects in the presence of exogenous c-Fos. Nevertheless, 
these data suggest that overexpression of c-Fos does not appear to alter TGF-P or 
TNF-a signalling. 
Finally, the last possible function of c-Fos could be related to cell survival. 
Previous studies showed that c-Fos might have pro- and anti-apoptotic function 
depending on the cell type and the apoptotic stimulus. Wenzel et al. demonstrated 
that c-Fos is essential for light-induced apoptosis of retinal photoreceptors (Wenzel 
et al., 2000). Also, overexpression of c-Fos stimulated the apoptosis of retinal gan- 
glion cells (Oshitari et al., 2002), and ectopic c-Fos induced apoptotic cell death in 
pro-B cells (Hu et al., 1996). On the other hand, c-Fos protected fibroblasts from UV 
induced apoptosis (Schreiber et al., 1995), and immature CD8(+)4(+) double-positive 
thymocytes from Ca2'- and cAMP-induced apoptosis (Ivanov and Nikolic-Zugic, 
1997). The TUNEL staining performed on osteoclast cultures following withdrawal 
of serum and growth factors showed that the number of apoptotic cells appeared to 
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be similar in both wild type and c-Fos transgenic cultures, suggesting that high levels 
of c-Fos had no effect on apoptosis in the osteoclast lineage. 
Taken together, these studies demonstrated that ectopic c-Fos expression 
has direct effects on cells of the osteoclast lineage. Specifically, overexpression of c- 
Fos enhances RANKL-induced osteoclastogenesis directly by upregulating the re- 
sponsiveness of osteoclast precursors to RANKL and M-CSF, but does not appear 
to play a role in modulating TGF-P and TNF-cE signalling or cell survival. 
5.7.3.2 Altered expression of osteoclastic markers and signalling molecules in 
c-fos transgenic cultures 
Similarly to the molecular analyses performed using c-fos knockout cells, 
semi-quantitative RT-PCR analysis of osteoclastic marker genes was performed, 
which further confirmed that osteoclastogenesis was enhanced in osteoclast precur- 
sors overexpressing c-Fos. Expression of mature osteoclast specific marker genes, 
such as CTR and cathepsin K, was increased. The increased cathepsin K expression 
may also be responsible for the increased bone resorption. On the other hand, TRAP 
and c-fms expression levels were the same in both transgenic and wild-type cultures, 
which, as in the case of the knockout cultures described earlier, may not be surprising 
since this in vitro system high levels of RANKL and M-CSF restrict cells to the 
osteoclast and macrophage lineages. Indeed, almost all the cells in cultures after 
RANKL stimulation were TRAP positive, and the selection of M-CSF-dependent 
precursors ensures that all cells are expressing c-fms. 
Interestingly, the expression of RANK, the receptor of RANKL, was signifi- 
cantly increased in c-Fos transgenic bone marrow cultures both before and after dif- 
ferentiation. The fact that M-CSF stimulates RANK expression on early-stage osteo- 
clast precursors (Arai et al., 1999), together with the observation that RANK expres- 
sion in M-CSF-dependent precursors isolated from c-Fos transgenic mice is higher 
than that from wild-type littermates, suggests that the high responsiveness of c-Fos 
transgenic precursors to M-CSF during osteoclastogenesis is at least partially due to 
the increased RANK expression after M-CSF stimulation. In addition, the increased 
RANK expression in c-Fos transgenic bone marrow cultures before and after differen- 
tiation could also explain the high responsiveness of c-Fos transgenic precursors to 
RANKL. Thus, more RANKL responsive cells present in the culture, or more recep- 
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tors, present on precursors, would result in increased RANKURANK signalling. It 
has been reported that RANK7 precursors differentiate into osteoclasts more effi- 
ciently than RANK+ cells in the presence of RANYM and M-CSF, as RANK- cells 
have higher proliferative activity (Arai et al., 1999). However, in this experiment 
here, cells were not fractionated. RANK7 and RANK+ cells were not separated and 
therefore it was not possible to evaluate the consequences of overexpression of c-Fos 
from both cell populations. 
TRAM is the cytoplasmic adapter protein that mediates RANKURANK 
signalling in osteoclast differentiation and activation via activating NF-icB and 
JNK/AP-1 pathways (Lornaga et al., 1999; Naito et al., 1999). The expression of 
TRAF-6 in c-Fos transgenic bone marrow cultures was higher than wild-type cultures 
even before RANKL treatment. These results suggest that exogenous c-Fos may 
potentiate osteoclast differentiation by inducing TRAF-6 expression in osteo- 
clast/macrophage precursors, and upregulating TRAF-6 transcription upon RANKL 
and M-CSF stimulation. 
As a target gene of c-Fos in osteoclast progenitors, fra-I expression was in- 
duced by exogenous c-Fos in precursors in the absence of RANKL similarly to 
TRAF-6. Moreover, fra- I expression was much higher in transgenic cultures after 
differentiation than that in wild type cultures, which is consistent with the in situ 
hybridisation results in the transgenic turnours. Thus, it is likely that high levels of c- 
Fos may enhance osteoclastogenesis via inducingfra-I expression, at least in the 
context of this transgenic mouse line. Another c-Fos-related protein, Fra-2, which is 
proposed to be a negative regulator of osteoclastogenesis (Hoebertz et al, 2003), is 
also expressed in osteoclast precursors and mature osteoclasts generated in vitro, 
however, there were no differences in fra-2 expression between wild-type and trans- 
genic bone marrow cultures. Similarly, IFN-, B expression in c-Fos transgenic bone 
marrow cultures was the same as wild type cultures. In osteoclast precursors, 1FN-P 
expression was absent and became detectable after differentiation. As described 
above, IFN-, B is both a c-Fos target gene and an inhibitor of osteoclastogenesis, thus, 
RANKL-induced c-Fos expression induces its own inhibitor (Takayanagi et al., 
2002b). This negative feedback is important for controlling osteoclast differentiation 
and bone resorption. In addition, overexpression of c-Fos by virus infection rescued 
the inhibitory effect of IFN-P in osteoclast differentiation (Takayanagi et al., 2002b). 
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In the c-Fos transgenic mice, overexpression of c-Fos doesn't increase IFN-P expres- 
sion which may be one of the mechanisms by which high c-Fos levels enhance& os- 
teoclast formation. 
Thus, positive signalling downstream of RANKURANK, such as TRAF-6 
andfra-1 (see also below), and negative regulatory mechanisms, such as IFN-, 6, may 
both be involved in mediating the effect of the c-Fos transgene on osteoclastogenesis. 
5.7.4 The relationship between c-fos levels, fra-I expression and osteoclast 
differentiation 
Finally, the correlation betweenfra-I expression and c-fos levels in both c- 
fos knockout and transgenic cultures prompted a further investigation of the short 
term response offra-1 to RANKL in the different mutants. Previous experiments 
showed that RANKL inducedfra-I expression in wild type M-CSF-dependent pre- 
cursors within 1 hour, while no induction was observed in c-Fos deficient adult 
spleen precursors (Matsuo et al., 2000). Experiments in this thesis using c-Fos 
knockout cells from 2-3 week old bone marrow and spleen, confirmed that fra-1 
mRNA expression level was not upregulated after I hour of RANKL stimulation. 
This correlates well with the fact that these cell populations do not differentiate into 
multinucleated osteoclasts. Interestingly, however, in newborn cultures, which do 
have the potential to form osteoclasts in the absence of c-Fos, RANKL inducedfra-1 
expression in c-Fos mutant bone marrow cultures, and the levels were even higher 
than in the wild-type cultures. In contrast, RANKL didn't induce fra-1 expression in 
newborn spleen cells, which cannot form osteoclasts. The difference in fra-1 induc- 
tion between newborn and 2-3 week bone marrow suggests that, specifically in mu- 
tant bone marrow osteoclast precursors, fra-1 expression is upregulated by some c- 
Fos-independent mechanisms, which is both age-dependent, and specific to bone 
marrow precursors. The absence of R-ANKL- inducedfra-I expression in newborn 
mutant spleen cells further confirmed that precursors in spleen are different from that 
in bone marrow. 
The relationship between c-fos, fra- I and osteoclast differentiation was also 
consistent in c-Fos transgenic experiments. In bone marrow precursors overexpress- 
ing c-fos, the levels of RANKL-stimulatedfra-I expression were higher than in wild 
type cells, and the induction occurred earlier and reached peak levels earlier. These 
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results clearly suggested that high levels of exogenous c-Fos augment RANKL- 
induced fra-I expression, and this could provide an explanation for the increased 
osteoclast formation seen in the transgenic cultures. 
Taken together, the regulation of both basal and RANKL-inducedfra-I ex- 
pression has paralleled very closely the levels of c-Fos in both the knockout as well 
as the transgenic cultures, in an age-dependent manner. The two exceptions are in the 
newborn and young c-Fos mutant bone marrow cultures, which is the only popula- 
tion which can form osteoclasts, and in whichfra-1 expression appears to be inde- 
pendent of c-Fos. Moreover, the regulation offra-1 has correlated well with the os- 
teoclastogenic potential of bone marrow versus spleen-derived precursors. 
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Chapter 6 
General discussion and conclusions 
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In vertebrates, the integrity of the skeleton depends on bone remodelling in 
which osteoclastic bone resorption is followed by osteoblastic bone formation. Dys- 
function of, and imbalance between osteoblasts and osteoclasts lead to bone meta- 
bolic diseases such as osteoporosis, in which bone resorption exceeds bone forma- 
tion, or osteopetrosis, in which bone formation exceeds bone resorption (Karsenty 
and Wagner, 2002). A detailed understanding of bone cell biology may therefore pro- 
vide fundamental insights into the etiology and treatment of bone diseases. 
Osteoclasts are multinucleated cells responsible for bone degradation. Osteo- 
clastic bone resorption is important for both bone development and bone remodelling. 
The differentiation and activation of osteoclasts are tightly regulated by cellular and 
hormonal factors in vivo. Transcription factors are involved in the early stages of 
osteoclast differentiation, regulating the development of bipotential precursors and 
commitment of precursors to the osteoclast lineage, and the role of transcription 
factors in osteoclastogenesis has been elucidated by targeted gene deletion and over- 
expression in mice (Karsenty and Wagner, 2002; Wagner and Karsenty, 200 1). 
Among the transcription factors identified so far, c-Fos is unique in that it 
appears to act at the branch point where osteoclast and macrophage differentiation 
diverge. Mice lacking c-Fos developed osteopetrosis due to complete absence of 
functional osteoclasts and their immediate precursors, however, the number of 
macrophages in mutant bone marrow was increased (Grigoriadis et al., 1994). There- 
fore, c-Fos knockout mice provide an ideal model for studying the biology of osteo- 
clast. On the other hand, c-Fos is a proto-oncogene, which belongs to the AP- I tran- 
scription family. Overexpression of c-Fos resulted in osteosarcomas with active bone 
remodelling. However, tumour formation was almost absent in c-Fos knockout mice 
expressing the c-Fos transgene (Wang et al., 1995), which suggests that high levels of 
c-Fos may enhance osteoclast formation which plays an important role in tumori- 
genesis. The aims of this project therefore, were to investigate the mechanisms by 
which c-Fos controls osteoclastogenesis, and how osteoclasts are involved in tumour 
development. 
Determining where the block in osteoclast-macrophage development occurs is 
an important step in discovering the function of c-fos in the differentiation of this 
lineage. Both in vivo and in vitro experiments showed that early M-CSF- and 
RANKL-responsive osteoclast progenitors are present in c-Fos mutant long bones. 
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Mapping the expression of osteoclast and macrophage specific markers shown in 
chapter 3 showed that in the osteoclast differentiation pathway, c-Fos functions at a 
point very close to NF-KB, downstream of PU. 1, M-CSF and RANK, and upstream 
of Mitf. 
Pathogenic defects in ostcoclastogenesis may be caused by defects intrinsic ei- 
ther to the osteoclast lineage or to the stromal cell lineage. Osteoblasts or bone mar- 
row stromal cells are required for osteoclast formation and activation in vivo. The 
production of RANKL and OPG, the two key factors for osteoclastogenesis, by 
mutant osteoblasts was confirmed in chapter 3. Although the ratio of RANKL: OPG 
in c-Fos knockout bone marrow compared to wild-type was not determined, the high 
expression and the apparently normal hormonal regulation suggested that it is un- 
likely that altered stromal cell expression of RANKL and OPG can explain the osteo- 
clast defect. 
Most in vitro differentiation assays studying the mechanism of the osteoclas- 
togenesis defect in osteopetrotic: animals have used spleen cells as the source of hae- 
matopoietic precursors. This is based on two main reasons. First, due to the drasti- 
cally reduced bone marrow space, it was always thought to be very difficult and 
impractical to isolate large numbers of bone marrow cells to study osteoclast differen- 
tiation. Second, in all osteopetrotic animals, extramedullary haernatopoiesis occurs in 
the spleen, in which the production and differentiation of precursors is normal - this 
was proven experimentally in the c-Fos knockout mice (Okada et al., 1994). How- 
ever, it was hypothesised in this thesis, and demonstrated in chapter 4, that M-CSF- 
dependent precursors derived from bone marrow are different from that of spleen, at 
least with respect to their absolute dependence on c-Fos for differentiation. This new 
concept may help to further understand the nature of osteoclast precursors and their 
distribution in the body. The bone marrow culture system developed in this project 
provides a new model for studying the differentiation potential of authentic osteo- 
clast precursors from osteopetrotic mice in vitro, and to investigate the factors which 
might rescue the differentiation block in these precursors. However, this model is not 
perfect. Even though M-CSF-dependent cells were isolated over a 2-day period, 
stromal cell contamination couldn't be ruled out, and this would apply more to the 
mutant cultures as there is a higher degree of unresorbed cartilage and bone present. 
Thus, the production of local factors other than RANKL or OPG, or cell-cell interac- 
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tions from this potential stromal cell contamination might affect cell proliferation and 
fusion of osteoclast precursors. Future experiments to address this are to perform 
longer time M-CSF incubation, or use other techniques such as MACS sorting for c- 
fms positive cells which will yield a stromal-free precursor population. This could 
also be complimented by examining the expression of stromal cell markers following 
purification. 
Nevertheless, it is first shown here that early stage osteoclast progenitors 
from mutant newbom bone marrow have limited potential to differentiate into func- 
tional mature osteoclasts in the absence of c-Fos, which is diminished in adults. This 
is the first report implying that c-Fos may not necessarily be an essential gene for 
osteoclast differentiation, and that there might be c-Fos-independent ways of gener- 
ating osteoclasts. This is consistent with previous results that bone marrow trans- 
plantation can fully rescue the osteopetrosis in newborn mutant mice, but not in 
adults (Okada et al., 1994). Moreover, the data shown in this thesis are supported by 
recent ongoing experiments in our laboratory using Embryonic Stem (ES) cells to 
generate osteoclasts. The results so far have shown that ES cells lacking c-Fos have 
the capacity to differentiate into osteoclasts with less efficiency than wild-type ES 
cells, but to an apparently greater extent than knockout newborn bone marrow cul- 
tures. Thus, these data further confirm that c-Fos is not essential for osteoclast dif- 
ferentiation, and suggested that the differentiation potential of precursors in the ab- 
sence of c-Fos is decreased during development. 
The mechanisms that substitute for c-Fos in newborn precursor differentia- 
tion are not clear. Presumably, other AP- I family members may be involved, and Fra- 
I is clearly one of them, for all the reasons discussed extensively in this thesis. This 
is supported by data in this thesis, sincefra-I levels were elevated in all instances 
where knockout cells gave rise to TRAP positive osteoclasts, and were diminished in 
knockout cells which failed to form osteoclasts. However, this possibility must be 
viewed carefully, since the expression offra-I is not restricted to the osteoclast line- 
age. As other cell types, such as macrophages can also expressfra-1, high levels of 
fra-I expression detected both in vivo and in vitro may reflect the higher number of 
macrophages present in mutant bone marrow. Moreover, loss-of-function experi- 
ments, have shown thatfra-I knockout mice developed normal bone structure with 
TRAP positive osteoclasts present (Schreiber et al., 2000). Thus, the mechanisms 
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by whichfra-I is upregulated, and roles offra-I in osteoclast differentiation in the 
absence of c-Fos need further investigation. 
The Jun family members, especially c-jun, may also play a role in osteoclast 
differentiation, although Matsuo et al. reported that none of the Jun proteins rescued 
differentiation in c-Fos knockout spleen cells (Matsuo et al., 2000). During osteoclas- 
togenesis, binding of RANKL to RANK activates signalling transduction pathways, 
such as NF-icB and JNK, via TRAF-6. JNK is one of the MAP kinases, which 
phosphorylates the N-terminal domain of Jun and modulates the transcriptional ac- 
tivity of AP-1. JNK contains at least 10 different isoforms encoded by three different 
genes: Jnk], Jnk2 and Jnk3. Osteoclastogenesis is impaired in haernatopoietic cells 
isolated from mice lacking JNKI, or c-Jun, or expressing a mutated form of c-Jun that 
cannot be phosphorylated by JNKs (David et al., 2002), which suggest that J-NKI- 
dependent c-Jun phosphorylation in response to RANKL is essential for efficient 
osteoclast formation. The level and function of c-Jun and JNK in precursors lacking 
c-Fos was not analysed in this project, and this represents an interesting area of fu- 
ture investigation. 
Finally, another candidate for substituting the function of c-Fos in osteoclast 
differentiation is NFATc I, which was recently reported to be a new c-Fos target. 
NFATc 1, a member of the NFAT (nuclear factor of activated T cells) family, is most 
strongly induced following RANKL stimulation, and it's expression is dependent on 
both the TRAF6 and c-Fos pathways (Takayanagi et al., 2002). Indeed, precursors 
overexpressing NFATO efficiently differentiated into osteoclasts even in the absence 
of RANKL. The expression of NFATc I in c-Fos mutant baematopoietic cells derived 
from knockout mice of different ages, and whether overexpression of NFATc I could 
rescue or enhance the c-Fos effect, would therefore be extremely interesting future 
experiments to see if this transcription factor could explain why osteoclasts can form 
in the absence of c-Fos. 
Additional cytokines which are known to stimulate osteoclastogenesis were 
added to c-Fos mutant cultures in attempt to rescue the differentiation block. Exoge- 
nous TGF-P could not substitute completely for c-Fos, but it did augment osteoclas- 
togenesis in newborn mutant bone marrow precursors, which suggests that TGF-P 
may act through both c-Fos-dependent and independent pathways during osteoclas- 
togenesis. Previous studies have shown that endogenous TGF-R is essential for os- 
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teoclastogenesis, since an anti-TGF-P antibody abrogated RANKL- and TNF-cc- 
induced osteoclast formation in vitro (Fox et al., 2000; Kaneda et al., 2000). The 
effect of overexpression of TGF-P in osteoclast precursors on osteoclastogenesis in 
the absence of c-Fos could be investigated by virus infection or by transgenic mice. 
TNF-a, on the other hand, failed to rescue the defect of osteoclastogenesis in c-Fos 
deficient precursors, which may be due to its pro-apoptotic effect (Barkett and Gil- 
more, 1999). Since TGF-P prolongs the survival of osteoclasts (Fuller et al., 2000), 
TNF-a combined with TGF-P may be more efficient in rescuing the defect of osteo- 
clastogenesis in the absence of c-Fos. 
With regard to overexpression of c-Fos, only previous circumstantial data 
suggested that high levels of c-Fos may enhance osteoclast formation directly. Here, 
it was proved for the first time by both in vivo and in vitro studies that overexpres- 
sion of c-Fos clearly has effects on osteoclast differentiation. However, the mecha- 
nisms by which overexpression of c-Fos uprcgulates the responsiveness of osteoclast 
precursors to RANKL and M-CSF are not clear. The survival of osteoclasts and their 
precursors was apparently not affected by the transgene and may be ruled out as a 
possible mechanism. However, the effect of exogenous c-Fos on cell proliferation was 
not investigated, and experiments such as BrdU staining should be performed in order 
to address this question. The evidence also suggested that signals downstream of the 
RANKLARANK pathway, such as TRAF-6 and fra-1, and negative regulatory fac- 
tors, such as IFN-P, may be involved in the effect of c-Fos transgene on osteoclasto- 
genesis and these studies remain to be performed. 
Finally, in the context of oncogenesis, experiments showed that osteoclasts 
are important for bone tumorigenesis (Clohisy and Ramnaraine, 1998; Wang et al., 
1995). Zhang et al. reported that injection of cancer cells intratibially and subcutane- 
ously in mice induced tumorigenesis. Administration of OPG completely prevented 
the establishment of mixed osteolytic/osteoblastic tibial tumours, but had no effect on 
subcutaneous tumour growth (Zhang et al., 2001). In c-Fos-induced osteosarcomas, 
numerous multinucleated osteoclasts and macrophages are present. Especially inter- 
esting was the observation that osteoclastic marker genes are also expressed in fibro- 
blastic areas of osteosarcomas not containing any bone, suggesting that exogenous c- 
Fos had the capacity to induce ectopic osteoclast formation. Transformed fibroblasts 
and/or pre-osteoblasts in these areas express high levels of RANKL and OPG, which 
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could support osteoclast formation from macrophages, that are present in high num- 
bers in the turnours. In terms of target genes, Fra-1 emerged as a clear target which 
might be important for c-Fos-induced osteoclastogenesis, at least in the context of 
osteosarcoma formation and tumour remodelling. It will therefore be important to 
check the in situ expression of the other c-Fos target genes in a systematic manner. 
Some interesting experiments remain in order to address the role of osteoclasts, and of 
Fra-1, on the progression of c-Fos-induced osteosarcomas. For example, it would be 
predicted from these studies that treatment of c-Fos transgenic mice with osteoclast 
inhibitors, such as OPG, would not inhibit tumour initiation, but progression. Also, 
whether tumour formation is altered in c-Fos transgenic mice crossed with Fra-1 
knockout mice, which have osteoclasts, would provide genetic evidence on the role of 
Fra-1 in osteoclast differentiation in c-Fos induced turnours. 
in conclusion, c-Fos affects osteoclast differentiation in a gene-dose depend- 
ent manner, and the effects are most likely mediated by its target genefra-1. The 
different differentiation potential between bone marrow and splenic haernatopoietic 
progenitors in the absence of c-Fos, provides further information on understanding 
the nature of osteoclast precursors, and suggests a need to re-evaluate the role of c- 
Fos in osteoclast differentiation. Furthermore, the culture system employed in this 
thesis provides a useful tool for studying osteoclastogenesis in osteoPetrotic animals. 
Finally, the enhancement of overexpression of c-fos on osteoclastogenesis, together 
with the ectopic osteoclast formation in c-Fos-induced osteosarcomas, aids in under- 
standing bone turnour progression, and is useful for identifying new approaches for 
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